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Abstract 
The synovial environment in rheumatoid arthritis (RA) is a milieu of Damage 
Associated Molecular Patterns (DAMPs), cytokines and immune complexes, which 
can modulate the activation or polarisation of myeloid cells. GM-CSF, which is a 
pivotal myeloid cell growth factor, is also a pro-inflammatory cytokine that 
drives aspects of RA immunopathogenesis. Inhibition of GM-CSF signalling has 
been successful in both mouse models and in clinical trials for RA, however, the 
specific effect of GM-CSF on myeloid cells in a synovial setting is not well 
understood. The aim of this thesis was to investigate the impact of the synovial 
environment and GM-CSF on myeloid cells in RA. 
GM-CSF stimulation induced monocytes to secrete substantial amounts of the 
chemokine CCL17. However, this induction of CCL17 was significantly inhibited 
upon co-stimulation with RA synovial fluid, but not osteoarthritis (OA) synovial 
fluid, whilst the expression of other chemokines was unaffected. TLR ligands 
also inhibited GM-CSF driven CCL17, however, through the use of MyD88/TRIF 
knockout mouse monocytes, we found RA synovial fluid inhibition of CCL17 was 
TLR-independent. Small Immune Complexes and IFNα also had the capacity to 
inhibit GM-CSF induction of CCL17, suggesting multiple mechanisms within the 
RA synovial fluid to prevent this induction. Despite the consistency of RA 
synovial fluid causing inhibition of the GM-CSF signalling pathway in comparison 
to OA synovial fluid, there were no distinct effects on macrophage polarisation. 
The RA synovial environment has more of an impact on monocyte activation in 
comparison to macrophage polarisation, as synovial fluid from other 
arthropathies had the comparable effects on macrophage phenotypes.  
This thesis concludes that RA synovial fluid contains several factors that inhibit 
GM-CSF induction of CCL17. This suggests a regulatory mechanism, preventing 
the excessive secretion of CCL17 by monocytes, thereby preventing exacerbation 
of immunopathogenesis.   
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Chapter 1 Introduction 
1.1 Rheumatoid Arthritis 
1.1.1 Clinical symptoms 
Rheumatoid Arthritis (RA) is an autoimmune disease with a chronic inflammatory 
pathology that primarily affects the small joints of the hands and feet (1,2). 
Clinically, the disease manifests as swelling and pain of multiple joints that can 
result in irreversible joint deformation (3). Peak onset of disease is between the 
age of 25 and 55. RA is characterised by: cell infiltration into the joint lining 
causing severe synovitis; angiogenesis; and bone and cartilage erosion caused by 
the synovitis (4). The joints are the main affected area, however, RA can also be 
considered a systemic condition as there are a number of co-morbidities 
associated in approximately 80% of RA patients (5). These include cardiovascular 
disease, osteoporosis, periodontal disease, gastrointestinal disorders, pulmonary 
problems and increased cancer risk (6). RA patients can expect their life 
expectancy to be 3 to 10 years lower than average (7).  
1.1.2 Classification 
The diagnosis of RA is made primarily on physical findings. There is no single test 
that can confirm or exclude diagnosis of RA; therefore a number of criteria are 
examined to aid diagnosis. These include: the number and location of joints 
affected; the presence and abundance of rheumatoid factor (RF) or anti-
citrullinated protein antibodies (ACPA) in the serum; the levels of C-reactive 
protein (CRP); erythrocyte sedimentation rate (ESR); and the duration of the 
symptoms (8). The 1987 American College of Rheumatology (ACR) classification 
criteria was focused on discerning patients with established RA, which was 
successful, however, this system led to a failure in identifying patients with 
early disease (8,9). New identification criteria were defined in the 2010 
ACR/EULAR classification criteria created to differentiate patients with synovitis 
and those patients at more risk of developing erosive RA (Table 1.1). Patients 
achieving a score of more than 6 were classified as having RA (10). Having the 
ability to differentiate patients into categories also benefits the identification of 
patients for clinical trials (8).
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Table 1.1 2010 ACR/EULAR RA classification criteria 
Symptom Score 
A. Joint Involvement  
1 large Joint 0 
2-10 large joints 1 
1-3 small joints (with or without involvement of large joints) 2 
4-10 small joints (with or without involvement of large joints) 3 
>10 joints (at least 1 small joint) 5 
  
B. Serology   
Negative RF and negative ACPA 0 
Low-positive RF or low-positive ACPA 2 
High-positive RF or high-positive ACPA 3 
  
C. Acute-phase reactants  
Normal CRP and normal ESR 0 
Abnormal CRP or normal ESR 1 
  
D. Duration of symptoms  
<6 weeks 0 
≥6 weeks 1 
 
1.1.3 Epidemiology 
The world prevalence of RA is approximately 0.5-1%, however incidence is 
declining over time. The annual incidence is now 25-50 cases per 100,000 (11). 
Interestingly, there is geographical variation in incidence of RA as in China and 
Japan, the incidence is low (0.2-0.3%) whereas in some native American 
populations the incidence is high (≥5%) (8,12). In the UK, prevalence of RA is 
0.8% with an incidence of 36 per 100,000 women and 14 per 100,000 men (13). 
There are few prevalence studies in developing countries, however there is some 
evidence to suggest a significantly lower prevalence (0.1-0.5%) of RA in 
developing countries in comparison to North America and Northern Europe (14). 
This suggests there are potential genetic and/or environmental factors that can 
increase the potential for disease onset. Importantly, in recent years evidence 
has been generated to support both genetic and environmental risk factors in RA 
susceptibility. 
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1.2 Risk Factors for RA 
1.2.1 Genetic  
In the last couple of decades a substantial amount of work has been done to 
investigate the link between genetics and RA predisposition. Numerous studies 
have been undertaken and it is clear that there is no one gene responsible for RA 
but rather a complicated multi-gene landscape. Genome-Wide Association 
Studies (GWAS) have identified more than 100 loci associated with RA risk, 
however the effect of an individual locus is low (15).   
Although one gene cannot explain the genetic predisposition in RA, the initial 
observation in genetic studies revealed that Human Leukocyte Antigen (HLA) was 
associated with the onset of RA. It remains as the best characterised genetic risk 
factor (16). The HLA are located in the class II region of the Major 
Histocompatibility Complex (MHC). Several of the HLA-DRB1 alleles are 
associated with RA in multiple populations. These alleles share an epitope, 
which is a short amino acid sequence, located in the hypervariable region of the 
DRB1 molecule (16-18). The shared epitope hypothesis suggests that the specific 
antigen-binding groove is affected, supporting the role for T cells in RA (19). 
Recent studies have also suggested that HLA-DR3 is associated with ACPA 
negative RA patients, highlighting different molecular signatures for the disease 
subgroups (20,21). 
There are multiple RA risk loci that have been identified from GWAS studies. For 
example, PTPN22 was identified by GWAS, and is associated with several 
autoimmune conditions. It encodes lymphoid tyrosine phosphatase (LYP), which 
in the disease-associated variant has increased activity. T-cell receptor and B-
cell receptor signalling was reduced in carriers of this variant leading to the 
survival of autoreactive T cells. RF and ACPA have also been associated with the 
PTPN22 polymorphism (15,16). Despite the numbers of loci that have been 
identified, outside of the HLA loci, these only represent 5.5% of the total risk of 
developing the disease. Furthermore, there are other risk factors such as 
environmental risks that have been associated with development of RA (15) 
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1.2.2 Environmental  
Various environmental factors for example smoking, diet and infection have 
been associated with the onset of RA, however, cigarette smoking the strongest 
identified factor (22). Smoking attributes to 25% of all RA cases, which increases 
to 35% for seropositive RA (patients classified as RF and ACPA positive)(Section 
1.4.7) (23). Smoking increases susceptibility for RA, with the risk more apparent 
in men than women, with several studies demonstrating a dose response 
between heavy smoking and RA, with the risk remaining high even after ceasing 
to smoke (7,22-25). The mechanism causing the increased risk of RA from 
smoking is not fully understood, however, there have been some studies to 
suggest several mechanisms. The cigarette chemical tetrachlorodibenzo-P-dioxin 
(TCDD) has been found to affect general immunity by upregulating the 
inflammatory cytokines IL-1β, IL-6 and IL-8 through the stimulation of NFκB and 
ERK pathways (7,26). Smoking has also been linked to the shared epitope of HLA-
DRB1 and the production of ACPAs. HLA-DRB1 is known to be specific to 
seropositive RA patients, and in smokers, citrullinated proteins are abundant in 
the lungs. Citrullinated α-enolase is an autoantigen for RA that has linked HLA-
DRB1 allele and smoking as risk factors for RA (27). 
Several microorganisms have also been implicated in the development of RA due 
to high titres of antibodies against Epstein-Barr Virus, Mycobacterium 
tuberculosis or human papillomavirus as well as others in sera of RA patients. 
However, this is controversial as no specific microbe directly causes RA. It is 
thought that microorganisms may trigger the development of RA in individuals 
with a genetic susceptibility (7). 
Dietary factors, including vitamin D and omega-3 fatty acids have been shown to 
have a protective effect for auto-inflammatory diseases including RA. Vitamin D 
prevents the onset of Collagen-Induced Arthritis (CIA) in mice, and has been 
shown to prevent the onset of RA in genetically susceptible patients. In already 
diagnosed RA patients, vitamin D intake has been correlated with lower disease 
activity. The mechanism is perhaps due to upregulated anti-inflammatory 
cytokines and inhibited more pro-inflammatory cytokines (23,28). Omega-3 
decreases pro-inflammatory mediators through leukotrienes and prostaglandins, 
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but has had modest effects on RA risk. However, consumption of fish has been 
shown to improve RA symptoms (29,30).    
1.2.3 Gender 
Gender plays a part in the susceptibility to RA. Women are 2 to 4 times more 
likely to develop RA than men, with women less likely to go into remission than 
men (13,31). In women, RA is also more likely to develop at times of flux in sex 
hormones. Interestingly, studies have found pregnancy protective, with RA 
patients going into remission, however relapsing after pregnancy during breast-
feeding is high. This is thought to be due to the major changes in hormone levels 
(32,33).  There are many studies to suggest that the Oral Contraceptive Pill is 
protective in the development of RA, confirming the link between sex hormones 
and RA (23,34). Innate and adaptive immune cells have the oestrogen receptor, 
suggesting that oestrogen can have an impact on the immune response. 
Oestrogen prevents T cell dependent responses and neutrophil adhesion to the 
endothelium, preventing extravasation into the tissue (35). 
1.3 Other Inflammatory Erosive Diseases 
1.3.1 Osteoarthritis 
Osteoarthritis (OA) is a common chronic musculoskeletal disorder affecting 15% 
of the world’s population. It is a disease associated with ageing, joint trauma 
and obesity. OA is not an autoimmune disease and has long been thought as a 
non-inflammatory mechanical disease of weight-bearing joints with 
destabilisation to the joint causing mechanical damage (36,37). However, more 
recent findings suggest that OA does have an underlying inflammatory element 
and that there is synovial inflammation before the structural change in the joint. 
There are also several immune processes that are ongoing within the synovium in 
OA, primarily from the innate immune response, with Toll Like Receptor (TLR) 
signalling playing a major part in immunopathology (37). Currently the only 
treatments for OA sufferers are pain relief and knee replacements with 
replacements only viable for approximately 15 years (38,39).  
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1.3.2 Psoriatic Arthritis 
Psoriatic arthritis (PsA), second to RA in incidence of inflammatory arthritis, has 
less than a 0.1% occurrence in the population (40), but interestingly affects 40% 
of people with psoriasis (41). Clinically, PsA has very similar manifestations as 
RA, with small joint arthropathies, however, unlike RA, erosive bone damage is 
uncommon (42). PsA has a strong genetic link, with 15% of people having a 
relative with the same condition. CD8 T cells are thought to have a major role in 
PsA pathology, however autoantibodies are absent from disease (43). The 
cytokine IL-17 and the IL-17 receptor family members are also crucial to the 
pathogenesis of PsA. There are increased levels of IL-17 in psoriatic joints, which 
is thought to be the reason for increased synovial fibroblast proliferation and 
bone remodelling (44). Anti-IL-17 and anti-IL-17R antibodies are now 
therapeutics used for the treatment of both PsA and psoriasis (45). 
1.4 Immunopathology of RA 
In a healthy joint, the synovial membrane consists of few cells, primarily 
fibroblast-like synoviocytes and macrophages in the intimal lining layer. During 
inflammation, predominantly CD4+ T cells infiltrate into the synovium (Figure 
1.1). Other immune cells for example dendritic cells and B cells are recruited 
and form tertiary lymphoid follicles with T cells, in the synovium (1). The influx 
of these immune cells, as well as the production of autoantibodies causes the 
disease pathology.  However, RA is a heterogeneous disease, and currently there 
is no molecular signature. Dennis et al., 2014, suggest that RA pathologies can 
be subdivided into homogeneous molecular phenotypes. Within these 
homogeneous molecular populations, cellular differences have been observed in 
gene-expression profiles. Through FACS analysis, fibroblasts, macrophages and T 
cells were observed in all molecular clusters, whereas B cells were found only in 
lymphoid and myeloid clusters. This suggests that some cell types are more 
prevalent in some types of disease than others; however, there is as yet no 
definitive categorisation of RA phenotypes due to the level of heterogeneity. 
This heterogeneity within RA explains why all patients to do not respond to 
treatment in the same way. However, the homogeneous molecular phenotypes 
of RA are caused by specific cellular mechanisms (20,46) (Figure 1.1).  
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Figure 1.1 Synovial Immunopathogenesis 
A normal joint in comparison to the RA joint. In the RA joint, multiple immune cells including 
monocytes, macrophages, fibroblasts, dendritic cells, T cells and B cells are involved in 
pathogenesis. 
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1.4.1 Monocyte and Macrophage lineage in RA 
1.4.1.1 Monocytes 
Monocytes are a conserved leukocyte population that derive from 
haematopoietic stem cells in the bone marrow in either the foetal liver or the 
adult bone marrow (47,48). Monocytes depend on Macrophage Colony 
Stimulating Factor (M-CSF) for survival, as mice deficient of the M-CSFR had 
monocytopenia (48,49). After leaving the bone marrow, monocytes circulate for 
a couple of days in the blood before entering the tissues to receive 
environmental cues for further differentiation into monocyte-derived cells (50). 
Monocytes are heterogeneous and can be defined by their CD14 and CD16 
expression. CD14 is a co-receptor for TLR4, therefore important in the binding of 
LPS, whereas CD16, also known as FCγRIII has a low affinity for IgG (51). 
Monocytes are subdivided into: classical, which are CD14++CD16-; intermediate, 
which are CD14++CD16+ ;or non-classical, which are CD14+CD16++. Classical 
monocytes are the most abundant of the monocyte phenotypes with 10 fold 
greater numbers than the non-classical monocyte in circulation (52).  Classical 
monocytes are also CCR2high CXCR1low whereas the intermediate and non-classical 
monocytes are CCR2lowCXCR1high. This is important as it reflects the chemokines 
in which they bind. Classical and intermediate monocytes are both pro-
inflammatory with classical monocytes responding to CCL2 to migrate into the 
site of inflammation, and intermediate monocytes binding CXCL8 and CXCL6 
(53). The intermediate monocytes normally account for about 10% of the 
monocytes in the blood in healthy people, however in RA their numbers increase 
to 11.7% ± 5.6%. This highlights the importance of monocytes in disease 
pathogenesis (54).  
Monocytes, upon inflammatory cues, become immune effector cells that have 
the ability to migrate into inflamed tissues from the blood. Monocytes produce 
cytokines and chemokines upon activation, and also have the ability to 
differentiate into inflammatory monocyte-derived cells (50). 
In RA, the CD16 positive, intermediate monocytes are highly represented mainly 
in the lining layer of the synovial tissue. These monocytes that express CD16 also 
have a high expression of TLR2 in comparison to monocytes without CD16, with 
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no difference in the expression of TLR4. They produce cytokines such as TNFα, 
IL-1β, IL-6 and IL-8 as well as more anti-inflammatory cytokines such as IL-10 
and IL-1RA (55). On arrival to the synovium, monocytes are subject to a milieu of 
many cytokines, chemokines, DAMPs and immune complexes. In response to 
many synovial factors, monocyte differentiation is initiated. Monocytes can also 
modify their responses, releasing cytokines and therefore causing the activation 
of T cells (56). Upon entry into the synovium, a monocyte is exposed to a variety 
of stimuli. Prior to differentiation, the response of a monocyte is not well 
understood; therefore this thesis aims to investigate monocyte responses to 
synovial stimuli. 
1.4.1.2 Macrophages 
Macrophages are tissue resident cells that maintain tissue homeostasis. In 
homeostasis, macrophages are involved in the phagocytic clearance of cellular 
debris and erythrocytes (57). They are termed professional phagocytes as they 
express receptors such as scavenger receptors and phosphatidylserine receptors 
that recognise apoptotic or necrotic cells and are not present on all cells 
(58).There are multiple macrophage lineages and more recently, it has been 
determined that tissue resident macrophages are not monocyte derived. They 
are terminally differentiated cells that are embryonic derived (50). Genetic 
fate-mapping techniques have led to the understanding that macrophages are 
derived from the yolk-sac and can self renew in the tissue (59). In inflammation 
both tissue derived macrophages and monocyte derived macrophages have 
distinctive roles(60). 
During inflammation, monocytes are recruited into the tissue where they receive 
environmental cues and differentiate into cells such as macrophages. 
Macrophages are heterogeneous as the environmental cues received upon 
differentiation from monocytes reflect their phenotype (47).  
Macrophages or monocyte-derived cells are highly plastic, but have historically 
been classified into two distinct groups: M1 or M2; M1 macrophages are 
traditionally differentiated with IFNγ, IFNγ and LPS, or GM-CSF and they have a 
more pro-inflammatory phenotype; and M2 macrophages are IL-4, IL-4 and IL-13, 
IL-10 or M-CSF stimulated macrophages, which have a more regulatory 
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phenotype (61-63). M1 macrophages or classically activated macrophages are 
considered more pro-inflammatory as upon stimulation, they produce cytokines 
such as TNFα, IL-1β, IL-6 and IL-12 as well as chemokines and growth factors. 
They also express high levels of MHC class II, with co-stimulatory molecules to 
present antigen to T cells, thereby activating the adaptive immune response 
(64). M2 or alternatively activated macrophages are thought to be more 
regulatory as they produce IL-10, can antagonise M1 responses and promote the 
resolution of inflammation (58) (Figure 1.2). However, this classification of 
macrophage phenotypes is not representative of macrophages in vivo as the 
classifications were determined from in vitro monocyte-derived macrophages. In 
the tissue, the environmental milieu influences differentiation and activation 
therefore leading to a spectrum of macrophage phenotypes (57). Despite this 
understanding that macrophages are heterogeneous, there are guidelines for 
macrophage classification dependent on expression of transcription factors, 
chemokines, cytokines and scavenger receptors amongst others, which are 
specifically for in vitro derived macrophages (63). These guidelines are useful 
for clarity between culture conditions that were previously used for M1 or M2 
macrophages, however, this does not relate to disease specific macrophages or 
allow for the spectrum of macrophage phenotypes (Figure 1.2). 
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Figure 1.2 Macrophage Differentiation and Polarisation. 
A) Traditional terminology for macrophage differentiation. Macrophages differentiated in vitro from 
monocytes with specific identified stimuli, differentiated into either M1 or M2 macrophages. B) The 
widely accepted concept that due to the large variety of stimuli received in the tissue, macrophages 
are not easily categorised, but have a spectrum of activation. 
  
In RA, macrophages are responsible for the release of many pro-inflammatory 
cytokines that influence T cell polarisation (Section 1.4.4). IL-12 is involved in 
Th1 polarisation (Section 1.4.4), whereas IL-1β, IL-6 and IL-23 are involved in 
Th17 polarisation. The stimulation by macrophages to skew CD4+ T cells to a 
Th17 phenotype has been considered to perpetuate inflammation due to a 
positive feedback loop between the Th17 cells and macrophages (56). 
Macrophages are present in the intimal lining layer of the synovium, which they 
share with fibroblast-like synoviocytes (FLS). FLS play a pivotal role in RA 
pathogenesis and joint destruction through the secretion of Matrix 
Metalloproteinases, which leads to cartilage destruction and bone erosion (65). 
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FLS, once activated, secrete TNFα, IL-6 and IL-1, which prolongs inflammation 
and they also sustain regulatory feedback loops (66). The crosstalk between 
macrophages and fibroblast-like synoviocytes has been shown to modulate 
macrophage cytokine expression. Macrophage expression of TNF induced genes, 
such as type I interferons, were repressed by FLS, and interestingly IL-4 and 
growth factors such as M-CSF were up-regulated. FLS appear to influence 
macrophage polarisation to a more M2 phenotype (67). This M2-like phenotype of 
IL-10 producing macrophages is specific to the intimal lining macrophages, as the 
sub-lining macrophages have a more heterogeneous phenotype as there are some 
macrophages that secrete IFNγ and some that secrete IL-10 (68). Despite the 
variety of macrophages within the synovium, a large proportion secrete pro-
inflammatory cytokines such as TNFα, IL-6 and IFNγ, thereby exacerbating 
inflammation (69). However, it is unknown what the effect of the synovial 
environment is specifically on the macrophage phenotype. Therefore, this thesis 
aims to evaluate macrophage phenotypes after stimulation with synovial fluid. 
Macrophages are involved with the perpetual inflammation observed in RA due 
to the cytokines and chemokines they release, and their interaction with the 
adaptive immune response. Therefore, targeting macrophages has been 
considered in the treatment of RA. Some therapeutics already in use do 
indirectly target macrophages such as antibodies targeting TNFα, which is a 
cytokine that is readily released by activated macrophages (70).     
1.4.2 Dendritic Cells in RA 
Dendritic cells (DCs) are professional antigen presenting cells, which are 
recruited to the synovium upon the inflammatory insult (71). DCs can be 
classified into 2 major categories derived from a common DC precursor (CDP): 
conventional DCs (cDCs) and plasmacytoid DCs (pDCs). cDCs can then be further 
divided based on their expression of CD1c and CD141 (72,73). These all have a 
distinct function to either stimulate or inhibit the immune response (74). DCs 
are immature in the periphery, however, become activated in response to 
inflammatory mediators such as: pathogen associated molecular patterns (PAMP) 
via C type Lectin receptors or Toll Like Receptors (TLR); or by immune 
complexes (IC) via FCγ receptors (FCγR) (71). Chemokines are involved in the 
recruitment of DCs to the tissue, where they are exposed to the inflammatory 
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mediators. Once activated, DCs migrate to the lymph nodes where they present 
antigen to T cells and release cytokines that lead to T cell maturation (75). In 
RA, synovial DCs are more differentiated than precursors that are isolated from 
RA or normal peripheral blood due to the elevated expression of MHC Class II and 
adhesion molecules (76,77). Synovial fluid contains high numbers of both cDCs 
and pDCs in comparison to the blood suggesting a role for them in disease 
pathogenesis in both antigen presentation and through the release of 
inflammatory mediators (71). 
1.4.3 DAMPs in RA 
Damage Associated Molecular Patterns (DAMPs) are endogenous danger signals or 
alarmins that host molecules rapidly release from damaged or necrotic cells. 
DAMPs are a sterile inflammatory insult that causes activation of Pattern 
Recognition Receptors (PRRs), such as TLRs or C type lectin receptors (78,79). 
They have the ability to mediate an inflammatory response by stimulating the 
recruitment of cells to sites of tissue damage and by activating innate immune 
cells (80). DAMPs include proteins such as high mobility group box 1 protein 
(HMGB1), tenascin c, heat shock proteins, extracellular matrix proteins and the 
S100 group of proteins (81-83). Recent work has suggested that various DAMPS, 
released during synovial damage, are important in RA (82). One particular class 
of DAMP that is elevated in RA SF in comparison to OA synovial fluid are the S100 
proteins (84). It has also been suggested that the S100A9 protein could be used 
as biomarker for methotrexate responsiveness (85). The proteome of PBMCs and 
the serum of methotrexate responders, had higher levels of S100A9 in 
comparison to non-responders at the baseline before treatment (85).  Tenascin 
C, an extracellular matrix glycoprotein, has also been shown to be a contributing 
factor to inflammation and joint destruction in the zymosan-induced model of 
RA in mice. In Tenascin C knockout mice, the inflammation is not sustained in 
the model, and the mice are protected from joint destruction as cell infiltration 
and synovial thickening were reduced (86). In RA patients, Tenascin C was 
identified in circulation and was up-regulated in comparison to controls. After 
treatment with either Methotrexate or anti-TNFα therapy, circulating levels 
were decreased (87). High Mobility Box Group Protein 1 (HMGB1) is another 
DAMP associated with RA pathogenesis. It is a highly abundant and conserved 
protein that is normally within the cell nucleus. It becomes a DAMP when a cell 
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undergoes necrosis and it is released from the cell (88). In the mouse model of 
RA, CIA, inhibition of HMGB1 ameliorated disease, whereas addition of 
exogenous HMGB1 led to a worsening of disease (89). In RA, HMGB1 is up-
regulated in the serum, synovial fluid and synovial tissues, and an inhibitor has 
been considered as a clinical approach for RA treatment (90). DAMPs are pro-
inflammatory as can activate antigen-presenting cells such as monocytes or 
macrophages by binding to PRRs such as TLRs.  
TLRs have been implicated in RA due to their activation upon sensing DAMPS or 
PAMPs within the synovial environment (91). Upon ligand binding, the signalling 
cascade is either MyD88-dependent or MyD88 independent (Figure 1.3). MyD88-
dependent signalling leads to the activation of NFκB and the transcription of 
pro-inflammatory cytokines such as IL-6 and TNFα. MyD88-independent 
signalling, via TRIF, leads to the activation of NFκB and the transcription of type 
I interferons (92). Both MyD88-dependent and MyD88-independent TLR signalling 
have a role in RA, and FLS express high levels of TLRs triggering the secretion of 
multiple pro-inflammatory cytokines and degradative enzymes such as MMPs. 
Monocytes and macrophages in RA also express high levels of TLR2 and TLR4, 
which, when activated lead to the secretion of pro-inflammatory cytokines such 
as TNFα and IL-6 (93). 
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Figure 1.3 TLR Signalling 
TLR4 ligand, such as LPS, binds TLR4 with the co-receptor CD14, and downstream cascades 
signal either via MyD88; leading to a NFkB activation and transcription of pro-inflammatory 
cytokines, or via TRIF; leading to the activation of IRF3 and the transcription of Type I interferons.
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1.4.4 T cells 
There are several flavours of T cells, all with different roles, and RA is 
associated with a Th1 and Th17 immune response (94) (Section 1.4.5). T cells 
are classified as either CD4+ or CD8+. CD4+ T cells can then be divided into 
multiple subgroups depending on their cytokine expression profile. Th1 T cells 
are differentiated from naïve T cells through IL-12 and IFNγ stimulation. Th1 T 
cells are then identified through the predominance of the transcription factor T-
bet, and their production of IFNγ and IL-2. Th2 cells, however, are induced by IL-
4 stimulation; they express the transcription factor GATA3 and produce 
cytokines such as IL-4, IL-5 and IL-13 (95,96). A Th1 immune response evokes 
cell-mediated immunity, whereas a Th2 response induces an antibody-mediated 
response, and is therefore associated with allergy (97). Th1 and Th2 T cells were 
the fore-runners the with regard to T cell polarisation but it is now appreciated 
that there are alternative T cell subsets or polarisation states that differ based 
on their cytokine expression. These subsets include Th17 cells, which have been 
classified due to their production of IL-17A, however they also secrete IL-17F 
and IL-22 (98). They are induced from naïve T cells through stimulation with IL-
1β and IL-23, or TGFβ, IL-6 and IL-23 and they predominantly use RORγT as their 
transcription factor. Treg cells are a regulatory T cell, that are induced by TGFβ 
or IL-2. They are identified by expressing FOXP3 transcription factor, and 
produce TGFβ and IL-10 (95,96,98).  
1.4.5 T cells in RA 
The role of T cells in RA is much more varied and complex than the classical 
expansion of effector T cell clones upon recognition of presented antigen (99). 
In RA, there is not a specific auto-antigen to which T cells are targeted, 
however, some T cells would recognise autoantigen. T cells are a large 
proportion of the cells infiltrating into the synovium, and they are implicated in 
RA pathogenesis. From animal models and previous understanding, RA had been 
traditionally considered a Th1 driven disease. In the CIA mouse model, cytokine 
profiles were analysed and IFNγ was abundant as opposed to Th2 cytokines 
(100,101). Inhibition of IL-12 shown using a knockout mouse and inhibiting 
antibodies to IL-12, led to reduced disease in mice, suggesting a Th1 driven 
disease (101,102). However, more recent evidence has shown that Th17 cells 
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have a more of a role in RA pathogenesis. This became apparent when both IL-6 
deficient mice and IL-23 deficient mice had attenuated disease in the CIA model. 
Both IL-6 and IL-23 are required for Th17 development and the numbers of Th17 
cells in the IL-23 deficient mice were reduced (3,103,104). This finding has been 
confirmed through overexpression of IL-17, which exacerbated disease, or 
inhibiting IL-17, which improved disease (105-107). A high percentage of Th17 
cells have been identified in the synovial fluid of RA patients, compared with 
peripheral blood. IL-17 has also been found in abundance in the synovial fluid of 
RA patients (108,109). Despite the strong case for targeting IL-17 in RA, anti-IL-
17 therapy has not met primary endpoints in efficacy trials (110). However, 
trials are still continuing and there is hope for efficacy in combination with other 
therapies (111).  
Interestingly, there are other subsets of T cells found within the RA joint, which, 
under normal conditions are anti-inflammatory. Treg cells have suppressive 
functions, through suppressing other T cell subsets. They express high levels of 
the IL-2R, thereby up-taking IL-2 and depriving other T cells. They also express 
CTLA-4, which inhibits expression of co-stimulatory molecule CD80. They 
produce the more immunoregulatory cytokines: IL-10 and IL-35 (112). Treg cells 
(CD4+, CD25+) are present in the synovium, however they have a decreased 
ability to control an immune response, as they were unable to regulate pro-
inflammatory cytokines released by effector T cells. Interestingly, after anti-
TNFα treatment, their function was restored (113). 
1.4.6 B cells in RA 
B cells are abundantly found in the synovium of rheumatoid arthritis patients. 
They infiltrate into the synovium and form either diffuse or follicle aggregates 
(114). They have multiple roles including presenting antigen to T cells and the 
activation of T cells. The aggregation of B and T cells, in the form of tertiary 
lymphoid follicles in the synovial membrane, apparent in 60% of RA patients, 
facilitate their interaction (46,115). B cells also produce pro-inflammatory 
cytokines such as IL-6 and IFNγ and the chemokine, CXCL13 exacerbating 
inflammation through the recruitment and stimulation of macrophages and T 
cells (94,116). The differentiated plasma cells produce autoantibodies such as 
rheumatoid factor and anti-cilltrullinated protein antibodies (3,117).  
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There have been studies investigating the role of B cells in RA. µMT mice, which 
are B cell deficient, were resistant to the onset of CIA, although T cell reactivity 
to CII was unaffected between wildtype and µMT mice (118). This showed that 
depleting B cells could be effective as a therapy. Rituximab was initially 
developed for the treatment of lymphoma, through the targeting of CD20, 
present on neoplastic B cells, but not plasma cells (119). It was developed as an 
RA therapy due to the role of B cells in RA (120). Rituximab has been successful 
in some patients but not in others, highlighting the heterogeneity between RA 
sufferers and the variety of treatments required (121).   
1.4.7 Autoantibodies and Immune Complexes 
In RA, there is not a single autoantibody, unlike other autoimmune conditions 
such as Graves’ disease in which antibodies are targeted against the Thyroid 
Stimulating Hormone Receptor (122). However, in RA, several autoantibodies 
have been identified such as rheumatoid factor and anti-citrullinated protein 
antibodies (ACPA) (123,124). In the region of 80% of RA patients are rheumatoid 
factor positive which is an antibody, that is autoreactive against the antigenic Fc 
region of IgG (114). Approximately 75% of RA patients are ACPA positive. They 
have more severe disease than ACPA negative patients (125). ACPA are primarily 
IgG specific to proteins that have been citrullinated such as vimentin, 
fibrinogen, collagen, fibronectin and α-enolase (94,126,127). Citrullination is an 
enzymatic process involving the enzyme Peptidylarginine Deiminase (PAD) 2 or 4, 
which catalyses the conversion arginine to citrulline in a post-translational 
modification. These citrullinated proteins are targeted by autoantibodies in RA 
(128).  ACPAs are correlated with a more destructive form of RA, as it has been 
found that ACPAs can bind to osteoclast surfaces and cause osteoclast 
differentiation leading to bone resorption through the production of IL-8 
(125,129). In mouse studies, the addition of ACPA also causes trabecular bone 
loss (129). ACPAs form immune complexes and bind Fc receptors causing 
activation of monocytes and macrophages leading to the secretion of cytokines 
such as TNFα (127). The binding of immune complexes to cells positive for Fc 
receptors is also thought to induce the complement system, leading to 
exacerbated RA pathogenesis (130). 
36 
 
1.4.8 Synovial Fluid 
The volume of synovial fluid of a normal joint is minimal, and is thought to be 
for the transport of nutrients to the cartilage and lubrication of the joint (131). 
In a diseased joint, the amount of synovial fluid is increased, and contains 
immune cells. The synovial fluid of an RA patient is a complex milieu, containing 
inflammatory cytokines, cell debris, metabolites and immune complexes.  
There have been multiple studies into the contents of synovial fluid and whether 
there are potential biomarkers present (46,85,132). Studies have investigated 
the metabolite profile of RA synovial fluid with non-RA synovial fluid from 
Behçet’s disease, ankylosing spondylitis and gout patients. This analysis 
identified 22 metabolites that were present and higher in synovial fluid of RA 
patients compared with non-RA patients. These included succinate, asparagine 
and citrulline. Interestingly, there were also 10 metabolites that were down-
regulated in RA synovial fluid compared with the non-RA synovial fluid, including 
glycerol and isopalmitic acid. This suggests that the RA synovial fluid metabolite 
profile has some homogeneity with the potential for metabolic biomarkers (132). 
Proteomic analysis of synovial fluid has also been investigated with biomarkers 
and a greater understanding of disease pathogenesis as the potential outcome. 
135 proteins have been identified as differentially expressed at a greater than 3 
fold higher level than OA synovial fluid (133). These include the DAMP S100 
proteins, S100A8 and S100A9, which have been identified in multiple studies in 
RA synovial fluid at higher levels than in OA synovial fluid. Both have been 
suggested as biomarkers to discriminate between RA and other inflammatory 
arthritis (84,133). Of the proteins identified, the majority were extracellular 
matrix or cytoplasmic proteins, however proteins of the plasma membrane and 
nucleus were also identified. Proteins involved in the glycolytic pathway of 
metabolism were also up-regulated, linking the metabolite profile, and the 
potential importance of metabolic changes in a diseased joint (133). 
Interestingly, the proteomic profile is not constant, and changes from early RA 
to more established RA, suggesting that synovial fluid protein biomarkers could 
monitor disease progression (134). 
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PAD enzymes have been identified in RA synovial fluid and are active in 80% of 
synovial fluids tested (128). The presence of active PAD enzymes in synovial fluid 
of RA patients suggests that citrullinated proteins would also be present in 
synovial fluid. Citrullinated fibronectin has been observed in RA synovial fluid, at 
higher levels than in OA patients. However, the level of citrullinated fibronectin 
was not correlated with the level of ACPA in synovial fluid (135). 
The cytokines in synovial fluid are related to ACPA status, as ACPA positive 
patients have more T cell derived pro-inflammatory cytokines, including IL-1β 
and IL-17F, in comparison to ACPA negative patients (136). There are numerous 
cytokines and chemokines that have been observed in RA synovial fluid, 
including IFNα, TNFα, IL-1Rα, IL-1β, IL-10, IL-6, CCL17, CXCL8 and CCL5. These 
have all been found at higher levels than in OA synovial fluid, and some such as 
TNFα, IL-6 and IL-1β have been found to drive RA pathogenesis. Others such as 
IL-10 and IL-1Rα are thought to be involved in regulation of disease, whereas the 
role of the chemokine CCL17, is not as well defined in RA (137-142).          
1.5 Cytokine Pathways in RA 
Cytokines affect the majority of biological processes including disease 
pathogenesis, antigen response, specific cognitive changes, embryonic 
development and ageing (143). In relation to RA, there are cytokines that can be 
classed as pro- or anti- inflammatory. Cytokines play a major part in the 
pathogenesis of RA, and have been implicated in multiple aspects of disease 
processes (144). At each stage of disease from the onset to the resolution of 
disease, cytokines are involved (3). Cytokines have effects on specific target 
cells that can promote further immune responses through cell activation, cell 
localisation and cell longevity in the synovial environment (144). In RA, the pro-
inflammatory cytokines TNFα, IL-1, IL-6 and GM-CSF have been found in 
abundance in the joint at all stages of disease. However, anti-inflammatory 
cytokines IL-10 and TGFβ have also been found at high levels in the RA joint 
perhaps suggesting other roles for these cytokines (3,94,123,144). 
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1.5.1 TNFα  
Tumour Necrosis Factor-alpha (TNFα) is a pro-inflammatory cytokine that plays a 
major role in inflammatory disease, particularly in the pathogenesis of RA. TNFα 
is produced by a variety of cell types, but primarily by monocytes and 
macrophages. The secretion of TNFα is a major cause of synovitis in RA, through 
further induction of pro-inflammatory cytokines such as GM-CSF, IL-1, IL-6 and 
IL-8 by cells such as fibroblast-like synovial cells or monocytes and macrophages 
(145) (146). Stimulation of synoviocytes with TNFα leads to an increase in 
production of IL-6, IL-1 and TNFα, through an autocrine loop (147). The effect of 
TNFα on fibroblast-like synovial cells leads to the prolonged inflammation in the 
joint. TNFα has been implicated in cartilage degradation as stimulating 
chondrocytes with TNFα in ex vivo experiments using bovine and porcine 
cartilage discs, caused cartilage resorption and prevented further synthesis of 
proteoglycan (148,149). In TNF-receptor 1 deficient mice, incidence of disease 
was lower than wildtype controls, however the affected joints progressed to the 
same degree as the wildtype mice, suggesting potentially that it is primarily the 
onset of disease that is TNFα dependent (150). Due to the involvement in RA 
pathogenesis, TNFα was investigated as a potential therapeutic target, and is 
now used as a successful cytokine therapy (Section 1.8.1).  
1.5.2 IL-1 
IL-1 is subdivided into IL-1α and IL-1β, both of which are expressed in the RA 
synovial tissue, with IL-1β expressed, both at the mRNA and protein level, at 
much higher levels than IL-1α (151). IL-1 is produced by monocytes and 
macrophages and has wide ranging effects on synoviocytes, chondrocytes, B and 
T cells through binding to type I IL-1 receptors (152). IL-1β has also been found 
in the serum of RA patients, with levels correlated to disease activity. 
Interestingly, in mouse models of RA using IL-1 deficient mice, there was no 
change in paw swelling or disease incidence. Cartilage erosion was however 
greatly reduced, leading to an implication of IL-1 in the cartilage resorption and 
bone erosion phenotype of RA through the activation of osteoclasts and matrix-
enzyme production by chondrocytes (3,150,152). IL-1 was subsequently 
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investigated as a potential therapeutic, however, it had limited success as a 
cytokine therapy in RA (Section 1.9.1)    
1.5.3 IL-6 
IL-6 is a pro-inflammatory cytokine that has its effects on multiple cell types. 
This is in part due to having both membrane bound and soluble receptors (sIL-
6R), thereby increasing the number of responsive cells (153). IL-6 can induce the 
development of osteoclasts and in conjunction with other cytokines such as 
TNFα can result in bone erosion (154,155). IL-6 also stimulates neutrophil 
migration, and the differentiation of B cells into plasma cells. This is important 
as IgG, IgA or IgM rheumatoid factors as well as anti-citrullinated protein 
antibodies are increased in RA patients and therefore the increase in IL-6 in RA 
patients would lead to increased B cell activity further influencing synovial 
inflammation (153). Mice treated with a monoclonal antibody to IL-6 during the 
CIA model, showed reduced disease scores compared with a control treatment. 
Also, IL-6 knockout mice had significantly lower disease incidence than wildtype 
controls (103).  In patients, IL-6 and sIL-6R are upregulated in RA synovial fluid 
in comparison to OA (156,157). The level of IL-6 in the synovial fluid correlates 
with CRP, a measure of inflammation and therefore disease suggesting an 
important role for IL-6 in RA pathogenesis (157). The IL-6 signalling pathway has 
therefore been targeted, with antibodies generated against the IL-6R for RA 
therapy (Section 1.8.2). 
There are other cytokines that are important in RA pathogenesis. This includes 
GM-CSF, which will be discussed in Section 1.10. 
1.6 Chemokines in RA 
1.6.1 Chemokine structure and function 
Chemokines, or chemotactic cytokines, are small proteins that direct the 
migration of leukocytes (158). There are four conserved cysteines with 
intramolecular disulphide bonds, which dictate the tertiary structure of the 
chemokine. The nomenclature of chemokines is determined by the position of 
the first two cysteines. The cysteines of CC chemokines are adjacent, whereas in 
CXC chemokines, the cysteines are separated by one amino acid. (159). 
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Chemokines have multiple functions but their main role is to direct leukocyte 
migration in homeostasis and inflammation as well as to stimulate cells to  
release further pro-inflammatory mediators such as cytokines (160). 
To fulfil their function, chemokines bind specific chemokine receptors, which 
are G protein-coupled receptors (GPCRs), and cause rapid structural change 
within the cell through the conformational change of actin and activation of 
integrins (159). The length of the N-terminal domain determines ligand 
specificity as truncation of this domain can change receptor specificity, which is 
the case for CXCL7 and CCL2 (161). Chemokine receptors are classified according 
to the chemokine ligands in which they bind (162,163). However, not all 
receptors bind chemokines within their own class, as there are chemokine 
receptors that bind multiple chemokines (Table 1.2). There are 10 CC chemokine 
receptors and 6 CXC chemokine receptors as well as a single CX3CR and an XCR 
(162-164). The ability of chemokine receptors to bind multiple chemokines 
allows the system to have a redundancy mechanism (165). 
Multiple chemokines are involved in the immune response, however there are 
some that are considered to have important roles in RA pathogenesis. CXCL8, 
CXCL10 and CCL2 are chemokines that are secreted by innate immune cells such 
as monocytes and macrophages (158). CCL17 currently is not associated 
specifically with RA pathogenesis, however this thesis aims to investigate a 
potential role for this chemokine in disease.  
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Table 1.2 Chemokine Receptors and their chemokine ligands 
 
1.6.2 CXCL8 (IL-8) 
High levels of CXCL8 have been found in multiple areas of RA synovial tissue, 
including the synovial fluid and synovial membrane (166). Interestingly, the 
presence of CXCL8 in RA is not just confined to the inflamed joint, but 
systemically, as serum levels have been found at elevated levels. The level of 
CXCL8 in the sera correlated with the levels of CXCL8 in the synovial fluid 
suggesting a strong inflammatory response (166,167). The role of CXCL8 in RA is 
not well defined; however, there is evidence to suggest CXCL8 is involved in the 
recruitment of neutrophils to the inflamed joint and angiogenesis (160,167-169). 
The use of an anti-IL-8 antibody in the LPS induced arthritis model in rabbits, 
showed a reduction in neutrophil infiltration thereby leading to reduced 
inflammation in the synovial membrane. However, this was only at the early 
Chemokine Receptor Ligands 
CC Receptors  
CCR1 CCL3, CCL3L1, CCL5, CCL7, CCL8, CCL14, CCL15, CCL16, 
CCL23 
CCR2 CCL2, CCL7, CCL8, CCL13, CCL16 
CCR3 CCL5, CCL7, CCL8, CCL11, CCL13, CCL15, CCL24, CCL26, 
CCL28 
CCR4 CCL17, CCL22 
CCR5 CCL3, CCL3L1, CCL4, CCL4L1, CCL5, CCL8 
CCR6 CCL20 
CCR7 CCL19, CCL21 
CCR8 CCL1 
CCR9 CCL25 
CCR10 CCL27, CCL28 
  
CXC Receptors  
CXCR1 CXCL6, CXCL8 
CXCR2 CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXCL8 
CXCR3 CXCL9, CXCL10, CXCL11 
CXCR4 CXCL12 
CXCR5 CXCL13 
CXCR6 CXCL16 
  
CX3C Receptor  
CX3CR1 CX3CL1 
  
XC Receptor  
XCR1 XCL1 
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stage of inflammation, as in a later phase, there was mononuclear cell 
infiltration and inflammation of the tissue, due to other chemokines such as 
CCL2 (170). Therapies targeting CXCL8 with an anti-CXCL8 antibody have not 
been published but there was no clinical improvement in RA patients and there 
was a rise in total CXCL8 levels in circulation (160).  
1.6.3 CXCL10 
CXCL10, also known as IP-10, is induced by stimulation of monocytes with IFNγ 
and binds CXCR3 (Table 1.2) leading to the migration of activated T cells. 
Neutralisation of CXCL10 leads to an inability of effector T cells to be recruited, 
which was shown in a model of Experimental Autoimmune Encephalomyelitis 
(EAE) (171,172). CXCL10 is upregulated in the synovial fluid of RA patients 
compared to OA patient synovial fluid. In rheumatoid factor positive patients, 
serum levels of CXCL10 are also elevated (166). Macrophages and fibroblasts of 
the RA synovial tissue express high levels of CXCL10 (173). There is also evidence 
to suggest that CXCL10 induces osteoclastogenesis through the positive feedback 
loop with RANKL. RANKL induces CXCL10 in osteoclast precursors, which thereby 
upregulates RANKL expression in T cells in the synovium (174). A neutralising 
CXCL10 antibody has been used in the mouse model of CIA, which led to 
significantly inhibited infiltration of CD4+ T cells and macrophages into the 
synovium of the joint. Furthermore this led to decreased levels of RANKL and 
therefore attenuated bone erosion (174,175). Current studies, therefore, suggest 
that CXCL10 is important in rheumatoid arthritis pathogenesis, and the crosstalk 
between CXCL10 and RANKL drives the infiltration of inflammatory cells into the 
synovium and subsequent bone erosion (174).   
1.6.4 CCL2 
CCL2, also known as MCP1, is a chemokine that binds CCR2 and directs migration 
of monocytes. CCL2 is expressed by multiple immune cells and therefore plays 
an important role in the inflammatory response. In rheumatoid arthritis, CCL2 
and CCR2 are highly expressed in the synovial tissue (176). In a mouse model of 
CIA, using an anti-CCL2 monoclonal antibody during the initiation of CIA showed 
significantly lower disease scores, and significantly lower histological scores at 
multiple sites within the joint. Interestingly, when the anti-CCL2 antibody was 
43 
 
used as a therapeutic, during the progression of the disease, there was 
exacerbation of disease, with mice showing an increase in clinical and 
histological scores (177). This suggests that the infiltration of leukocytes into the 
joint is not specifically reliant on CCL2. Furthermore, a human clinical trial 
evaluating the blockade of CCR2, revealed that blockade had no positive effects 
and also led an increase in the circulation of bioactive CCL2: somewhat similar 
to the effect of blocking CXCL8 (160,178).  
1.6.5 CCL17 and CCR4 
CCL17 also known as Thymus and Activation-Regulated Chemokine (TARC) is 
found in abundance in the thymus and is released by CD1c+ dendritic cells upon 
stimulation with primarily thymic stromal lymphopoietin (TSLP). TSLP is induced 
by multiple cytokines such as TNFα, IL-1β and IL-4 in multiple cell types and is 
thought to play a role in RA. Mouse models of RA in TSLPR null mice have shown 
a decrease of severity and less incidence of disease in comparison to wild type 
mice suggesting a role for TSLP signalling in RA (179,180). After TSLP induces 
CCL17, it binds CCR4, and causes migration of CCR4 positive T cells.  
CCR4 is the receptor not only for CCL17 but also for CCL22. CCL22 is more 
potent at inducing CCR4 internalisation than CCL17 and has also been implicated 
in disease (181). Internalisation of the chemokine receptor is important for 
receptor desensitisation and the ability of cells to continuous changes in 
chemotactic gradients (181). CCR4 is primarily, but not exclusively, found on 
Th2 cells, and therefore there are several studies implicating CCL17 and CCL22 
in Th2 driven disease (180). Atopic dermatitis is an example of a Th2 specific 
disease and high levels of CCL17 have been found in the inflamed skin. In a 
mouse model, treatment with a steroid ointment led to a very large decrease in 
CCL17 expression and reduction in disease severity. This involvement of CCL17 in 
atopic dermatitis has led to its use as a biomarker (182). 
CCR4 is also expressed on Th17 cells (Section 1.4.4), which have been implicated 
in the pathogenesis of several autoimmune diseases such as multiple sclerosis as 
well as RA. Th17 cells have been found in abundance in the joints of RA patients, 
and positively correlated with disease progression. Synovial Th17 cells express 
CCR4, suggesting a role for CCR4 and its ligands in RA (183). 
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Interestingly, Treg cells also express CCR4, suggesting a more regulatory role for 
CCR4, CCL17 and CCL22. CCR4+ Treg cells have been shown to migrate towards 
the chemokine ligand CCL22 in lymphoid infiltrates surrounding breast cancer 
tumours (184). Tregs also migrate to inflamed lungs in allergic inflammation, 
attenuating inflammation (185). 
The role of CCL17 in RA is not as well understood. However, CCR4, the 
chemokine receptor for CCL17 has been studied. In the mouse model of CIA, 
CCR4 null mice had significantly reduced incidence of arthritis and significantly 
lower disease scores than the wildtype control(186). This suggests that there is a 
role for CCR4 positive cells in RA. There is limited data linking CCR4 to human 
disease, and there is no correlation linking CCR4 positive CD4 T cells with 
disease activity. However, CCR4 is expressed on PBMCs at significantly higher 
levels in RA patients than in healthy controls. As CCL17 is one of the 2 ligands 
for CCR4, potentially CCL17 is also involved in RA pathogenesis. CCL17 has been 
investigated in the RA patient sera, however there was no significant difference 
compared with controls (187). However, in RA synovial fluid, CCL17 is much 
more highly expressed than in OA synovial fluid (137).  
1.7 Treatment of RA 
The aim of therapy in RA is to maximise quality of life through the control of RA 
symptoms and prevention or joint erosion. The most effective way of enabling 
this control of symptoms is to dampen the inflammation in order to reach 
clinical remission whereby there is an absence of disease activity signs and 
symptoms (188). To measure the effectiveness of therapies, disease activity 
scores such as DAS28 and DAS40 as well as CDAI and SDAI are used as measures of 
clinical remission (189). 
1.7.1 DMARDs 
Disease Modifying Anti-Rheumatic Drugs (DMARDS) such as sulfasalazine, 
hydroxychloroquine and azathioprine are the first method of treatment for RA, 
with Methotrexate (MTX) the most commonly used in the first instance (190). 
The mode of action of methotrexate in RA is still not completely understood, 
however there are multiple areas in which it could be having its effects. MTX 
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was initially used as a specific antagonist to folic acid to have anti-proliferative 
effects on malignant cells by inhibiting synthesis of purines and pyrimidines. Low 
dose MTX was initially used as a treatment for RA as it was assumed the anti-
proliferative properties it possessed, would be beneficial to inhibit the 
proliferation of lymphocytes (191). This led to an improvement in disease and 
with the addition of folic acid to treatment, this prevented some of the toxicity 
associated with MTX (191). However, after multiple trials, it was determined 
that to dampen inflammation, MTX, had to have more wide-ranging effects than 
just an anti-proliferative effect on leukocytes (192). MTX has inhibitory effects 
on neutrophils as well as monocytes and macrophages, all of which impact upon 
synovial inflammation. At a biochemical level, MTX causes an overproduction of 
adenosine which prevents production of multiple inflammatory cytokines such as 
TNFα, IL-8, IL-12 and IFNγ from lymphocytes (192). These are just a few of 
multiple effects that have been discovered, and explain some of the mechanisms 
of MTX action in RA treatment. However, approximately only a third of patients 
respond well enough to MTX, and if there is not a great enough effect, biologic 
therapies are the next method of treatment (193,194). Interestingly, MTX has 
been described as the ‘anchor drug’ as the majority of clinical trials for new 
therapies, compare responses to MTX (193,195). 
1.7.2 Therapeutics 
Development of targeted biologic therapies were the next major advance in RA 
therapy as these drugs specifically target molecules responsible for disease 
pathogenesis (196). There are now multiple cytokine therapies that have been 
developed both with and without success, for example TNFα inhibitors such as 
etanercept, the IL-1 inhibitor anakinra, anti-IL-17 inhibitors such as Secukinumab 
and the anti-IL-6R Tocilizumab. There are other therapies such as abatacept 
which is an immunomodulatory drug that inhibits T cell activation through the 
CD80/86-CD28 costimulatory signal (196,197). There has also been specific cell 
targeted therapy such as rituximab, which is a monoclonal antibody that binds to 
CD20, on B cells, and leads to B cell depletion (196).  Small molecule inhibitors 
have also been developed, targeting signalling pathways that are important in 
the pathogenesis of RA such as Tofacitinib which inhibits JAK1 and JAK3, thereby 
preventing STAT1 activation, and preventing secretion of cytokines such as IL-6 
and IFNγ in naïve CD4+ T cells (198). 
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1.8 Successful cytokine therapies 
There has been varying success with the cytokine therapies that have been 
developed. TNFα inhibition was the first cytokine therapy to be developed and 
has been very successful; showing that targeting the cytokine network and 
disrupting the inflammatory communication mechanism can have a positive 
impact on disease outcomes (199).  
1.8.1 TNFα  Inhibition 
TNFα was initially determined as a good cytokine to target in RA as: several 
other pro-inflammatory cytokines depend on TNFα; both TNFα and the TNF-R 
are upregulated in diseased synovium; and an anti-TNFα antibody prevented 
joint destruction and decreased disease severity in the mouse model CIA (200). 
In the CIA model of RA, addition of an anti-TNFα antibody for a week preceding 
the induction of disease, and during the course of disease showed that the 
clinical score was significantly lower in the anti-TNFα treated animals in 
comparison to PBS treated controls. The histopathological analysis also showed 
less severe arthritis (201). In a CIA model using an anti-TNFα antibody as a 
therapeutic, 2-3 weeks after induction of disease, there was less TNF in the joint 
of immunised mice and significantly reduced footpad swelling at 1 and 3 months 
post induction of disease (202). A neutralising, chimeric anti-TNFα monoclonal 
antibody was first tested in man in 1993 and showed that the antibody was safe 
and positive for efficacy, with a 97% improvement of morning stiffness (203). In 
further clinical trials, it was established that inhibition of TNFα was effective in 
treating patients who were not responders to MTX (204). The mechanism of 
action of anti-TNFα therapy is due to the downregulation of cytokine cascade as 
cytokines such as IL-6, IL-1 and GM-CSF are downstream of TNFα stimulation. 
Also, the migration of leukocytes into the joint is decreased due to the 
downregulation of endothelial adhesion molecules such as ICAM-1, E-selectin and 
VCAM-1. Anti-TNFα also reduces angiogenesis via downregulation of VEGF 
(200,205). The success of TNFα inhibition has led to the development of multiple 
therapeutics targeting TNFα including etanercept, infliximab and adalimumab 
(206). These biologics all target TNFα, however, infliximab and adalimumab are 
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both antibodies against TNFα, whereas etanercept is a construct involving two 
p75 TNFα receptors coupled to the Fc portion of human IgG (207). 
1.8.2 IL-6R blockade 
After the success of inhibiting TNFα, blockade of IL-6 was investigated due to its 
role in RA pathogenesis (see 1.8.2). Initially, in the CIA mouse model, a 
monoclonal antibody to the IL-6R was administered at the initiation of disease 
and led to significantly decreased disease scores over the course of the disease 
period. Interestingly, in this model when the anti-IL6R antibody was tested at 
multiple different days after induction of disease, only when administered at 
day 0 or day 3 showed a reduction in disease (208,209). After the success of 
inhibition of IL-6R in mouse, this was translated into the clinic. Tocilizumab is a 
humanised monoclonal antibody that binds to both IL-6R and sIL-6R, and was 
developed for treatment of RA. In clinical trials, inhibition of the pro-
inflammatory effects by IL-6 through blockade of both soluble and membrane 
bound IL-6R by Tocilizumab showed significant improvements in disease with 
significantly more patients attaining ACR20, ACR50 and ACR70 than the placebo 
control (210). This has led to more treatment options, due to the numbers of 
patients that are non-responders or intolerant to DMARDS and anti-TNFα therapy 
(211).       
1.9 Unsuccessful cytokine therapies 
1.9.1 IL-1 inhibition 
IL-1RA is produced by synovial tissue and it localised primarily to the 
perivascular macrophages at both an mRNA and protein level. It binds to IL-1 and 
acts as a competitive inhibitor of IL-1 to its membrane bound receptor 
(212,213). As the addition of IL-1β directly induces arthritis when injected into 
joints, and blockade of IL-1 in CIA led to decreased bone resorption and 
degradation, IL-1 became a cytokine to target for the treatment of RA (213,214). 
Due to IL-1RA already endogenously inhibiting IL-1, recombinant IL-1RA 
(Anakinra) was investigated as a therapy in RA patients (215). In safety and 
efficacy trials, Anakinra caused 41% less radiologic joint damage compared with 
placebo receiving patients (213). However, a subsequent trail in patients who 
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were unresponsive to TNFα inhibition was unsuccessful, as after 3 months of 
therapy, only 8% of patients received an ACR20 response with none receiving an 
ACR50 or ACR70 response. There was also an increase in the mean level of C-
reactive protein and tender swollen joints showing that patients unable to 
respond to TNFα treatment, will also not respond to IL-1 blockade (216). Despite 
Anakinra not showing success in RA, it is a successful treatment for auto-
inflammatory conditions such as Juvenile Idiopathic Arthritis, gout, Cryopyrin 
Associated Periodic Syndromes and Adult Onset Still’s Disease (2,215,217,218). 
1.9.2 Unmet Need 
Despite the new cytokine therapies that have revolutionised RA treatment 
strategies, there are still a number of patients who do not respond to TNFα 
inhibition or IL-6R blockade. Only 60-70% of patients respond to TNF blockade 
regardless of DMARD status (219). Therefore, there are still a large percentage 
of patients who have no further treatment options and are living with a 
debilitating disease. It is for this reason, that there is still ongoing research into 
other biologics including other cytokine therapies. This project aims to look at 
the role of GM-CSF in RA with regards to Mavrilimumab, an anti-GM-CSFRα 
antibody that has been developed as a therapeutic for the treatment of RA.  
1.10 GM-CSF 
GM-CSF has traditionally been considered a growth factor important in the 
maintenance and differentiation of bone marrow derived monocytes. However, 
GM-CSF has since been shown to have multiple functions in the regulation and 
activation of granulocytes and macrophages during inflammatory insults, 
differentiation and proliferation (220,221). GM-CSF is therefore considered a 
pro-inflammatory cytokine due to the effects it has on cell activation.  
1.10.1 Biology 
GM-CSF is a cytokine that is secreted from multiple cell types including 
fibroblasts, T cells, B cells, endothelial cells, epithelial cells and macrophages 
(222). Stimulation from sources such as LPS or TNFα can lead to the secretion of 
GM-CSF from these cells (223). The GM-CSF receptor is heteromeric and formed 
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of an alpha and beta chain. Myeloid cells and non-haematopoietic cells such as 
alveolar epithelial cells and endothelial cells express the GM-CSFR, but it is not 
expressed on T cells (222-224). The β chain of the GM-CSFR constitutively 
associates with JAK2, however, both cytoplasmic domains are crucial for 
receptor activation (222,225). The binding of GM-CSF initiates JAK2 auto-
phosphorylation and activation of STAT5, MAPK or PI3K signalling pathways 
(Figure 1.4). JAK2 has potent signalling effects and therefore suppressor of 
cytokine signalling (SOCS) inhibits JAK2 by targeting it for degradation (221). 
GM-CSF has a range of functions on mature cells including polarisation of 
macrophages to what is considered an M1, pro-inflammatory phenotype, 
stimulating them to produce cytokines such as TNFα and IL-6 (226). GM-CSF 
primes neutrophils to become more phagocytic and upregulates the integrin 
CD11b causing more adhesion to the vascular endothelium and entry into the 
tissue (227). Mature dendritic cell cross-presentation is increased by GM-CSF 
stimulation and it can influence differentiation of monocytes (228). Elevated 
levels of GM-CSF have been associated with inflammatory conditions including 
RA (229). 
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Figure 1.4 GM-CSFR signalling 
The α and β chains of the GM-CSFR form a dodecamer with multiple GM-CSF binding sites. JAK2, 
which is constitutively associated with the β chain becomes activated upon GM-CSF signalling. The 
signalling cascades are via STAT5, MAPK or PI3K. SOCS is an inhibitor of JAK2.
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1.10.2 Clinical Relevance 
GM-CSF is considered to play a role in multiple inflammatory conditions. In RA 
there have been many studies to elucidate how GM-CSF exacerbates 
inflammation. It was initially thought that as GM-CSF causes the secretion of 
many pro-inflammatory cytokines, GM-CSF depletion could ameliorate disease by 
reducing TNFα and IL-1 (220,230). Interestingly, in GM-CSF null mice, there was 
no defect in myeloid cell development, however, in the lungs of these mice 
there was defective alveolar macrophage maturation and an accumulation of 
surfactant (231). The effect of the loss of GM-CSF in mice was studied in mouse 
models of RA, including the CIA model and mBSA/IL-1 experimental arthritis 
model. In both of these models of arthritis, the GM-CSF null mice had reduced 
disease scores, reduced incidence and improved histological scores (232,233). 
This was confirmed with both prophylactic and therapeutic treatment with an 
anti-GM-CSF antibody in the acute streptococcal wall arthritis model, where 
disease was significantly improved after antibody treatment (234,235). The 
opposite effect occurred when GM-CSF was overexpressed in the CIA model of 
arthritis. Recombinant GM-CSF treatment of mice led to significantly worse 
disease and histological scores in comparison to the vehicle controls (236). This 
mouse data both using a GM-CSF knockout and therapeutic treating with an anti-
GM-CSF antibody confirmed that GM-CSF has a pathogenic role in murine models 
of RA. These studies led to further investigation and the initiation of targeting 
GM-CSF with monoclonal antibodies in human disease. 
1.10.3 Targeting GM-CSF 
GM-CSF and its receptors are found in abundance in the synovial membrane and 
synovial tissue of patients with RA in comparison to healthy controls and OA 
patients (237). Co-localisation of the GM-CSFRα with CD68 and CD163 was also 
observed suggesting expression of the GM-CSFRα on monocytes and macrophages 
(238). Translating the data observed in mice, into human began with in vitro 
studies, demonstrating that PBMCs stimulated with GM-CSF could produce TNFα 
in a dose dependent manner (239). Inhibition of GM-CSF signalling was possible 
via blockade of GM-CSF itself through neutralising antibodies or specific binding 
of antibodies to the receptor. This has led to two therapeutics, Mavrilimumab 
and MOR103 that are currently being tested in clinical trials (229).  
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Mavrilimumab (CAM3001) is a fully human monoclonal antibody, which targets 
the α chain of the GM-CSFR. In an initial mouse model, Mavrilimumab showed a 
dose dependent reduction in clinical score in already established CIA (238).  
Acceptable safety profiles were observed in cynomolgus monkeys, and the phase 
I clinical trial using a single, escalating intravenous dose of Mavrilimumab in 
patients with RA demonstrated an appropriate safety profile (240,241). Phase IIa 
clinical trials showed improved signs and symptoms of RA patients on 
methotrexate treatment but with active disease. This was demonstrated as the 
DAS28-CRP was improved at the highest doses of 50 and 100mg at week 2, which 
continued throughout the 12 week treatment. The phase IIb clinical trial was 
also successful with all the primary endpoints achieved. The AR50, ACR70 and 
DAS28 remission score was also significant at the highest dose of 150mg in 
comparison to the placebo (242). 
MOR103 is a fully human, high affinity monoclonal antibody targeted to GM-CSF, 
which was initially developed for the treatment of multiple sclerosis (MS). This 
has now reached phase IIb trials for the treatment of MS, however for the 
treatment of RA, the phase Ib and phase IIa trials examined safety in a dose 
escalation study. Preliminary evidence suggested that MOR103 was efficacious 
with improvements in DAS28 scores at both 1.0 and 1.5mg/kg groups (229,243). 
The results of targeting both GM-CSF and its receptor in clinical trials are 
positive. Inhibiting GM-CSF signalling prevents pro-inflammatory cytokine 
secretion, which attenuates pathogenesis (229).  However, the downstream 
effects of GM-CSF blockade are still unknown. 
1.11 Hypothesis and Aims 
The effect of GM-CSF on cells of the myeloid compartment in rheumatoid 
arthritis is not well understood, therefore the aim of this project has been to 
unravel the impact of GM-CSF on myeloid cells in the synovial environment. We 
hypothesised that GM-CSF up-regulates chemokines in monocytes and that the 
synovial environment impacts myeloid cell phenotypes leading to an increase in 
inflammatory mediators.  
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GM-CSF exacerbates the mouse model of RA, CIA, through the induction of pro-
inflammatory cytokines such as TNFα and IL-1β (234). Mavrilimumab has also 
shown success in clinical trials through the inhibition of GM-CSF (244). However, 
the mechanisms of GM-CSF on RA pathogenesis have not been investigated in a 
human system. The purpose of this project is to create an in vitro system to 
mimic disease, to further analyse myeloid cells, specifically monocytes and 
macrophages. The secretion of chemokines from monocytes will then be 
examined after GM-CSF stimulation, in synovial stimuli. Also the effect of the 
synovial environment on macrophage phenotypes will be assessed to determine 
whether the macrophage changes its phenotype when polarised with disease 
stimuli and whether Mavrilimumab treatment alters this.  
We hypothesise that GM-CSF will be involved mechanistically in leading to an 
inflammatory monocyte in the synovial environment. Also, that the synovial 
environment will exacerbate the secretion of inflammatory mediators from 
monocytes. The monocyte-derived cells or macrophages derived with synovial 
fluid, we hypothesise to have a distinct inflammatory phenotype that respond to 
Mavrilimumab treatment. The following aims will specifically be addressed: 
• How do monocytes respond to GM-CSF stimulation and does the synovial 
environment impact this? 
• How is the secretion of CCL17 regulated in monocytes in an inflammatory 
environment? 
• Can synovial fluid be used to create a disease-like macrophage that can 
be used as a robust tool for analysing phenotypic changes in response to 
therapeutics? 
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Chapter 2 Materials and Methods 
2.1 Patients and Controls 
All samples were obtained from buffy coats, healthy volunteers or RA patients. 
The RA patients were identified from Rheumatology clinics in Glasgow Royal 
Infirmary and fulfilled the 2010 ACR/EULAR criteria for RA. For the peripheral 
blood samples, patients were not taking biologic therapies and they had active 
disease. Samples were obtained after written consent, with ethical approval 
granted by the West of Scotland Research Ethics Committee. 
2.2 Primary Human Cell Culture 
2.2.1 Isolation of PBMCs from buffy coats and peripheral blood 
Peripheral blood mononuclear cells (PBMCs) were separated from human buffy 
coats (Scottish National Blood Transfusion Service) by density gradient 
centrifugation. Buffy coats were diluted in dPBS (Gibco) at a 1:1 ratio whereas 
peripheral blood was not diluted. 5-8ml was layered onto 3ml Histopaque-1077 
(Sigma-Aldrich) in 15ml centrifuge tubes. This was centrifuged at 400g for 30 
minutes, at room temperature with no brake. The PBMC layer was removed, 
transferred into a 50ml falcon tube and washed twice in sterile dPBS (Gibco), 
centrifuging between washes (300g, 1x 10 minutes, 1 x 5 minutes). Cells were 
then resuspended in 10ml cell separation media (Appendix). In order to count 
viable cells, 50µl cell suspension was added to 200µl dPBS. This was further 
combined at a 1:1 ratio with trypan blue (Sigma) for dead cell exclusion, 
counted using a haemocytometer and visualised using a light microscope. The 
value obtained from one main square was equal to the number of cells x 106 in 
10ml. After a further centrifuge at 300g for 5 minutes, cells were resuspended at 
5 x 107 per ml in cell separation media (Appendix) and added to a capped 6ml 
polystyrene tube (BD falcon). 
2.2.2 Purification of T cells from PBMCs 
CD4+ T cells were separated using the EasySep CD4+ enrichment kit (Stem Cell 
Technologies), to negatively select for CD4 cells. Initially, the antibody cocktail 
was added to the PBMCs at a concentration of 50µl/ml for 10 minutes at room 
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temperature. The magnetic beads were added at a concentration of 100µl/ml 
for 5 minutes at room temperature. The volume was made up to 2.5ml before 
placing in a purple magnet (Stem Cell Technologies) for 5 minutes. The required 
CD4+ cells were negatively selected by inverting the magnet, with the tube 
inside. These cells were counted (2.2.1), divided into 3 equal samples and 
centrifuged. Of these CD4+ samples, 2 were further processed to generate 
CD45RA+ and CD45RO+populations. These separations were also using negative 
selection kit, therefore to separate CD45RA+ cells, a CD45RO Tetrameric 
Antibody Complex (TAC) depletion kit (Stem Cell Technologies) was used. Cells, 
at 5 x 107/ml, were incubated with the antibody, at a concentration of 20µl/ml 
for 15 minutes. 100µl/ml of Anti-biotin TAC was added for 10 minutes, prior to 5 
minutes with 50µl/ml magnetic beads, and 5 minutes in the magnet before 
inverting the magnet and isolating the CD45RA+ cells. For the CD45RO selection, 
a CD45RA TAC depletion kit (Stem Cell Technologies) was used. The CD45RA TAC 
was added to the cells for 15 minutes, prior to the addition of 50µl/ml magnetic 
beads for 5 minutes. The tube was placed in the magnet for 5 minutes, inverted 
and the CD45RO cells collected.  
2.2.3 T cell stimulation 
The CD4+, CD45RA+ and CD45RO+ T cells were cultured at 1 x 105 cells per well in 
T cell media (see appendix) in 96 well plates with or without 5 x 104 
αCD2/CD3/CD28 beads (Miltenyi Biotech) per well and human recombinant 
CCL17 (Peprotech) at 100ng/ml or 500ng/ml.  Cells were cultured for 24 or 48 
hours, where supernatants were collected and analysed for GM-CSF secretion by 
ELISA (2.7.2) 
2.2.4 Purification of Monocytes from PBMCs 
Monocytes were separated using the EasySep Human monocyte enrichment kit 
(Stem Cell Technologies), to negatively select for CD14+ cells without depleting 
CD16+ cells, as per manufacturer’s instructions. Firstly, the antibody cocktail 
was added to PBMCs (Section 2.2.1) at a concentration of 50µl/ml, incubating on 
ice for 10 minutes. The addition of the magnetic beads at a concentration of 
50µl/ml followed this for 5 minutes on ice. The tube was then made up to 2.5ml 
with cell separation media and the cap removed before adding to a purple 
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EasySep magnet (Stem Cell Technologies). After 2.5 minutes incubation, the 
magnet, with the tube inside, was inverted, and these negatively selected cells 
collected. The cells remaining in the tube were resuspended in a further 2.5ml 
cell separation media, and placed back in the magnet a further 2 times for 
maximum return. Enriched cells were counted as specified in 2.2.1, washed, 
centrifuged (300g, 5 minutes) and resuspended in complete RPMI media (see 
appendix) at the desired concentration for each experiment. 
2.2.5 Macrophage differentiation 
Recombinant human M-CSF (Peprotech) was added at 100ng/ml and 1ml of cells 
at 1x106/ml were seeded in 24 well plates (Corning, Sigma Aldrich) and 
incubated at 37°C, 5% CO2 for 7 days. Cells were washed twice with warm sterile 
dPBS, and the complete media replaced with 300µl media with 100ng/ml M-CSF 
for M0 phenotype, 20ng/ml IFNγ (Sigma-Aldrich) for M1 phenotype, 100ng/ml IL-
4 (R&D systems) for M2 phenotype, and 100ng/ml GM-CSF (R&D systems) for M-
GM phenotype. 
2.2.6 Monocyte stimulation 
Monocytes and macrophages were stimulated with 2.5%, 5% or 10% synovial fluid 
in complete media (detailed in figures) from Rheumatoid Arthritis, Osteoarthritis 
or Psoriatic Arthritis patients for 24 hours at 37°C. LPS (Invivogen) was used at 
15.63ng/ml or 10ng/ml (detailed in figures).  CAM3001 (Mavrilimumab) and 
CAT004 (Isotype) were used from a top concentration of 10µg/ml in monocyte 
stimulations. Tofactitinib (LC Labs), using DMSO as the vehicle, was used at a 
top concentration of 1000nM in 0.001% DMSO. All pre-treatments were for 30 
minutes prior to initiation of the assay. 
2.2.7 Monocyte genetic manipulation 
NTER transfection reagent (Sigma Aldrich) was used according to manufacturer’s 
instructions. In brief, control siRNA (Dharmafect) and SOCS3 siRNA (Dharmafect) 
were pre-incubated with the NTER peptide at a concentration of 50nM for 15 
minutes at 37°C. 1x105 monocytes were cultured in RPMI with 10% human serum 
in 300µl in a 24 well plate. The siRNA-NTER peptide complex was added drop-
wise into each well and cultured for 6 or 24 hours (detailed in figures) prior to a 
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media change and further stimulation for 24 hours. Transfection efficiency was 
confirmed by FACS (Section 2.9) using labelled, control siRNA. Knockdown was 
confirmed by qPCR (Section 2.6.3) using Taqman primers for SOCS3 (Life 
Technologies, Hs02330328_s1), and beta-actin as the housekeeping control (Life 
Technologies, Hs01060665_g1).  
2.3 Immune Complexes 
2.3.1 Small Immune Complex Formation 
Using the previously established method (245), Staphylococcal Protein A (SpA)  
immunoglobulin complexes were formed using human IgG and SpA. 25µg/ml 
human IgG (Jackson Immunochemicals) was centrifuged at 8000g to remove large 
IgG complexes, and incubated with 1.56µg/ml SpA (Repligen) (1:4 molecular 
weight ratio) for 1 hour at 37°C. This allowed the formation of complexes with 4 
IgG molecules and 2 SpA molecules. After the formation of the complexes, dPBS 
was added to dilute the complexes, for a final 1 in 20 dilution for use in assays. 
Equivalent amounts of Human IgG, and SpA were used alone as controls for SIC. 
2.3.2 Depletion of Immune Complexes from Synovial Fluid 
Protein A (Life Technologies), Protein G (Life Technologies) or Protein A/G/L 
(Biovision, Cambridge Biosciences) magnetic beads were placed in an eppendorf, 
washed with the appropriate buffer, according to manufacturer’s instructions, 
and placed on a magnet. The supernatant was removed, and 2 further washes 
with dPBS were performed, with vortexing in between. 500µl synovial fluid was 
added directly to the beads at the recommended concentration (supplier 
dependent), and incubated at room temperature with end over end mixing for 1 
hour. The eppendorfs were placed back on the magnet, and the depleted 
synovial fluid removed. This synovial fluid was placed back onto a magnet to 
ensure all magnetic beads had been removed. The depleted synovial fluid was 
then used to stimulate monocytes. 
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2.4 Fluorescent labelling 
2.4.1 Pacific blue labelling of antibody 
Using the pacific blue monoclonal antibody labelling kit (Life Technologies), 
CAT004 (MedImmune) was fluorescently labelled. The conjugation reaction was 
performed by adding 10µl 1M sodium bicarbonate buffer to 1mg/ml antibody 
(diluted in PBS). 100µl of the protein solution was added to the vial of reactive 
dye and inverted several times to fully dissolve the dye. This was incubated at 
RT for 1 hour with inversions every 15 minutes. To prepare the spin column, the 
resin was added to the top of the column allowed to settle and then centrifuged 
for 3 minutes at 1100g. 100µl of the reaction volume was added drop-wise to the 
centre of the spin column and allowed to absorb into the gel bed. This was 
centrifuged at 5 minutes at 1100g and the labelled protein collected in the spin 
column. The labelled CAT004 was then used for FACS (Section 2.9) 
2.5 Mice 
2.5.1 Extraction of bone marrow monocytes 
Bone marrow was extracted from either WT C57BL/6 mice or MyD88/TRIF 
knockout mice (courtesy of Prof Rick Maizel, Edinburgh). Mice were euthanized 
and the hind legs including both the femur and tibia were removed. Bone 
marrow was flushed from the bones using complete MEM-α in a 5ml syringe. To 
break any cell clumps, the cell suspension was pipetted up and down before 
passing through a 70µm cell strainer (VWR). The cell suspension was washed in 
complete MEM-α, centrifuged at 300g for 5 minutes before red blood cell lysis 
using ACK lysis buffer (Life Technologies). Cells were then counted as previously 
described (2.2.1) and resuspended at 1 x 108 per ml in cell separation buffer in 
6ml capped polystyrene tube (BD falcon). Monocytes were separated from the 
bone marrow using a mouse monocyte enrichment kit (Stem cell). In brief, cells 
were incubated on ice with normal rat serum at 50µl/ml of cells and enrichment 
cocktail at 50µl/ml of cells for 15 minutes. Cells were then washed by topping 
up the sample tube with cell separation buffer and centrifuged at 300g for 10 
minutes. The cells were resuspended at 1 x 108 per ml and incubated with biotin 
selection cocktail at 60µl/ml of cells for 15 minutes at 4°C. Following this 
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incubation, the magnetic particles were added at 150µl/ml of cells for 10 
minutes at 4°C. The total volume was then brought to 2.5ml before placing the 
tube in a purple magnet (Stemcell Technologies) for 5 minutes. The magnet, 
with the tube inside, was inverted into a falcon and as it was a negative 
selection, the cells in the falcon were counted and washed at 300g for 5 
minutes.  
2.5.2 Stimulation of monocytes 
Monocytes were cultured in 200µl in 96 well plates at a concentration of 5 x 
105/ml for 24 hours. All conditions had 1ng/ml recombinant mouse GM-CSF 
added, with or without 10ng/ml LPS, or 5% RA synovial fluid from 3 patients. 
Supernatants were collected after 24 hours and analysed by ELISA (Section 
2.7.2). 
2.6 Transcript Analysis 
2.6.1 RNA extraction 
Supernatant was removed from monocyte or macrophage cell cultures and cells 
were lysed using 350µl RLT buffer from the RNeasy mini kit (Qiagen). The lysates 
were transferred to eppendorf tubes, vortexed to break up clumps, transferred 
to QIAshredder tubes (Qiagen) and centrifuged at full speed for 2 minutes. 70% 
ethanol was then immediately added to the flow through and transferred to the 
top of a spin column from the RNeasy mini kit (Qiagen). The manufacturer’s 
instructions for the RNeasy kit were then followed. In brief, the flow through 
from the QIAshredder plus 70% ethanol was spun through the spin column at 
8000g for 15 seconds. The flow through was discarded and the column washed 
with RW1 buffer at 8000g for 15 seconds. An on-column DNase digest was 
performed at this point by adding 80µl DNase incubation mix (10µl DNase in 70µl 
RDD buffer) for 15 minutes at room temperature. Following the DNase digest, 
columns were washed with RW1 buffer at 8000g for 15 seconds followed by a 
wash at 8000g for 15 seconds with RPE buffer. The flow through was discarded 
and RPE was added to the column again for a 2 minute centrifuge at full speed. 
The collection tube was then changed and the column spun at 8000g for 1 
minute to dry out the membrane. The column was transferred to an eppendorf 
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tube and the RNA eluted in 30µl RNase free water by centrifuging at 8000g for 1 
minute. The RNA concentration, and quality or potential contamination was 
measured using a Nanodrop 1000 (Thermo Scientific). 
2.6.2 cDNA synthesis 
To make cDNA, 10µl of a specified concentration of RNA (dependent on 
experiment) was added to 3ul random primers from the Affinity Script cDNA 
synthesis kit (Agilent) and 2.7µl RNase free water. The samples were mixed and 
incubated at 65°C for 5 minutes, then at room temperature for 10 minutes. 2µl 
of 10x affinity script RT buffer, 0.8µl dNTP mix, 0.5µl RNase block ribonuclease 
inhibitor and 1µl Affinity script multiple temperature RT were added to each 
sample before mixing and put in a PCR machine (Applied Biosystems 2720 
Thermal Cycler) (Table 2.1) 
Table 2.1 cDNA synthesis 
 
 
 
 
 
2.6.3 qPCR 
2.6.3.1 Primer Design 
Primers (forward and reverse)(Table 2.3) were either used from the literature, 
from primer bank, or were designed using primer 3 software by using the mRNA 
sequence from NCBI (National Centre for Biotechnology Information). Primers 
were designed with an amplicon size of 100-150 base pairs, the primer size of 
18-23 base pairs in length, with 40-60% GC nucleotide content, a maximum 3’ 
complementarity of 1, a maximum self-complementarity of 2 and a melting 
temperature between 59.5 and 61°C. NCBI blast was used to confirm the 
efficiency of primer designs and amplicon size was measured using Ape – A 
plasmid editor v1.17. 
Temp Time 
25°C 10 minutes 
42°C 5 minutes 
55°C 60 minutes 
70°C 15 minutes 
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2.6.3.2 Primer Validation 
2ul cDNA, 1µl of forward and reverse primer (Table 2.3), 25µl Red Taq (Bioline) 
and 21µl nuclease free water were added to PCR tubes, to run on an end point 
PCR (Table 2.2).
Table 2.2 End Point PCR 
Temp Time Cycles 
94°C 5 minutes 1 
94°C 15 seconds 35  
55°C 30 seconds 
72°C 30 seconds 
72°C 10 minutes 1 
 
Samples were run on a 1.8% agarose gel with 0.01% ethidium bromide at 110v 
until the 1kb+ ladder (Invitrogen) had migrated the full length of the gel. The gel 
was visualised with ethidium bromide using a UV transluminator. The primers 
were confirmed by checking the observed band size with the known amplicon 
size. 
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2.6.3.3 Primer Sequences 
Table 2.3 Primer Sequences 
Gene Forward sequence 5’-3’ Reverse sequence 5’-3’ 
APOL1 
APOL2 
APOL3 
APOL6 
CCL17 
CCL22 
CD23 
CD36 
CD64 
CLEC4E 
CSF1R 
CXCL8 
LILRA2 
LILRB3 
IRF4 
IRF5 
IRF7 
MRC1 
TNF 
GUSB 
GAPDH 
TTCGAATTCCTCGGTATATCTTG 
ATGATGAAGCCTGGAATGGA 
GCCTGGAAGAGATTCGTGAC 
AAGTGAGGCTGGTGTTGGTT 
GCAAAGCCTTGAGAGGTCTTGA 
GTCCTGTTCCCATCAGCGAT 
GGGAGAATCCAAGCAGGAC 
CTGAAACACAATGCACAGAGAGA 
TGGGAAAGCATCGCTACAC 
GGCTGTGACCGGAACTGTG 
CTGCCCAGATCGTGTGCTC 
AGAAGTTTTTGAAGAGGGCTGAGA 
CAGCCACAATCACTCATCAGA 
GGAGATACCGCTGCCACTAT 
ACCCGGAAATCCCGTACCA 
TGTCAGTGCAAGGTGTTCTGG 
CCCAGCAGGTAGCATTCCC 
GGGTTGCTATCACTCTCTATGC 
CCCTGTGAGGAGGACGAAC 
CTCATTTGGAATTTTGCCGATT 
AATCCCATCACCATCTTCCA 
CACCTCCAGTTATGCGTCTG 
TCAGAGCTTTACGGAGCTCAT 
CTTCAGAGCTTCGTAGAGAGCA 
CGTCTTGTAGCTCCACGTCTT 
CGGTGGAGGTCCCAGGTAGT 
CAGGCTGGAGACAGAGATGGA 
GGAAGCTCCTCGATCTCTGA 
AAAGATGCGAAATGTCACAACAC 
GCACTGGAGCTGGAAATAGC 
CCGAGTGAAGATCCCCTTTTTA 
AGGTTGAGGGTCAGGACTTTTT 
CAGACCCACACAATACATGAAGTG  
AGGGTGGGTTTGCTGTAGG 
GGTGGGTTTGCTGTAGGC 
GGCAACCATTTTCACAAGCTG 
TTTGCGGTCAGGCCATTCT 
GCAGCAGTTCCTCCGTGTAG 
TTTCTTGTCTGTTGCCGTAGTT 
TGAGCCAGAAGAGGTTGAGG 
AGGTCTCCAACTGGCATTAGAA 
TGGACTCCACGACGTACTCA 
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2.6.3.4 qPCR 
Transcripts were analysed by qPCR in triplicate in 384 well plates (Starlabs) by 
adding to each well 1µl cDNA, 0.15µl primer pair, 5µl SYBR green (Invitrogen, 
Life Technologies) and 3.85µl nuclease free water (Life Technologies, UK). A 
non-template control (NTC) was used in place of cDNA for each primer set to 
ensure no contamination.  Plates were sealed using adhesive plate sealers 
(Starlabs) and centrifuged at 400g for 1 minute. Plates were analysed using the 
Applied Biosystems 7900HT Sequence Detection System with a 50°C start 
followed by 94°C for 10 minutes, then 40 cycles of 94°C for 15 seconds and 60°C 
for 30 seconds. Data was exported from RQ manager as amplification data. All 
genes were normalised to the housekeeping GUSB after initial experiments, 
which were normalised to GAPDH (detailed in figures). ΔCt was generated for 
each sample through the subtraction of the gene of interest from the 
corresponding house keeping Ct value. The 2-ΔCt value was then calculated and 
the relative quantitation further calculated in comparison to a control, using the 
2-ΔΔCt formula.  
2.6.4 Taqman Low Density Array 
TLDAs were custom designed (Life Technologies) initially with 32 genes (Table 
2.4) and then 2 plates of 16 genes (Table 2.5). Plates were at room temperature 
for 30 minutes prior to starting the assay. cDNA samples (300ng) were diluted to 
50µl and 50µl Taqman Universal Mastermix II No UNG (Life Technologies) was 
added. The sample was then added to the designated port on the plate, 
centrifuged twice (1200rpm, 1 minute) using the Sorvall/Hereaus centrifuge with 
the specified TLDA buckets. Plates were sealed using a low density array sealer. 
Table 2.4: Macrophage TLDA card 
APOL1 APOL2 APOL3 APOL6 CCL13 CCR7 CD36 CLEC4E 
CSF1 CSF1R CSF2 CSF2RA CXCL11 CD23 CD64 FGL2 
FN1 IRF4 IRF5 IRF7 LILRA2 LILRB3 MRC1 MSR1 
PPARG TLR1 TLR2 TLR4 TLR6 UBC GUSB GAPDH 
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Table 2.5: Monocyte TLDA cards 
 
2.6.4.1 TLDA Analysis 
Plates were analysed using the Applied Biosystems 7900HT Sequence Detection 
System using SDS2.4 and RQ manager before exporting the results data and using 
Applied Biosystems Data Assist to generate the ΔCt and RQ for each sample. 
2.7 Cytokine and Chemokine Analysis 
2.7.1 Sample Preparation 
Cell culture supernatants were centrifuged (500g, 5 minutes) to pellet the cell 
debris. The supernatants were removed and diluted in assay buffer accordingly. 
Plasma samples were centrifuged at full speed for 10 minutes to eliminate 
histopaque contamination.   
2.7.2 ELISA 
ELISAs were performed as per the manufacturer’s instructions, which had slight 
variations depending on supplier (Table 2.6). In brief, half volume, high-binding 
plates (Fischer Scientific) were coated with capture antibody in PBS or 
recommended coating buffer overnight at 4°C. Plates were washed 4-5 times in 
PBS + 0.5% Tween (PBST) and blocked in assay buffer for 1 hour to prevent non-
specific antibody binding. The block was aspirated and the samples or standards 
added either with or without the detection antibody for 2 hours (RT with 
shaking). If the detection antibody was not added with the samples, this was 
added after the samples were aspirated and washed a further 4-5 times in PBST, 
for 1 or 2 hours (RT with shaking). After the detection antibody incubation, the 
plates were washed 4 times in PBST. The streptavidin-HRP was diluted in assay 
buffer and added to plates for 30 minutes (RT with shaking). A further 4 washes 
were performed after this step and Tetramethylbenzidine (TMB) substrate 
CCL2 CCL22 CD36 GAPDH MRC1 CREB1 IL8 CXCL10 
CCL17 CD1C IL6 IL12B CSF2 CCL3 CCL4 UBC 
CLEC4E CSR2RA TLR4 GAPDH IRF5 TNF CD1A CD200R1 
CCL20 CD209 CHI3L1 STAB1 CXCL2 CD163 CCR2 UBC 
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solution (eBioscience) added until the standard curve had developed, which 
ranged between 5 and 30 minutes depending on the analyte. Once developed, 
4N sulphuric acid was used to stop the reaction, and plates read at 450nm using 
Tecan Sunrise Absorbance reader. Data was exported to Excel and analysed 
ensuring the points of the standard curve were on the logarithmic phase, 
straight line of the curve. The equation for the straight line was used to 
calculate the unknown values. Any points outside the parameters of the standard 
curve were not included and re-run with further dilutions or if the sample was 
run neat, these samples were labelled as not detected. 
Table 2.6: ELISA kits 
Cytokine/Chemokine Species Supplier Detection Range 
IL-6 Human Life Technologies 15.62-1000pg/ml 
IL-8 Human Life Technologies 15.62-1000pg/ml 
TNFα Human Life Technologies 15.62-1000pg/ml 
CCL17 Human Biolegend 3.9-250pg/ml 
CCL17 Human R&D Systems 7.81-500pg/ml 
CCL22 Human R&D Systems 7.81-500pg/ml 
GM-CSF Human R&D Systems 15.62-1000pg/ml 
CCL17 Mouse R&D Systems 31.2-2000pg/ml 
 
2.7.3 Luminex 
A 10-plex Human chemokine panel (Life Technologies) and a base kit (Life 
technologies) were used to quantify chemokine levels as per the manufacturer’s 
instructions. In brief, standards were prepared using assay diluent. Beads were 
prepared by vortexing and sonicating. 95µl of the bead solution was added to 
each well and washed. 50µl incubation buffer, followed by 100µl standards or 
blanks were added to the plate. 50µl assay diluent was added to the remaining 
wells, followed by the addition of 50µl of samples leading to a 1 in 2 dilution of 
samples.  Plates were incubated at room temperature for 2 hours in the dark 
with shaking. Plates were then washed twice, followed by the addition of 95µl 
biotinylated antibody solution. They were incubated in the dark at room 
temperature for 60 minutes. The plates were washed twice after the incubation 
and 95µl Streptavidin-RPE solution was added to the plates, they were covered 
and incubated at room temperature with shaking for 30 minutes. The plates 
were then washed 3 times and wrapped in foil and stored at 4°C overnight in 
buffer. The following day, the wash buffer was replaced in the wells, and the 
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plates were incubated at room temperature with shaking for 10 minutes prior to 
running on the Bio-Rad Bio-Plex machine. The Bio-Plex Manager 4.1 programme 
was used, and machine instructions were followed. The data was exported as a 
Microsoft Excel file and analysed using Microsoft Excel and Graphpad Prism 6.0c. 
2.7.4 Meso-Scale Discovery (MSD) Multi-Array 
The chemokine 10 plex and cytokine 9 plex both using the 10 spot plate format 
were used and manufacturer’s instructions were followed. In brief, supernatants 
were diluted 1 in 2 for the cytokine plates and 1 in 4 for the chemokine plates. 
The cytokine plates were then blocked in blocking solution for 1 hour at room 
temperature with shaking, followed by 3 washes in PBS + 0.05% Tween. 
Standards and samples were diluted and added for 2 hours at room temperature 
with shaking. The detection antibody solution was added on top of the samples 
and standards for 1 to 2 hours at room temperature with shaking. After 3 more 
washes in PBS + 0.05% Tween, read buffer was added to each well and the plates 
read using an MSDSECTOR Imager. Data was analysed using Microsoft Excel and 
Graphpad Prism 6.0c.  
2.8 Immunohistochemistry (IHC) 
2.8.1 Antigen Retrieval 
Paraffin Embedded synovial membranes which had been previously sectioned 
were heated at 60°C for 35 minutes to soften the wax. The slides were then 
deparaffinised and hydrated through a xylene and graded alcohol series. Briefly, 
slides were added to xylene for 2 x 5 minutes, 100% ethanol, 90% ethanol and 
70% ethanol each twice for 3 minutes. The final hydration step was putting the 
slides in running water for 5 minutes. Following the hydration, slides were 
washed in Tris Buffered Saline with 0.05% Tween (TBST) for 5 minutes before 
antigen retrieval in citrate buffer. The citrate buffer (Appendix) was preheated 
for 5 minutes in a microwave before the addition of the slides for a further 8 
minutes. After cooling, the slides were washed in TBST before the endogenous 
peroxidase activity was quenched by incubating the sections in 0.5% H2O2 in 
methanol for 30 minutes. The sections were then washed for 5 minutes in TBST 
and sections ringed with a wax pen (Vector Laboratories). 
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2.8.2 Primary Antibody and ImmPress™ Secondary 
After the initial preparation of the sections, the slides were blocked for non-
specific binding by incubating sections with 2.5% normal horse blocking serum 
for 30 minutes in a humidified chamber. The serum was tapped off and slides 
were incubated overnight at 4°C with primary antibody (Table 2.7) in 2.5% horse 
serum/2.5% human serum in TBST. The slides were brought to room temperature 
and washed in TBST for 5 minutes. They were then incubated in ImmPRESS 
reagent specific to the host species of the primary antibody for 30 minutes. 
After a 5 minute wash in TBST, sections were incubated in Impact DAB 
chromagen solution until the stain intensity develops for a maximum 2 minutes.  
 Table 2.7: IHC Primary Antibodies
 Raised 
in 
Supplier Clone Isotype Supplier Concentration 
GM-
CSFRα 
Rabbit Genetex Polyclonal DA1E New 
England 
Biolabs 
10µg/ml 
CCR4 Rabbit Novus 
Biotechne 
Polyclonal DA1E  2µg/ml 
CCL17 Rabbit Abcam Polyclonal DA1E  2.6µg/ml 
CD3 Mouse Vector PS1 IgG2a Dako 1µg/ml 
CD68 Mouse Dako PGM1 IgG1b Dako 1µg/ml 
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2.8.3 IHC scoring 
Rheumatoid arthritis and Osteoarthritis sections were scanned using an Aperio 
ScanScope XT, followed by analysis using Aperio ImageScope software. 
2.8.3.1 Percentage of positive staining 
The sections were analysed as initmal lining, sub-lining, interstitium and 
aggregates. For each compartment, 3 areas for each section were scored and 
averaged. The scoring was analysed as percentage of positive cells, with <25% = 
1, 26-50% = 2, 51-75% = 3 and >76% = 4. The areas scored were matched for each 
tissue for CCL17, CCR4, GM-CSFRα, CD3 and CD68.  
2.8.3.2 Positive cell count 
The lining layer was scored at a 40x magnification, counting all positively 
stained cells in the field of view. Five areas were scored for each tissue and 
each antibody (CCL17, CCR4, GM-CSFRα, CD3 and CD68). This was repeated in 
RA and OA sections, and the number of positive cells from the 5 counted areas 
was averaged for analysis.  
2.9 Flow Cytometry (FACS) 
2.9.1 Assessment of cell purity - Human 
CD14+ cells were analysed for purity after separation from buffy coats. 1 x 106 
cells were transferred to 6ml tubes, the volume brought to 1ml with FACS buffer 
(Appendix) and centrifuged at 300g for 5 minutes. The supernatant was removed 
and antibodies were added for CD16-PE, CD3-APC, CD14-APC-Cy7, CD19-FITC 
(Table 2.8) for 20 minutes at 4°C in the dark. After this incubation, the cells 
were washed once more with 500µl FACS buffer and then resuspended in 300µl 
FACS buffer. Samples were analysed on the MACS QUANT (Miltenyi). All FACS 
data were analysed using FlowJo 10 software (TreeStar).  
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2.9.2 Assessment of cell purity – Mouse 
Enriched monocytes were analysed for purity by using 5 x 105 cells in 6ml tubes 
(BD, Falcon). These cells were washed in 1ml PBS at 300g for 5 minutes followed 
by a wash in FACS buffer (300g, 5 minutes). The supernatant was removed and 
antibodies were added for CD11b-V450, Ly6C-PerCP-Cy5.5 and GR1-APC (Table 
2.8) for 20 minutes at 4°C in the dark. Following this, excess antibody was 
washed off in FACS buffer (300g, 5 minutes) and cells were resuspended in 250µl 
FACS buffer before analysis using the MACS QUANT (Miltenyi Biotech) 
2.9.3 Apoptosis analysis 
Monocytes were analysed for apoptosis by transferring the cultured cells into 
eppendorfs, centrifuging at 400g for 5 minutes and then washed with 1ml PBS. 
The cells were resuspended in 1ml Annexin V binding buffer (BD) and centrifuged 
once again. The cells were then resuspended in 100µl Annexin V binding buffer 
and 5µl Annexin V-FITC (BD) added per sample for 15 minutes at room 
temperature in the dark. There was a further wash in 1ml Annexin V Binding 
Buffer and resuspended in 200µl and 5µl PI (BD) added before analysis on the 
MACS QUANT (Miltenyi Biotech).    
2.9.4 Phospho FACS 
Separated monocytes (2.2.4) were incubated with 5% synovial fluid or 10ng/ml 
LPS in complete RPMI for 4 hours in capped 6ml tubes (BD, Falcon) 37°C, 5% CO2. 
After incubation, cells were dissociated with cold dPBS (300g, 5 minutes) 
followed by a wash in warm (37°C) 0.1% BSA in dPBS (300g, 5 minutes). Washed 
cells were fluorescently labelled with surface markers CD14–PE-CF594, CD16–PE, 
CD19–AF700, CD3–V450 (Table 2.8) in 50µl 0.1% BSA in dPBS for 5 minutes. For 
antibody concentrations, see Table 2.8. For unstimulated tubes, 0.1% BSA in 
dPBS was added to the tubes and for stimulated cells, 1ng/ml GM-CSF in 50µl 
0.1% BSA in dPBS was added for 10 minutes at 37°C, 5% CO2. This incubation time 
was set after a trial at 10,15 and 20 minutes with 10 minutes the optimum time. 
Cytofix was added directly to the cells to stop any further signalling, for 15 
minutes at room temperature. Cells were washed in cell wash (BD) followed by a 
wash in 0.1% BSA in dPBS (300g, 5 minutes). Cells were then permeabilised with 
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400µl Perm III buffer (BD) for 30 minutes at 4°C. This permeabilisation buffer 
was extensively washed (3 times) initially with cell wash (BD), followed by 0.5% 
BSA in dPBS. Cells were resuspended in 50µl 0.5% BSA in dPBS and stained with 
STAT1-PerCP-Cy5.5, STAT3-AF488 or STAT6-AF488 and STAT5-AF647 (Table 2.8) 
for 30 minutes at 4°C. The excess antibody was washed off in 0.5% BSA in dPBS 
(300g, 5 minutes) and cells were resuspended in 200µl 0.5% BSA in dPBS. Cells 
were analysed using the LSR II analyser (BD).   
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Table 2.8 FACS antibodies 
Specificity Reactive Species Clone Fluorochrome Supplier µl/Test 
Annexin V Human  FITC BD   5 
CD3 
CD3 
Human 
Human 
 
UCHT1 
APC 
V450 
BD 10 
0.5 
CD14 
CD14 
Human 
Human 
MφP9 APC-Cy7 
PE-CF594 
BD 
BD 
5 
2 
CD16 Human 3G8 PE BD 1 
CD19 
CD19 
Human 
Human 
 FITC 
AF700 
BD 
BD 
10 
2 
PI   PI BD 5 
STAT5  
(pY694) 
Human 47 AF647 BD 2 
STAT 3 
(pY705) 
Human 4/P-
Stat3 
AF488 BD 2 
STAT1 
(pY701) 
Human 4a PerCP-Cy5.5 BD 2 
STAT6 
(pY641) 
Human 18/P-
Stat6 
AF488 BD 2 
CD11b Mouse M1/70 V450 BD 5 
Gr1 Mouse RB6-8C5 APC BD 5 
Ly6C Mouse AL21 PerCP-Cy5.5 BD 5 
 
2.10 Limulus Assay 
Immune complex depleted synovial fluids and neat synovial fluids were analysed 
for endotoxin contamination and 10ng/ml LPS was used as a positive control. 
The endotoxin was analysed using the Limulus Amebocyte Lysate (LAL) Kinetic 
kit (Lonza). The manufacturer’s instructions were followed, but briefly, the 
endotoxin standard was vortexed for 15 minutes before serial dilutions were 
made with the LAL reagent water, in endotoxin free glass tubes, for the 
standard curve. The top standard was a concentration of 5.0EU/ml and 4 
following 10 fold dilutions. The standards, samples, and controls were added to 
the microplate for 10 minutes at 37°C. Immediately prior to addition to the 
plates, the Kinetic QCL reagent was reconstituted with LAL reagent water and 
added to the wells. The plate was then measured at a wavelength of 405nM as a 
kinetic using the WinKQCL software.   
2.11 Statistical Analysis 
All statistical analysis was performed using GraphPad Prism 6 software 
(GraphPad). Different statistical tests were used depending on the data being 
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analysed. For the analysis of 3 or more groups of data with only one variable, a 
One-way ANOVA or non-parametric equivalent was used. The Bonferroni’s post 
test was used if the overall analysis detected significance. For the comparison of 
3 or more groups of data but with 2 variables (i.e dose response of various 
stimulations) the two-way ANOVA was used. Figure legends detail the statistical 
test used for each of set of data. A p value less than 0.05 was considered 
significant. 
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Chapter 3 GM-CSF/CCL17 axis in RA 
3.1 Introduction 
GM-CSF was traditionally identified as a maturation factor for macrophages 
(1.3.1.2), however, this role was broadened once it was discovered at sites of 
inflammation. It is now appreciated that GM-CSF has pro-inflammatory 
properties, which are important in RA pathogenesis (133,236,246,247). The 
initial arthopathy associated observation came from studies that were using 
human recombinant GM-CSF as a post-chemotherapy treatment. Joint pain was 
observed after 1 day of GM-CSF treatment, which disappeared gradually after 
GM-CSF treatment was halted (159,233,248). Following this observation, 
manipulating GM-CSF in animal models of RA further supported the importance 
of this molecule in rheumatic disease pathogenesis. In brief, daily injections of 
GM-CSF into mice with Collagen Induced Arthritis (CIA) significantly increased 
disease severity (236). In accordance with this finding, GM-CSF knockout mice 
have significantly reduced disease severity when compared to WT mice, and 
interestingly heterozygous mice have an intermediate score (233).  A therapeutic 
treatment regime, using a GM-CSF antibody (234), and more recently an anti 
GMCSFR alpha antibody (238),  also significantly reduced CIA disease scores. This 
has now been translated into humans, with Mavrilimumab: a human monoclonal 
antibody to GM-CSFRα. Clinical trials have shown promising results, with an 
improvement in DAS28-CRP when compared to placebo (244,249). These data 
have shown that GM-CSF has a role in RA pathogenesis and inhibition attenuates 
signs and symptoms of disease.  
In addition to a GM-CSF associated pathology in RA, there has also been 
significant work done to evaluate the role of TLRs in RA pathology. TLRs are 
expressed at high levels on both peripheral blood derived monocytes, and tissue 
resident macrophages from RA synovial membranes (241,250-252). PAMPs and 
DAMPs are ligands that can activate TLRs and these have therefore been 
implicated in synovial inflammation. Each TLR recognises specific ligands such as 
TLR4, which is a receptor that recognises, amongst others, the PAMP 
Lipopolysaccharide (LPS) and the DAMP Tenascin C (80,86,252). In disease, 
multiple TLRs can be activated, and it has been suggested that targeting more 
than one could be a potential for therapeutic treatment (80,252,253). TLRs 
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signal through the adaptor molecules MyD88 or Mal/TIRAP and TRAM/TRIF, but 
ultimately activate the transcription factor NFκB, through the phosphorylation 
and degradation of IκB from the NFκB-IκB complex (234,253-255). NFκB then 
transcribes genes for pro-inflammatory cytokines and chemokines such as TNFα, 
IL1 and CXCL8 (IL-8) (235,253,256,257).  Consequently TLRs are thought to be 
important regulators of inflammatory cytokine and chemokine expression (250).  
In RA, many chemokines have been studied, such as CCL2, CXCL8 and CXCL10 
(section 1.5), however there is limited research into CCL17, despite its receptor, 
CCR4, being expressed in RA tissue (258). In RA, synovial tissue has significantly 
higher levels of CCL17 mRNA than OA or healthy donor tissue (259). CCL17, 
previously known as Thymus and Activation-Regulated Chemokine (TARC), was 
discovered in 1996 to be constitutively expressed in the thymus and to induce T 
cell migration (260). Thymic Stromal Lymphopoietin (TSLP) stimulated dendritic 
cells secrete CCL17 and co-stimulation of TSLP with TLR ligands leads to an 
increase in CCL17 expression (261,262). CCL17 binds to CCR4, with CCL22 the 
only other common ligand for this receptor (263). More recently, CCL17 via CCR4 
has been shown to chemoattract Th17 and Treg cells (186,264). Studies into 
CCR4 and its role in RA show that in CIA, CCR4 null mice have significantly lower 
disease scores over time (186). This suggests that CCR4 ligands (CCL17 or CCL22) 
could play a role in RA pathogenesis. 
Many in vitro studies have used GM-CSF to differentiate monocytes into 
macrophages or DCs. However, the early effect of GM-CSF on monocyte biology, 
in particular the production of chemokines and cytokines has not yet been fully 
investigated. When monocytes enter the inflamed joint, they enter a milieu of 
cytokines, including GM-CSF, DAMPs and PAMPs. The aim of this study was 
initially to understand what effect GM-CSF stimulation has on monocyte 
functional outcome: including cytokine / chemokine secretion, before they 
further differentiate. The additional co-stimulation of TLR ligands, mimicking 
the activation upon entry into the synovium was also investigated, with the 
hypothesis that further cytokines and chemokines would be secreted. This 
relationship between chemokines, the GM-CSFRα, monocytes/macrophages and 
T cells in the synovium were also examined to try and understand the 
immunopathology.  
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Chapter Aims: 
• To investigate the effect of GM-CSF with and without TLR ligand co-
stimulation on the cytokine and chemokine production by monocytes. 
• To determine how CCL17 production by monocytes influences T cell 
activation. 
• To evaluate the spatial relationship in the RA synovial membrane tissue of 
CCL17, its receptor CCR4, GM-CSFRα and monocytes/macrophages and T 
cells. 
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3.2 Results 
3.2.1 Chemokine secretion in GM-CSF stimulated monocytes. 
In vitro, GM-CSF is classically used to differentiate monocytes into macrophages 
and/or dendritic cells (265,266). However, little is known about the initial 
impact of GM-CSF on monocyte biology. In order to determine the influence of 
GM-CSF on monocytes before differentiation, monocytes were isolated from 
human buffy coats using a monocyte enrichment kit (StemCell 
Technologies)(Section 2.2.3), negatively selecting for CD14+ monocytes without 
depleting CD16+ monocytes. Cell purity was analysed by flow cytometry. 
Typically, the composition of PBMCs after histopaque separation was 52% CD14+, 
CD16+ or CD14+CD16+ monocytes, 34.9% were CD3+ T cells and 4.58% were CD19+ 
B cells (Figure 3.1A & B). After separation monocyte purity was 82 ±10% (mean ± 
standard deviation)(Figure 3.1C). Importantly, contaminating populations were 
also assessed, revealing that there was only minor contamination of purified 
monocytes was T and B cells (Figure 3.1D). The monocyte purity was a limitation 
of the separation, however as predominantly monocytes and macrophages are 
GM-CSFR positive, stimulation with GM-CSF ensured more specific targeting for 
chemokine analysis.  
To determine the effect of GM-CSF stimulation on monocytes, monocytes were 
stimulated with 0.1ng/ml or 1ng/ml GM-CSF for 24 hours and supernatants were 
analysed for CCL17 secretion by MSD (Section 2.7.4). For a broad view of 
chemokine secretion in GM-CSF stimulated monocytes, other chemokines were 
simultaneously  evaluated. With increasing concentrations of GM-CSF 
stimulation, monocytes upregulated their secretion of CCL17 (Figure 3.2). This 
was the most consistently up-regulated chemokine of those analysed with little 
variation between the buffy coat donors. With no GM-CSF stimulation, very little 
(<20pg/ml) CCL17 was secreted; however, with 0.1ng/ml GM-CSF stimulation, 
this increased by approximately 100 fold (mean ± SD). At 1ng/ml, there was 
significant up-regulation in CCL17 production in comparison to no GM-CSF 
stimulation (Figure 3.2). There was also a dose dependent increase in CCL22 
secretion with GM-CSF stimulation, however, this was not a significant increase 
due to the variation observed between monocyte donors. CXCL8 production was 
also significantly increased after GM-CSF at 1ng/ml in comparison to no 
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stimulation. There was no difference in CCL3, CCL4, CCL11 and CXCL10 
production after GM-CSF stimulation, however, there was a large level of 
variability between monocyte donors. This suggests these chemokines were not 
reliably regulated by GM-CSF in monocytes. However, CCL17 and CCL22, the 
ligands for CCR4, were both up-regulated by GM-CSF, highlighting the 
importance of both monocytes and these chemokines in RA pathogenesis, prior 
to monocyte differentiation. This is potentially an important process in 
exacerbation of inflammation, as infiltrating monocytes that are exposed to GM-
CSF, can secrete CCL17 leading to the recruitment of CCR4+ T cells (Section 3.1). 
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Figure 3.1 Human Monocyte Purity Check 
An example of monocytes separated from human buffy coats analysed for purity by flow cytometry. 
A) Percentage of monocytes in total PBMCs. B) T cell and B cell percentage of PBMCs. C) 
Monocyte purity after enrichment from PBMCs. D) T cell and B cell contamination in monocyte 
separation. 
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Figure 3.2 Chemokine Induction after GM-CSF stimulation of monocytes 
Monocytes separated from human buffy coats (n=4) were stimulated in complete media or with the 
addition of human recombinant GM-CSF at 0.1ng/ml or 1ng/ml for 24 hours at 37°C. Supernatants 
were collected and analysed by MSD for chemokine secretion. Horizontal line indicating the 
median. Statistically analysed using Kruskal-Wallis non-parametric test, followed by Dunn’s post 
test. * = p<0.05 
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3.2.2 CCL17 secretion in RA monocytes. 
The data described above shows that CCL17 is produced by monocytes after GM-
CSF stimulation. To elucidate whether monocytes from RA patients, have the 
same capacity, or even an enhanced capacity, to produce CCL17 when 
stimulated with GM-CSF, monocytes derived from the peripheral blood of RA 
patient (n=7) and healthy controls (n=7) were isolated, and compared. In brief, 
monocytes were stimulated with increasing concentrations of GM-CSF for 24 
hours, after which, supernatants were collected and analysed for CCL17 by 
ELISA. In both RA and healthy monocytes, GM-CSF stimulation induced equivalent 
secretion of CCL17 (Figure 3.3A). A bell shaped response was observed, where 
there was an increase in secretion of CCL17 with increasing GM-CSF stimulation 
peaking between 1ng/ml and 10ng/ml GM-CSF, whilst at 100ng/ml GM-CSF 
stimulation, the induction of CCL17 decreased. This potentially suggests that at 
higher concentrations, monocytes are insensitive to GM-CSF or the monocyte 
phenotype changes with greater GM-CSF stimulation and monocytes respond 
differently. These results demonstrate that RA monocytes have the same 
capacity as healthy monocytes to secrete CCL17, which suggests that any 
dysregulation leading to RA pathogenesis is not via the monocyte response to 
GM-CSF. 
The production of CCL17 is not only restricted to monocytes and previous work 
has demonstrated that T cells stimulated with IL-4 (267) or dendritic cells (DCs) 
stimulated with Thymic Stromal Lymphopoietin (TSLP) can also secrete CCL17 
(268). As monocytes and DCs are both haematopoietic stem cell derived, and it 
is not known whether TSLP will have similar effects on monocytes. Monocytes 
were separated from human buffy coats and stimulated with increasing 
concentrations of TSLP or GM-CSF. Consistent with previous data, GM-CSF (in a 
dose-dependent manner) induced CCL17 (Figure 3.3B). TSLP was unable to 
induce CCL17 at any concentrations, however a positive control for TSLP 
stimulation would be required to confirm this finding. GM-CSF can be used in the 
differentiation of monocyte derived cells such as inflammatory DCs (73). 
Therefore, GM-CSF could up-regulate TSLPR in during the differentiation 
process. 
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Figure 3.3 CCL17 induction in RA monocytes and TSLP inability to induce CCL17. 
A) Monocytes were separated from human peripheral blood from RA patients (n=7) or healthy 
controls (n=7) and stimulated with recombinant human GM-CSF at increasing concentrations for 24 
hours. Supernatants were collected and analysed by ELISA for CCL17. At 0ng/ml, 5 donors had 
undetectable levels of CCL17. Horizontal line indicates the mean. B) Monocytes were separated 
from human buffy coats (n=4) and stimulated with increasing concentrations of GM-CSF or TSLP 
for 24 hours. Supernatants were collected and analysed for CCL17 by ELISA. Statistics used: 2-
way ANOVA performed on the dataset in B) followed by Bonferroni’s post test ** = p<0.01, *** = 
p<0.001.   
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3.2.3 TLR ligands inhibited GM-CSF induction of CCL17 in 
monocytes. 
The data described in sections 3.2.1 and 3.2.2 demonstrated that monocytes 
from RA patients and healthy controls produced CCL17 under GM-CSF 
stimulation.  The synovial milieu contains PAMPs and DAMPs, many of which are 
TLR ligands. TLR ligands have previously been shown to up-regulate cytokine and 
chemokine responses such as CXCL8 and TNFα, in monocytes (269) Therefore, to 
determine the effect of TLR ligands on GM-CSF driven CCL17 induction in both 
healthy and RA patients, monocytes were co-stimulated with LPS. RA and 
healthy monocytes were co-stimulated with increasing concentrations of GM-CSF 
in the presence or absence of 10ng/ml LPS.  
In both healthy and RA monocytes, LPS prevented the induction of GM-CSF 
driven CCL17. With GM-CSF stimulations of 1ng/ml and 10ng/ml, there was 
significant inhibition of CCL17 observed in both healthy and RA monocytes 
(Figure 3.4A).  The TLR4-mediated inhibition of CCL17 was unexpected, as LPS is 
known to induce the secretion of other pro-inflammatory cytokines and 
chemokines in monocytes.  
To determine whether the inhibition of CCL17 by LPS on GM-CSF stimulated 
monocytes was specific to TLR4 alone, multiple TLR ligands were used to assess 
specificity. The following TLR ligands were evaluated as they covered a range of 
receptors. In brief, we chose FSL1 (a TLR2/6 ligand), Clo97 (a TLR7/8 ligand) 
and Poly I:C (a TLR3 ligand). Consistent with the previous data (Section 3.2.1), 
GM-CSF was able to induce CCL17 and this was significantly inhibited by LPS. 
Importantly, this induction of CCL17 was significantly inhibited by all TLR ligands 
analysed (Figure 3.4B). This suggests that regardless of the TLR ligand used, the 
underlying TLR-mediated signalling cascade was activated, resulting in inhibition 
of GM-CSF-mediated CCL17 induction.  
In order to confirm that the GM-CSF-mediated signalling led to an up-regulation 
of transcript that would subsequently be translated into protein, CCL17 
transcriptional analysis was undertaken. Furthermore, the impact of TLR4-
mediated signalling on transcript and protein levels was also evaluated. 
Monocytes stimulated with GM-CSF alone or GM-CSF with LPS were cultured for 
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0, 6, 18 and 24 hours with cells lysed at each time point for transcriptional 
analysis. The transcripts of CCL17, CCL22 and CXCL8 were analysed. GM-CSF 
stimulation caused an induction of CCL17 transcript between 6 and 18 hours, 
which continued until 24 hours. The monocytes co-stimulated with LPS were 
unable to induce CCL17 transcript, with a significantly lower level of CCL17 
transcript at 18 and 24 hours (Figure 3.5). Suggesting that TLR4-mediated 
signalling events prevent transcription of CCL17 rather than post-translational 
inhibition. 
CCL22 is the only other common ligand with CCL17 for CCR4 (263). The CCL22 
protein was not significantly up-regulated by GM-CSF stimulation (Figure 3.2), 
however, we aimed to determine whether TLR-mediated signalling had any 
effect on the CCL22 transcript. The transcript for CCL22 was not significantly 
induced by GM-CSF at 18 and 24 hours, unlike the other CCR4 ligand, CCL17 
(Figure 3.5). The co-stimulation of GM-CSF with LPS also prevented CCL22 
induction. This is a potentially interesting finding, alluding to a mechanism in 
which TLR-mediated signalling inhibits GM-CSF induction of CCR4 ligands.  
CXCL8 was analysed as a positive control, as LPS would be expected to cause an 
increase in CXCL8 transcript expression (82,270). The data showed that GM-CSF 
alone induced low levels of CXCL8 transcript (Figure 3.5). However, at 6 hours 
after co-stimulation, LPS caused an increase in transcript expression. At 18 and 
24 hours after LPS co-stimulation, the level of transcript had returned to the 
same level as GM-CSF alone.  
The transcriptional analysis of CCL17 confirmed that up-regulation of the 
transcript directly led to the increase in protein (Figure 3.2). Inhibition of CCL17 
protein was caused by TLR-mediated signalling that impacted CCL17 
transcription rather than protein secretion (Figure 3.5). CCL22 transcript 
induction by GM-CSF, was also inhibited by LPS, suggesting a CCR4 ligand specific 
phenomenon, as CXCL8 transcript was up-regulated with LPS co-stimulation.
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Figure 3.4 LPS or TLR ligand inhibition of CCL17 in GM-CSF stimulated monocytes 
A) Monocytes were isolated from RA peripheral blood (n=7) or healthy peripheral blood (n=7) and 
were stimulated with increasing concentrations of GM-CSF or co-stimulated with GM-CSF and 
10ng/ml LPS for 24 hours. Supernatants were collected and analysed for CCL17 by ELISA. 
Statistically analysed using 2-way ANOVA followed by Bonferroni’s post test. ** = p<0.01, *** = 
p<0.001, **** = p<0.0001. B) Monocytes isolated from buffy coats (n=3) stimulated with 1ng/ml GM-
CSF with or without 10ng/ml LPS, 10ng/ml FSL1, 1µg/ml Clo97 or 50µg/ml Poly I:C for 24 hours. 
Supernatants were collected and analysed for CCL17. Left panel: raw concentrations, right panel: 
% change relative to GM-CSF alone condition. Statistically analysed using one-way ANOVA 
followed by Bonferroni’s post test **** = p<0.0001. 
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Figure 3.5 Transcriptional analysis of CCL17, CCL22 and CXCL8 after GM-CSF and LPS co-
stimulation. 
Monocytes isolated from human buffy coats (n=3) were stimulated with 1ng/ml GM-CSF in the 
presence or absence of 10ng/ml LPS. Cells were lysed at 0, 6, 18 and 24 hours after incubation. 
RNA was extracted and CCL17, CCL22 and CXCL8 transcripts analysed by qPCR. Results 
analysed in relation to housekeeping (GUSB) and Relative Quantification (RQ) calculated by 2-ΔΔcT 
relative to time 0. Statistically analysed using 2-way ANOVA followed by Bonferroni’s post test. * = 
p<0.05.  
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3.2.4 Investigation into the mechanism of LPS inhibition of CCL17 
The finding that LPS can significantly inhibit the induction of CCL17 in 
monocytes upon GM-CSF stimulation was an unexpected and novel finding, as 
LPS exacerbates secretion of other pro-inflammatory cytokines and chemokines 
such as TNFα and CXCL8 (270). In parallel to the work undertaken in this thesis 
on-going studies performed by collaborating scientists at MedImmune 
investigated the mechanism underlying LPS-mediated inhibition. From that data 
(personal communication), it was hypothesised that Suppressor of Cytokine 
Signalling 3 (SOCS3) was essential for inhibition by LPS. SOCS3 is downstream of 
GM-CSFR signalling, as a negative regulator of cytokine signalling (Figure 
1.2)(221). Therefore, in order to establish whether SOCS3 was involved in the 
process of inhibition by LPS, SOCS3 was down-regulated using siRNA technology. 
Initial experiments were performed to maximise transfection efficiency and 
knock down of the gene. To maintain monocytes in a setting that was supportive 
of survival and which would not lead to overt maturation, cells were cultured in 
human serum (271). To determine whether monocytes would still respond to GM-
CSF and secrete CCL17 after initial culture in human serum, monocytes were 
cultured for 24 and 48 hours before stimulation with GM-CSF in the presence or 
absence of LPS. This was in comparison to monocytes that were stimulated with 
GM-CSF and LPS at 0 hours (Figure 3.6). Monocytes that were stimulated with 
GM-CSF at 0 hours, produced approximately 1000pg/ml of CCL17, which was 
almost completely inhibited by LPS. After 24 hours of culture in 10% serum 
before stimulation with GM-CSF for 24 hours, monocytes secreted about 
125pg/ml CCL17, which was inhibited by LPS. After 48 hours of culture in 10% 
serum, before stimulation with GM-CSF, the ability of monocytes to produce 
CCL17 was effectively inhibited, with levels in the region of 40pg/ml. Therefore, 
in order to allow sufficient time for siRNA knockdown, prior to initiation of the 
assay, but still with the ability for CCL17 to be induced by GM-CSF, the 24 hour 
culture in human serum was used for further experiments. 
The 24 hour period of culture in human serum allowed time to transfect the cells 
with siRNA prior to initiation of the assay. In order to establish the optimum 
conditions for siRNA transfection and knockdown, the initial transfection was for 
24 hours to maximise time for the knockdown. Transfection efficiency was 
determined by transfecting the cells with AF-488 labelled control siRNA (Figure 
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3.7A). FACS analysis showed that 77% of the cells were still viable after 24 hours, 
and that of the live cells, 51.8% took up the labelled siRNA. Multiple 
concentrations of SOCS3 siRNA were tested in comparison to the control siRNA 
for knockdown of SOCS3 after 24 hours of transfection. 6.25nM was variable 
between the 2 monocyte donors, whereas 12.5nM, 25nM and 50nM were all 
successfully able to decrease the SOCS3 transcript (Figure 3.7B). However, 
despite successful knockdown of SOCS3, monocytes stimulated with GM-CSF, in 
both the control and SOCS3 siRNA, were unable to produce CCL17 (Figure 3.7C). 
The level of CCL17 secreted in the negative siRNA control was variable between 
donors but was still induced. The initial data suggests that transfection alone 
affects the monocyte’s ability to secrete CCL17 upon GM-CSF stimulation. In 
order to maximise monocyte viability, the transfection time was decreased to 
ensure a recovery period. The aim was to ensure delivery of siRNA into the cell, 
but also to remove the transfection reagent, which may have been having an 
inhibitory effect on the cell. In an exploratory experiment (n=1), a 6 hour 
transfection with 50nM siRNA, SOCS3 siRNA successfully knocked down the SOCS3 
transcript (Figure 3.7D). Monocytes recovered for 18 hours, prior to stimulation 
with GM-CSF in the presence or absence of LPS. The negative control, which was 
not exposed to siRNA or transfection reagent, produced 130pg/ml CCL17 with 
stimulation (Figure 3.7E). However, exposure to the control siRNA and SOCS3 
siRNA prevented induction of CCL17.  
In summary, transfection of monocytes (regardless of target) results in an 
inability to respond to GM-CSF stimulation and therefore secretion of CCL17. The 
current data suggests that this is due to interference from the transfection 
reagent that prevented GM-CSF signalling.
88 
 
 
Figure 3.6 Delayed assay start with monocytes cultured in human serum. 
Monocytes were separated from human buffy coats (n=3) and cultured in 10% human serum 
opposed to FBS. Monocytes were either stimulated at 0h with GM-CSF with or without 10ng/ml 
LPS, or cultured in human serum for 24 or 48 hours before the initiation of the assay stimulation of 
GM-CSF with or without 10ng/ml LPS. For the monocytes cultured before the initiation of the 
assay, the media was changed at the same time as the stimulations. After the addition of GM-CSF 
with or without LPS, monocytes were cultured for 24 hours, supernatants were collected and 
analysed for CCL17 by ELISA. 
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Figure 3.7 siRNA knockdown of SOCS3 in monocytes. 
Monocytes were cultured in media containing 10% human serum and transfected with the siRNA-
NTER peptide complex, which had been pre-incubated together for 15 minutes, for 24 hours (A, B 
and C) or 6 hours (D and E). A) Using labelled control AF488-siRNA, transfection efficiency was 
analysed by FACS. Cells were also stained with DAPI prior to analysis on a MACS QUANT to 
assess cell death. B) Control siRNA, and 4 concentrations of SOCS3 siRNA were used to 
determine the most effective concentration for use in further experiments (n=2 for 6.25nM and 
12.5nM, n=1 for 25nM and 50nM). C) 50nM siRNA (control or SOCS3) was used to transfect 
monocytes, after 24 hours of transfection, media was changed and monocytes were stimulated 
with GM-CSF with or without LPS. D) and E) 50nM siRNA (control or SOCS3) was used to 
transfect monocytes for 6 hours (n=1). Media was changed, and at 24 hours, monocytes were 
stimulated with GM-CSF with or without LPS for 24 hours. After culture, cells were lysed for 
transcriptional analysis of SOCS3 knockdown by qPCR (D) and supernatants were collected for 
analysis by ELISA for CCL17 (E).
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3.2.5 Activated T cells produced GM-CSF, but CCL17 does not 
exacerbate GM-CSF secretion. 
The ability of monocytes to produce CCL17 suggests that they may have a role in 
recruiting CCR4+ T cells to the inflamed tissue. We hypothesised that monocytes 
producing CCL17 upon GM-CSF stimulation, would not only be able to potentially 
recruit CCR4+ T cells to the particular area/tissue, but also induce secretion of 
GM-CSF in a positive feedback loop. In order to assess this hypothesis, CD4+ T 
cells were divided into memory and naïve T cells via the presence of CD45RA and 
CD45RO. Naïve T cells would not be expected to express CCR4 as expression 
increases upon differentiation into memory T cells (272). The T cells were then 
cultured with or without anti-CD2/CD3/CD28 beads in the presence or absence 
of increasing concentrations of CCL17.  
After 24 hours, total CD4 T cells produced approximately 500pg/ml GM-CSF when 
activated with anti-CD2/CD3/CD28 beads (Figure 3.8A). Anti-CD2/CD3/CD28 
bead stimulation of total CD4 T cells was essential for the production of GM-CSF. 
Importantly, CCL17 had no impact (be it negative or positive) on GM-CSF 
secretion in total CD4 T cells. The CD45RA+ T cells produced about 300pg/ml 
GM-CSF and the CD45RO+ T cells produced in the region of 400pg/ml GM-CSF.  
After 48 hours, all analysed subsets of T cells failed to induce GM-CSF without 
stimulation from anti-CD2/CD3/CD28 beads (Figure 3.8B). However, the 
activated CD4 T cells produced approximately 1000pg/ml GM-CSF, with the 
CD45RA+ T cells secreting about 600pg/ml GM-CSF and the CD45RO+ T cells 
secreting about 1000pg/ml. The increasing concentrations of CCL17 made no 
difference to the level of GM-CSF produced. This data suggested that CCL17 had 
no impact on any of the T cell subsets, however if there was the opportunity, 
future work could include analysis of CCR4 expression in relation to the ability of 
T cells to produce GM-CSF.   
Although we do not show that CCL17 is involved in a positive feedback loop, 
these data demonstrate that activated CD4+ T cells secrete GM-CSF. This 
suggests that recruitment of CCR4+ T cells into the tissue would lead to 
exacerbation of of GM-CSF secretion when activated, through contact with 
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antigen-presenting cells or potentially inflammatory cytokines, thereby 
stimulating monocytes to further secrete CCL17. 
92 
 
 
 
Figure 3.8 GM-CSF production in T cells after CCL17 stimulation 
CD4 T cells were isolated from buffy coats (n=3) and further separated into CD45RA+ T cells and 
CD45RO+ T cells. CD4+, CD45RA+ and CD45RO+ T cells were cultured in the presence or absence 
of anti-CD2/CD3/CD28 beads and with 0, 100 or 500ng/ml CCL17 for 24 hours (A) or 48 hours (B). 
Supernatants were collected after culture and analysed for GM-CSF by ELISA. n.d = not 
detectable.  
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3.2.6 Immunohistochemistry analysis of RA synovial membranes 
highlighted the spatial distribution of CCL17, CCR4, GM-
CSFRα  with CD3 and CD68. 
The relationship between GM-CSF stimulated monocytes, CCL17 and CCR4 T cells 
has been analysed in an in vitro system (Section 3.2.5). In order to understand 
the relationship between these cells in the RA tissue, synovial membranes were 
analysed by immunohistochemistry. CCL17 was examined to determine whether 
there was a relationship between the locality of CCL17 and CCR4 positive cells or 
GM-CSFRα positive cells. CD68 and CD3 were analysed to assess the spatial 
relationship between CCL17, CCR4, GM-CSFRα with CD68 and CD3.  
Synovial membranes from RA patients (n=8) were sectioned consecutively. They 
were then stained with primary antibodies towards GM-CSFRα, CCR4, CCL17, 
CD3 and CD68. The sections were scanned using an Aperio ScanScope XT 
microscope and the intimal lining layer, sub-lining layer, interstitium and 
aggregates or follicles were analysed and scored for each specific stain in the 
individual compartments (Figure 3.9). The staining was imaged (Figure 3.10) and 
scored (Figure 3.11) for each compartment of the RA synovial membrane. CCL17 
staining was variable between the RA synovial membranes, however it was 
relatively highly expressed across all compartments of the section. CCR4 staining 
was similarly expressed across all compartments of the synovial membrane, but 
to a lesser degree. GM-CSFRα was highly expressed in the intimal lining layer, 
with a high percentage of cells expressing GM-CSFRα in the sub-lining and 
interstitium. The aggregates had significantly lower levels of expression than the 
intimal lining and the interstitium. Similarly, CD68 was highly expressed in the 
intimal lining and interstitium, with expression in the sub-lining and aggregates 
significantly lower. The lowest CD68 expression was in the aggregates with a 
significantly lower percentage of positive cells than in all other areas of the 
synovial membrane. Interestingly CD3 was not as highly expressed as CCR4, as 
there was minimal detection in the intimal lining, and high levels in the 
aggregates, implying in this context that CCR4 is expressed on cells other than 
CD3+ cells. The GM-CSFRα staining profile was similar to CD68 expression in the 
intimal lining suggesting that they could be co-expressed.   
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Based on the observed staining, it is justifiable to surmise that there are 
potentially interactions between GM-CSFRα positive cells, CCL17 and CCR4 
positive cells as they are similarly located within the tissue. This proposes that 
the in vitro finding observed could be relevant within the RA synovial 
membrane. 
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Figure 3.9 RA synovial membrane pathology 
Representative images of RA synovial membrane indicating the compartments scored in further 
figures. A) Rabbit polyclonal IgG stained section with haematoxylin counter stain. 1.5 times 
magnification with arrows indicating aggregates or follicles. B) GM-CSFRα stained section with 
haematoxylin counter stain. 20 times magnification with black brackets indicating intimal lining and 
the white brackets indicating the sub-lining.
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Figure 3.10 Immunohistochemistry of RA synovial membranes of CCL17, CCR4, GM-CSFRα , 
CD3, CD68. 
Sections were stained for CCL17, CCR4, GM-CSFRα, CD3 and CD68. They were scanned using 
an Aperio ScanScope XT microscope and analysed using Aperio Imagescope software. 
Representative images of lining layers (intimal and sub-lining), follicle and interstitium of the 8 RA 
synovial membranes analysed. Relevant isotype inset.  
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Figure 3.11 RA synovium scoring compared intimal lining, sub-lining, interstitium and 
aggregates. 
Sections stained in Figure 3.10 were scored for the percentage of cells positive for CCL17, CCR4, 
GM-CSFRα, CD3 and CD68. The staining score was:  <25% of positive cells  = 1, 26-50% = 2, 51-
75% = 3, >75% = 4. 3 areas for each tissue of each area (intimal lining, sub-lining, interstitium and 
aggregates) were scored and averaged for each section (n=8). This was repeated for each 
antibody analysed. Horizontal bar indicates the mean. Statistically analysed using one-way ANOVA 
followed by Bonferroni’s post test. * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001.  
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3.2.7 Histological comparison between RA and OA synovial 
membranes. 
The RA synovial membranes that were analysed showed the abundance of the 
GM-CSFRα in the intimal lining layer, coinciding with CD68 expression. CCL17 
was observed in all compartments of the synovial membrane in a similar pattern 
with CCR4. CD3 had low expression in the lining layers but significantly more in 
the aggregates. To understand whether this was specific to the RA synovial 
membrane, OA synovial membranes were analysed as a comparison arthropathy 
(Figure 3.12). OA sections were scored in the same way as the RA sections. 3 
areas of the intimal lining layer and the sub-lining layer were scored for each  
synovial membrane (Figure 3.13). The representative images in Figure 3.12 show 
a difference between the RA and OA synovial lining layer pathology. The OA 
synovial membrane had a much thinner lining layer with far fewer cells than in 
the RA sections. The architecture of the RA synovial membrane lining was much 
more inflamed with more aggregates and immune cells. CCL17, GM-CSFRα and 
CD68 were highly expressed in both RA and OA synovial lining layer, with CCR4 at 
a slightly lower level and CD3 barely present at all. The scoring showed no 
difference between RA and OA in CCL17, CCR4, GM-CSFRα, CD3 or CD68 in the 
intimal lining, and only a difference in the CD3 of the sub-lining showing 
significantly less staining in the OA sections than the RA (Figure 3.13). This 
scoring did not represent the staining observed, as clearly the RA synovial 
membranes were much more inflamed and had a greater cellular infiltrate, 
enlarging the synovial lining. To account for this, the sections were re-scored by 
counting the number of positively stained cells in a 40x magnification field of 
the synovial lining (Figure 3.14). This scoring with absolute numbers of positively 
stained cells, was much more representative and showed significantly fewer 
positively stained cells for CCL17, CD3 and CD68 in the OA sections. However, 
GM-CSFRα and CCR4 appear to be slightly lower in OA synovial membranes than 
RA synovial membranes, but there was no significant difference. The 
interstitium was also compared between RA and OA synovial membranes. Only 
CD68 was significantly lower in OA than RA in the interstitium, with CCL17, CCR4 
and GM-CSFRα at comparable levels. CD3 was low in both RA and OA, which was 
why there was no difference.  
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These results show that the staining pattern and overall pathology should inform 
the method of scoring to give a true and accurate representation of the 
observed staining. As the RA synovial membranes were more inflamed, and 
therefore had a greater cell number, they were pathologically different to OA. 
Furthermore, the greater cell number observed in RA synovial membranes 
translated to a greater number of positively stained cells in comparison to OA, 
suggesting a more inflamed environment. Due to the increased level of CCL17 in 
RA synovial membranes in comparison to OA, this suggests that CCL17 could have 
a greater role in RA than OA. 
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Figure 3.12 IHC of synovial lining of RA and OA sections 
OA synovial membranes were histologically stained for CCL17, CCR4 GM-CSFRα, CD3 and CD68 
to directly compare with the RA synovial membranes (Figure 3.10). This figure represents the RA 
(n=8) and OA (n=3) synovial membranes analysed. The same scoring system as the RA synovial 
membranes was adopted. The relevant isotype inset.  
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Figure 3.13 RA histological scoring compared with OA in intimal lining, and sub-lining. 
Histological scoring of the RA and OA synovial membrane intimal lining and sub-lining layers. The 
scores are averaged from 3 areas of each section and for each antibody stain. <25% of positive 
cells  = 1, 26-50% = 2, 51-75% = 3, >75% = 4. For RA, n=8 and for OA, n=3. Statistically analysed 
using an unpaired T-Test with * = p<0.05. 
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.  
Figure 3.14 Positive cell count of RA and OA synovial lining. 
Score comparing RA (n=8) and OA (n=3) synovial membranes by counting the number of positively 
stained cells in the field of view for 5 areas of synovial lining at 40x magnification. To account for 
differences between RA and OA lining, thickness, the whole field of view was counted, including 
the intimal and sub-lining layers. Absolute cell numbers graphed with the horizontal bar indicating 
the median. Statistically analysed with a Mann-Whitney Test. * = p<0.05. 
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Figure 3.15 Interstitium of RA compared with OA 
Histological comparison between the interstitium of RA patient synovial membranes and OA patient 
synovial membranes. (A) Representative images of staining in the interstitium of RA (n=8) and OA 
(n=3) patients. (B) Score of an average of 3 counted areas of each section in (A) <25% of positive 
cells  = 1, 26-50% = 2, 51-75% = 3, >75% = 4. For RA, n=8 and for OA, n=3. Statistically analysed 
using an unpaired T-Test with * = p<0.05 
104 
 
3.3 Discussion 
There has been an increasing body of evidence supporting the role of GM-CSF in 
RA. GM-CSF has been reported at high levels in the RA joint (228,273), and 
monocytes are one of the major infiltrating cells to the inflamed tissues. This 
chapter has evaluated the effect of GM-CSF on monocytes, as these cells traffic 
into the inflamed tissue and are subject to many inflammatory stimuli including 
GM-CSF. GM-CSF caused monocytes to secrete multiple chemokines, rising with 
increasing GM-CSF concentrations (Figure 3.2). CXCL8, also known as IL-8, was 
secreted at high levels upon GM-CSF stimulation, which is in accordance with 
previous literature (274). The variation observed between the different 
monocyte donors was large, particularly with the production of CCL3, CCL4 and 
CCL11, as some monocyte donors responded to GM-CSF, and secreted large 
levels of chemokine whereas others had no response at all. This variation made 
it hard to interpret the data, however the consistency of CCL17 secretion in all 
monocyte donors upon GM-CSF stimulation, led us to further evaluate this 
chemokine.  
In RA, there is dysregulation of the immune system causing chronic inflammation 
(94). We hypothesised the response to GM-CSF in RA patients could be 
exacerbated, as it is thought that circulating cells are pre-primed, and could 
therefore be hyper-responsive (275). Therefore we sought to elucidate whether 
monocytes from RA patients had a greater capacity to secrete CCL17 upon GM-
CSF stimulation. RA monocytes secreted comparable levels of CCL17 as the 
healthy monocytes suggesting that these monocytes were not hyper-responsive 
to GM-CSF (Figure 3.3A). Interestingly, with higher concentrations of GM-CSF 
(100ng/ml) the level of CCL17 produced did not saturate as might be expected 
but decreases. The reason for this is unknown, however, it has been found that 
macrophages upon GM-CSF stimulation do not produce CCL17 (MedImmune, 
unpublished), therefore it is possible that the monocytes after 24 hours with 
high concentrations of GM-CSF are already committed to a differentiated 
macrophage, and therefore are no longer required to producing as much CCL17. 
Upon entering the rheumatoid joint, the migrating monocytes would be subject 
to GM-CSF and as we have found, they would produce CCL17. CCL17 has 
previously been described to be a chemokine secreted by dendritic cells in the 
inflamed lung and skin in response to TSLP (262,268). TSLP has recently been 
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implicated in RA pathogenesis, with significantly higher levels of the protein in 
synovial fluid of RA patients compared with OA patients. There was also a 
significant decrease in the level of TSLP as disease improved upon treatment 
with anti-TNFα therapy, and in a TNFα dependent mouse model, neutralising 
TSLP led to improved disease scores. (268,276). Furthermore, monocytes are 
known to expresses the TSLP Receptor (TSLPR) (276), so we aimed to define 
whether monocytes, like dendritic cells, could produce CCL17 upon TSLP 
stimulation. Monocytes were unable to secrete CCL17 when treated with TSLP 
despite expressing the TSLP receptor (277) (Figure 3.3B), suggesting discrete, 
separate mechanisms of CCL17 production by monocytes and dendritic cells. 
However, a positive control, using dendritic cells to confirm activity of TSLP, 
would be required for any conclusions. 
The synovial milieu, that monocytes enter, contains DAMPs and PAMPs, and 
therefore we investigated whether co-stimulation of monocytes with PAMPs 
would effect the CCL17 secretion. RA monocytes were compared with healthy 
monocytes to determine whether they both have the same response to LPS. 
Surprisingly, the co-stimulation of monocytes with GM-CSF and LPS caused 
inhibition of CCL17 (Figure 3.4A). This was consistent across RA and healthy 
monocytes. To elucidate whether this was just a TLR4 specific phenomenon, we 
used several TLR agonists, which all caused inhibition of the CCL17 pathway 
(Figure 3.4). This was an unexpected finding, as LPS is known to exacerbate the 
production of cytokines and chemokines in monocytes such as IL-6, TNFα and 
CXCL8 (IL-8) (255). We therefore aimed to confirm these findings by examining 
the transcript expression over time with GM-CSF and LPS stimulation. Upon GM-
CSF stimulation, the CCL17 transcript became more highly expressed between 6 
and 18 hours until 24 hours, whereas LPS prevented any CCL17 transcript 
upregulation (Figure 3.5). This suggests LPS prevents GM-CSF induced CCL17 
transcription, either directly or indirectly. Intriguingly, the CCL22 transcript was 
also up-regulated by GM-CSF, however this was much more variable between the 
monocyte donors. The transcript also appeared to be inhibited by LPS. CCL22 
was not as consistent as CCL17, and would need to be analysed for a greater 
time to see a difference. Despite not seeing an upregulation in CCL22 protein 
after 24 hours of GM-CSF stimulation (Figure 3.2), collaborators have found 
CCL22 to be highly up-regulated after 48 hours (data not shown). Therefore, the 
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kinetics of this transcript would need to be analysed for a longer period of time. 
The inhibition of CCL17 and CCL22 by LPS is interesting as they are both ligands 
for CCR4, suggesting a CCR4 ligand specific phenomenon. Furthermore, as CCR4 
is a chemokine receptor on Th17 cells (186), TLR-mediated inhibition of CCR4 
ligands is potentially a regulatory mechanism to prevent excessive migration of 
Th17 cells  into the inflamed tissue. Due to multiple TLR ligands in the synovial 
fluid, it would also be interesting to confirm the effect of the synovial fluid on 
GM-CSF driven CCL17. Therefore we are going to further investigate this in 
Chapter 4. To confirm that the LPS was effective and the observations with 
CCL17 and CCL22 were correct, we analysed the CXCL8 transcript, and as 
expected saw an up-regulation in the transcript after 6 hours with GM-CSF and 
LPS co-stimulation. Therefore, the CCL17 inhibition by LPS was a true and novel 
observation, leading us to question the mechanism causing this inhibition. 
A parallel investigation into the cause of TLR-mediated inhibition of GM-CSF 
driven CCL17 transcription suggested inhibition could be regulated by SOCS3. We 
attempted to investigate whether SOCS3 was involved but whilst we could 
successfully reduce SOCS3 expression in cells using siRNA, the transfection 
reagents significantly modified the behaviour of primary monocytes and 
therefore we were unable to draw any conclusions from these experiments. 
Further experiments of negative regulators of inflammation should be 
considered. 
To assess the impact of GM-CSF induction of CCL17 in monocytes, we analysed 
the effect of CCL17 on non-activated and activated T cells to determine whether 
they up-regulated GM-CSF secretion. We hypothesised that CCL17, produced by 
monocytes under GM-CSF stimulation, caused CCR4 positive T cells to up-
regulate GM-CSF in a positive feedback loop. Total CD4 cells were analysed and 
they were also divided into naïve (CD45RA+) and memory (CD45RO+). The CCR4+ 
T cells would be in the memory compartment, as previous studies have 
identified high levels of CCR4 expression in memory T cells (278,279), and naïve 
T cells were used as a comparator. All categories of T cell, when activated, 
secreted GM-CSF, with memory T cells producing more than the matched naïve T 
cells (Figure 3.8). T cells have previously shown to secrete GM-CSF (222,280), 
however the effect of CCL17 on this secretion was unknown. Increasing 
concentrations of CCL17 over 24 or 48 hours had no effect on the level of GM-
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CSF produced. This suggests that CCL17 in this system, acts purely as a 
chemokine, instigating the migration of CCR4+ T cells to the tissue, where upon 
activation by antigen, produce GM-CSF (Figure 3.16). Previous studies also 
support this hypothesis, as CCL17 causes CCR4+ T cells to migrate towards the 
chemokine (281). Interestingly, GM-CSF has been shown to be produced by Th17 
cells, and an RORγT binding site is present in the GM-CSF promoter, suggesting 
Th17 cells are the main producers of GM-CSF (228,282,283). This supports our 
hypothesis that CCR4+ T cells such as Th17 cells produce GM-CSF. However, 
there is also evidence to suggest that other T cells can produce GM-CSF. These 
include cells that are Th1, Th2 and Th17 independent as they do not express 
their master transcription factors or their signature cytokines, however they 
secrete GM-CSF (228,280,284). Some propose that these GM-CSF producing T 
cells are in fact a distinct, pathogenic subset (280,284,285). Our data also 
supports this theory as naïve T cells, which were not expected to produce GM-
CSF, also secreted GM-CSF, however, this was at lower levels than memory T 
cells. Despite the subset or classification of T cells, (whether they are Th17, or a 
specific GM-CSF producing T cell) they migrate to the inflamed tissue in response 
to CCL17, and secrete GM-CSF when they receive activation cues.  
This data was analysed in vitro, therefore, to determine the relevance to the RA 
synovial tissue, synovial membranes were analysed by immunohistochemistry. 
This allowed us to evaluate the relationship between GM-CSFRα and CCL17 with 
CCR4 and in relation to CD68 and CD3. To gauge where these proteins were 
located within the tissue, they were scored in the intimal lining, sub-lining, 
interstitium and the aggregates or follicles (Figure 3.10,Figure 3.11). These 
areas have been well defined in the RA synovial membranes for scoring (286-
288). This analysis therefore initially defined that CCL17 was in all areas of the 
tissue, CCR4 was not specific to one area whereas CD3 was not highly expressed 
in the lining layers but was more apparent in the follicles. CD3 and CCR4 would 
be expected to be co-expressed as most of the literature indicates CCR4 is a 
chemokine receptor on T cells, specifically Th2, Th17 and Treg 
cells(186,264,281). However, there have been some studies indicating that CCR4 
is also present on other cells. CCR4 has been identified on monocytes at higher 
levels on RA peripheral blood monocytes than on normal peripheral blood 
monocytes (289). CCR4 has also been found on platelets (290), but is in the main 
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expressed on T cells. Therefore, the unexpected, differing expression of CCR4 
with CD3, could potentially be explained by Katschke et al., with CCR4 
expression at higher levels on RA monocytes. This therefore could also be the 
case in the synovial membrane. The CCR4 expression in the synovial lining was 
high and this theory could therefore be explained by the high level of CD68 also 
present in the intimal and sub-lining. CD68 was high in the lining layers, and 
significantly lower in the aggregates. This was consistent with previous analysis 
(291). GM-CSFRα had a similar distribution as the CD68, which was also 
consistent with the literature, as they have been shown to be co-expressed 
(238). Finding CCL17 in all areas of the synovial membrane suggests that it is 
playing a part in RA pathogenesis. It was variable between RA donors, but we 
also found the responsiveness of monocytes to produce CCL17 after GM-CSF 
stimulation quite variable, some with as much as 10 fold differences (Figure 
3.3A). To improve the understanding of how CCL17, CCR4 and GM-CSFRα 
interact, double fluorescent microscopy would have allowed us to examine the 
specific cell types expressing CCR4 and GM-CSFRα. It would also shown the 
interaction of CCL17 with the cells of the synovial membrane. Double 
fluorescent microscopy was attempted (data not shown), however there were 
issues with spectral overlap that were proving too difficult to overcome in the 
time period. For this reason, consecutive sections were analysed to give the 
greatest understanding possible without co-staining. As these proteins were all 
found in the RA synovial membrane, and potentially support our hypothesis 
outlined in Figure 3.16, we wanted to assess whether these observations were 
specific to RA synovial membranes.  
OA synovial membranes were used as a comparator arthropathy, as the 
mechanism of disease is recognised to be less inflammatory with different 
factors driving disease in comparison to RA. The ideal comparator would be 
healthy synovial membrane, however, this tissue was unavailable. The OA tissue 
was able to provide insight into whether or not the expression of the proteins we 
analysed in RA, was disease specific or an aspect of synovial pathology. The 
initial observation of the OA synovial membranes was how the synovial lining 
layer was much thinner in comparison to RA. Also, the cells were much more 
widely distributed in the interstitium and there were no aggregates. There is 
heterogeneity between OA synovial membranes, as aggregates have been 
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observed in other OA tissues, however there were none in the sections analysed 
in this study. Furthermore, in the 3 OA synovial membranes I examined, the 
intimal lining layers were similar in their thickness, however in more inflamed 
OA tissues, this can be much thicker and it is in the inflamed tissues where 
aggregates are more likely to occur (292,293). The initial scoring system we used 
was the same that was used with the RA synovial membranes, by dividing the 
tissue into compartments (Figure 3.12,Figure 3.13). This showed no difference 
between the RA and OA synovial membranes in the intimal lining layer, which we 
decided was not representative of the sections. Therefore we used a different 
scoring system that involved counting the positive cells in a 40x magnification 
field. This method was much more representative of the inflammatory status of 
the tissue, and took into account the thickness of the lining layer. This led to 
significant differences in CCL17, CD68 and CD3 expression between RA and OA 
synovial lining. There was still no statistical difference in GM-CSFRα and CCR4 
expression between RA and OA, however there was a slight decrease in the 
numbers of positive cells in the OA sections. The low number of analysed OA 
synovial membranes potentially explains this, and to improve the reliability of 
the results, increasing the number of sections analysed would allow a more 
accurate representation. GM-CSF has also been implicated in OA pain and it 
could have a role in the inflammatory aspects of OA, suggesting a role for GM-
CSFRα expression in OA tissue (294). Despite not having statistical significance in 
all of the analysed proteins, this data begins to reveal that there is a difference 
between RA and OA synovial membranes. This was particularly apparent with the 
increased immune cell population in RA and the number of cells positive for 
CCL17. The immunohistochemistry supported our rationale, that CCL17 is 
involved in RA pathogenesis, the RA synovium is highly inflamed with CD68 and 
CD3 cells and that GM-CSFRα is highly expressed.  
In summation, these findings have found a novel aspect of biology, in which 
monocytes under GM-CSF stimulation, produce CCL17. CCL17 is unable to 
activate CCR4+ T cells to produce GM-CSF, however activated CD4 T cells will 
produce GM-CSF and CCL17 as a chemokine, attracts more CCR4+ T cells to the 
tissue. The GM-CSF signalling pathway can be inhibited by TLR ligands, via an as 
yet unknown mechanism, proposing a unique TLR/GM-CSFR signalling 
interaction. To give this work context to RA disease pathology, RA synovial 
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membranes were analysed and show CCL17, GM-CSFRα and CCR4 expressed in 
the same compartments of the tissue, suggesting interactions. Interestingly, the 
circulating levels of CCL17 and CCL22 were reduced in patients following 
treatment with anti-GM-CSFRα (Mavilimumab) suggesting a role for these 
chemokines in RA (295). Therefore, further investigation is required to evaluate 
monocytes under synovial environment conditions.  
 
Figure 3.16 Schematic detailing our hypothesis. 
Monocytes secrete CCL17 upon stimulation with GM-CSF. This chemoattracts CCR4 T cells to the 
tissue, where they are activated by antigen presenting cells (APCs), or receive cues from cytokines 
such as IL-23, IL-12 and IL-2 to secrete GM-CSF. This GM-CSF then stimulates the monocytes to 
secrete CCL17 in a positive feedback loop. The initial factor driving this loop is unknown, as without 
the monocyte, there would be no CCL17, therefore no T Cell recruitment. Without T cells, there 
would be no GM-CSF and therefore no stimulation of the monocytes. However, TLR ligands that 
are autologous to the synovial fluid can inhibit this pathway by preventing GM-CSFR signalling in 
the monocyte thereby preventing CCL17 secretion.
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Chapter 4 The impact of the synovial 
environment on the GM-CSF/CCL17 axis 
4.1 Introduction 
The previous chapter analysed the effect of GM-CSF on monocytes. After 
identifying GM-CSF as a potent cytokine that induced monocytes to secrete 
CCL17, the capacity for this pathway to be inhibited by TLR ligands was also 
identified.   
The synovial environment is a complex milieu that contains endogenous TLR 
ligands such as HMGB1 and S100 proteins. These endogenous proteins can be 
cytosolic proteins released as result of cell damage or necrosis. They are also 
known as Danger Associated Molecular Patterns (DAMPs) and are involved in 
perpetuating inflammation due to the downstream TLR pathways (91). TLR 
activation leads to the secretion of pro-inflammatory factors such as IL-1β, TNFα 
and MMPs, which are known to further activate immune cells or lead to tissue 
degradation (80,255). The synovial milieu, that contains DAMPs, is 
heterogeneous between RA donors, however, it has been profiled proteomically 
and metabolically to try and identify biomarkers (132,133).  
Proteomic analysis of RA synovial fluid and OA synovial fluid identified several 
up-regulated proteins in RA synovial fluid in comparison to OA. In particular, 
several DAMPs including S100A8, S100A9 and S100A12 were up-regulated 9-fold, 
29-fold and 33-fold respectively in comparison to OA (133). They were also found 
to be highly expressed in RA synovial fluid in comparison to OA synovial fluid in a 
previous study (84). The increase in S100 protein expression in RA synovial fluid 
has led to research on their role. They can bind TLRs and lead to monocyte 
activation (269). There were other proteins that were up-regulated in RA 
synovial fluid such as Coronin A, actin binding protein 1, and fibrinogen-like 2 
amongst several others, highlighting its complexity and the number of mediators 
that could exacerbate inflammation (133). 
DAMPS in the synovial milieu are not the only factors that are associated with RA 
pathogenesis. There are also immune complexes that form in the synovial tissue 
such as rheumatoid factor and ACPA immune complexes that are present in the 
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majority of RA patients and are associated with a more destructive disease 
phenotype (296). ACPAs are auto-antibodies to citrullinated proteins such as 
fibrinogen, fibrin and vimentin (94,297,298). Immune complexes activate 
monocytes and macrophages through FcγRs, leading to up-regulation in the 
secretion of pro-inflammatory cytokines such as TNFα (299,300). There is also 
evidence to suggest that immune complexes engage both FcγR and TLRs. In 
macrophages stimulated with citrullinated fibrinogen (cFib) alone or 
citrullinated fibrinogen immune complexes (cFib-IC), the cFib activated TLR4 
and the MyD88 pathway, and cFib-IC engaged both FcγR and TLR4. Inhibiting 
TLR4 significantly reduced the amount of TNFα secreted from macrophages, 
highlighting the exacerbated inflammatory response (298). 
To add to the DAMPs and immune complexes in the synovial milieu that can 
activate cells, there are also cytokines that enhance inflammation. Cytokine 
profiles of RA synovial fluid has indicated an increase in TNFα, IL-1α, IL-2 and 
IFNα in comparison to OA synovial fluid (301-303). IFNα is a member of the type 
I interferon family and was highly up-regulated in sero-positive RA (302). Type I 
interferons have increasingly been implicated in RA pathology as an up-
regulation of interferon stimulated genes have been identified in RA patients. 
IFNα increases MHC expression and activation of macrophages and lymphocytes 
(3). Interestingly, type I interferon responses may identify a clinically distinct 
subset of RA, by a distinct molecular phenotype, with increased activity from 
the innate immune system (304).      
The heterogeneity of RA synovial fluid has made the understanding of its impact 
on cells difficult to interpret. The previous chapter analysed the effect of GM-
CSF on monocytes and the impact on monocytes of TLR agonist co-stimulation. 
To understand the effect of the GM-CSF stimulation on monocytes in a synovial 
environment, this chapter aims to dissect the effect of synovial fluid on GM-CSF 
stimulated monocytes.  
Chapter Aims: 
• To assess the cytokine and chemokine content of RA synovial fluid. 
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• To analyse the impact of synovial fluid co-stimulation on GM-CSF 
stimulated monocytes. 
• To elucidate the underlying mechanism causing the observed effect by 
synovial fluid.  
114 
 
4.2 Results 
4.2.1 RA synovial fluid contains a higher concentration of 
cytokines and chemokines in comparison to OA. 
The synovial milieu, despite several studies analysing its content, is a 
heterogeneous environment that is incompletely defined. To assess the cytokine 
and chemokine content of synovial fluids, RA and OA synovial fluids were 
analysed by MSD (Section 2.7.4). RA synovial fluids can interact with antibody 
based assays due to rheumatoid factor leading to up-regulated readings, whereas 
MSD technology contains a buffer that prevents this. The RA synovial fluids had 
variable levels of cytokine (Figure 4.1). 2 of the 4 RA synovial fluids had elevated 
levels of GM-CSF, IFNγ, IL-12p70 and IL-10. All 4 RA synovial fluids had higher 
levels of IL-6 and TNFα compared to OA synovial fluids, however, there was no 
significant difference between the cytokine levels of RA and OA synovial fluids. 
The OA synovial fluids had very little of all analysed cytokines apart from IL-6 
where there were slightly increased levels, however this was variable between 
the fluids.  
The OA synovial fluids had a greater chemokine content than cytokine, and in 
some instances comparable with the RA synovial fluids. This was the case for 
CCL3, CCL4, CCL13, CCL17 and CCL22, suggesting that these synovial fluids could 
be from OA patients with a more substantial inflammatory component in their 
disease (305)(Figure 4.2). The RA synovial fluids had slightly increased levels of 
CCL2, CXCL8 and CXCL10, however this was not to a significant level potentially 
due to the small numbers analysed.  
The comparison of synovial fluids from RA and OA patients showed that there 
was a large level of variability between donors, but on the whole the RA synovial 
fluids had more inflammatory mediators than the OA synovial fluids. Several 
studies have shown up-regulated levels of cytokines and chemokines in RA 
synovial fluid in comparison to OA synovial fluid (137,301,302). Therefore in 
order to compare with the literature, it would be important to increase the 
number of analysed synovial fluids, as heterogeneity between synovial fluids 
makes them difficult to conclusively analyse. 
115 
 
 
Figure 4.1 Cytokines in Synovial Fluid 
RA synovial fluids (n=4) and OA synovial fluids (n=3) were analysed using cytokine multiplex MSD 
technology. Horizontal bars represent median.  Statistical analysis using Mann-Whitney Test. No 
statistical differences observed. 
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Figure 4.2 Chemokines in Synovial Fluid 
RA synovial fluids (n=4) and OA synovial fluids (n=3) were analysed using chemokine multiplex 
MSD technology. Horizontal bars represent median. Statistical analysis using Mann-Whitney Test. 
No statistical differences observed. 
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4.2.2 Synovial fluid impacts GM-CSF stimulated monocyte CCL17 
secretion. 
RA synovial fluid contains cytokines and chemokines (Figure 4.1, Figure 4.2), 
however there variability was observed between different patients. Chapter 3 
assessed the ability for TLR ligands to inhibit GM-CSF induced CCL17. Therefore, 
as RA synovial fluid is known to contain many endogenous TLR ligands or DAMPS, 
the effect of RA synovial fluid on GM-CSF stimulated monocytes was 
investigated. Furthermore, the evaluation of synovial fluid on GM-CSF stimulated 
monocytes mimicked the impact of the synovial environment on monocytes upon 
entry into the synovium in RA. Monocytes were co-stimulated with GM-CSF 
(1ng/ml) and synovial fluid (2.5% and 5%) for 24 hours, after which supernatants 
were analysed for chemokine expression. Co-stimulation of GM-CSF with RA or 
OA synovial fluid had no effect on CCL2 and CCL11 secretion in comparison to 
GM-CSF alone (Figure 4.3A). RA synovial fluid had varying effects on CXCL8 
induction when co-stimulated with GM-CSF, however, there was no significant 
induction above the level of GM-CSF alone. Co-stimulation of GM-CSF and RA 
synovial fluid caused no showed no significant inhibition CCL22, but it did appear 
to have a slight decrease in induction. OA synovial fluid had no impact on CCL22 
induction. Interestingly, co-stimulation of GM-CSF with OA synovial fluid, at both 
2.5% and 5% caused a significant inhibition of CCL3 and CCL4, whereas RA 
synovial fluid co-stimulation had no effect on these chemokines.  
CCL17, which was induced by GM-CSF, and inhibited by TLR ligands (Figure 3.4), 
was significantly inhibited by RA synovial fluids at both 2.5% and 5% (Figure 
4.3B). OA synovial fluid had a much more variable effect on GM-CSF driven 
CCL17. Each synovial fluid caused a different response, as co-stimulation with 
GM-CSF in some instances caused exacerbation of CCL17 in comparison to the 
GM-CSF alone control, whereas in others caused inhibition or no change. This 
suggests that there is a factor consistently present in RA synovial fluid, but not 
in OA synovial fluid, that causes inhibition of GM-CSF induced CCL17. 
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Figure 4.3 Synovial Fluid impact on GM-CSF induced chemokines. 
Monocytes isolated from buffy coats (n=4) were stimulated with 1ng/ml GM-CSF with or without 
2.5% / 5% synovial fluid from RA patients (n=4) or OA patients (n=4) for 24 hours. Supernatants 
were collected and analysed by MSD for multiple chemokines (A) and CCL17 (B). Data analysed 
as percentage change due to the large variation between monocyte donors, with GM-CSF alone 
made to 100% and all other conditions compared to this. GM-CSF alone absolute values ranged 
between 300 and 6000pg/ml. Synovial fluid stimulated monocytes analysed as induction, to 
discount any chemokine already in the synovial fluid. Statistically analysed using one-way ANOVA 
and bonferroni’s post test. * = p<0.05 and ** = p<0.01.  
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4.2.3 Transcript analysis of the kinetics of synovial fluid 
inhibition. 
RA synovial fluid caused significant inhibition of CCL17 protein induction by GM-
CSF. There was heterogeneity between the OA synovial fluids, leading to varied 
capacities to inhibit CCL17. Therefore to investigate the mechanism of synovial 
fluid inhibition of CCL17, RA synovial fluids were used due to their robust 
inhibition. LPS prevented CCL17 transcript induction (Figure 3.5), so it was 
investigated whether RA synovial fluid also affected CCL17 transcription. A time 
course analysing the CCL17 transcript was undertaken, where monocytes were 
co-stimulated with GM-CSF and RA synovial fluid, and transcripts were analysed 
at 6, 18 and 24 hours relative to 0hr. The CCL17 transcript was induced by GM-
CSF stimulation between 6 and 18 hours (Figure 4.4). The RA synovial fluids 
analysed both prevented induction of the transcript. The monocyte donors were 
variable in their induction of CCL17 transcript, however there was still a 
significant difference at 18 and 24 hours between the GM-CSF stimulated 
monocytes and co-stimulated monocytes with GM-CSF and RA synovial fluid. The 
CCL22 transcript was also up-regulated at 18 and 24 hours after GM-CSF 
stimulation. Similarly, the RA synovial fluids prevented induction of this 
transcript, as there was significantly lower CCL22 transcript at 18 and 24 hours. 
The CXCL8 transcript was induced by GM-CSF at 6 hours, but RA synovial fluids 
were not able to inhibit the induction of this transcript. However, the mRNA 
peak for CXCL8 was potentially before the 6 hour time point and therefore 
missed. The transcript and protein data were similar, suggesting that the 
inhibition of CCL17 protein by RA synovial fluid was due to inhibition of 
transcription (Figure 4.3B). 
These data data shows that the observed induction of the CCL17 protein was 
directly due to the increase in transcript expression, as expected, however the 
inhibition by synovial fluids, observed in the protein, can be attributed to the 
failure of transcription of CCL17. The CCL22 transcript induction did not 
correlate with the protein observation although it was similar, as the transcript 
was significantly inhibited by RA synovial fluid, but only a slight decrease in 
CCL22 protein. This was not significant or as robust as the effect of RA synovial 
fluid on the transcript. However, this analysis suggests a CCR4 ligand specific 
phenomenon, whereby RA synovial fluid inhibits GM-CSF stimulated monocyte 
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induction of these chemokines in a similar manner to LPS as observed in Chapter 
3. 
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Figure 4.4 Time course assessing synovial fluid effect on transcripts. 
Monocytes isolated from buffy coats (n=3) were stimulated with GM-CSF or co-stimulated with 5% 
RA synovial fluid (n=2). Transcripts (CCL17, CCL22 and CXCL8) were analysed at time 0, 6, 18 
and 24 hours after stimulation. Analysis in comparison to GUSB housekeeping and RQ calculated 
in relation to time 0. Statistically analysed using 2-way ANOVA with Bonferroni’s post test. ** = 
p<0.01, *** = p<0.001.  
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4.2.4 Synovial fluid inhibition of CCL17 is not via extracellular 
inhibition of a secreted factor. 
The CCL17 transcript was up-regulated after GM-CSF stimulation between 6 and 
18 hours (Figure 4.4). This was an extended period of time between GM-CSF 
stimulation and CCL17 transcript up-regulation. Therefore it was hypothesised 
that GM-CSF could be inducing the secretion of an extracellular factor, that 
further stimulated the monocytes and led to CCL17 transcription. The synovial 
fluid could then potentially inhibit this extracellular secreted factor.  
To evaluate whether a secreted factor, via GM-CSF signalling, led to CCL17 
secretion, conditioned media was used. Conditioned media was made by 
incubating monocytes, from 3 individual buffy coat donors, for 4, 6 and 8 hours 
with 1ng/ml GM-CSF. The media was then pooled before addition to further 
monocytes. Conditioned media alone caused CCL17 induction in monocytes, 
which was potentially due to presence of GM-CSF in the media (Figure 4.5). 
Therefore, to overcome this issue, monocytes were pre-treated with 
Mavrilimumab (CAM3001) to prevent residual GM-CSF in the media causing an up-
regulation in CCL17. Monocytes pre-treated with mavrilimumab were unable to 
induce CCL17 secretion after conditioned media treatment. 
This data suggested that the up-regulation of CCL17 transcription after GM-CSF 
signalling was not indirect via a secreted factor. Therefore, this data supports 
the theory that RA synovial fluid inhibition of CCL17 is via intracellular signalling 
inhibition rather than extracellular inhibition. GM-CSF leads to the transcription 
of the CCL17 gene via JAK2 and STAT5 (Figure 1.4). It has been shown that 
STAT5 leads to the transcription of the transcription factor IRF4 and it is IRF4 
that induces transcription of the CCL17 gene (345). Therefore, synovial fluid 
could be inhibiting either transcription of IRF4 or the transcription of CCL17 by 
IRF4.  
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Figure 4.5 Conditioned media from GM-CSF stimulated monocytes was unable to induce 
CCL17. 
Monocytes isolated from buffy coats (n=3) were stimulated with 1ng/ml GM-CSF for 4, 6 and 8 
hours whereby supernatants were collected and pooled from the donors and frozen. Monocytes 
from 3 further buffy coats were pre-treated with CAM3001 or CAT004 for 30 minutes before the 
addition of the conditioned media for 24 hours. 1ng/ml GM-CSF used to stimulate control 
monocytes. Supernatants were collected and analysed for CCL17 by ELISA. 
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4.2.5 Delaying the co-stimulation with RA synovial fluid still 
inhibited GM-CSF induced CCL17. 
The transcriptional time course showed how the CCL17 transcript was not up-
regulated by GM-CSF until between 6 and 18 hours, however the delay from GM-
CSF signalling to CCL17 transcription was not due to an intermediate 
extracellular secreted molecule. Therefore, inhibition of CCL17 by RA synovial 
fluid was intracellular, but the time at which the inhibition was occurring was 
unknown. To assess when the inhibition by synovial fluid occurred, a further 
time course was performed. This time course involved adding synovial fluid at 
multiple time points after the monocytes were stimulated with GM-CSF, with the 
level of CCL17 protein analysed after 24 hours. With the addition of RA synovial 
fluid at 0 hours, CCL17 was significantly inhibited (Figure 4.6). However, when 
the RA synovial fluid was added at up to 4 hours after the initial stimulation with 
GM-CSF, the CCL17 transcript was still inhibited. At 6 hours after GM-CSF 
stimulation, the RA synovial fluid was less able to inhibit CCL17 and there was an 
increase in the variability between the monocyte donors. When the synovial fluid 
was added to the GM-CSF stimulated monocytes after 8 hours, there was no 
longer any inhibition and much more variable responses from each monocyte 
donor.  
This data implies that the signalling cascade downstream of GM-CSF receptor 
resulting in CCL17 induction is complex, allowing the synovial fluid to have 
ability to inhibit CCL17 transcription despite addition 4 hours after GM-CSF 
stimulation. The synovial fluid potentially inhibits factors that are much further 
downstream of GM-CSF receptor signalling, or leads to promoter silencing or 
transcript degradation.  
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Figure 4.6 Time course analysing when synovial fluid inhibited CCL17 
Monocytes isolated from buffy coats (n=3) were stimulated with 1ng/ml GM-CSF. RA synovial fluid 
(n=1) was added at 0, 1, 2, 4, 6 or 8 hours after the initial GM-CSF stimulation. Supernatants were 
taken at 24 hours after GM-CSF stimulation and analysed for CCL17 by ELISA. Statistically 
analysed using a 2-way ANOVA with Bonferroni’s post test. ** = P<0.01. 
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4.2.6 Synovial fluid inhibition of CCL17 is TLR independent. 
RA synovial fluid inhibition of GM-CSF induced CCL17 was a robust finding that 
occurred in all analysed synovial fluids to all monocyte donors. To have such a 
consistent effect suggests a factor present within all RA synovial fluids. The 
mechanism of this inhibition was unknown, but as the synovial milieu contains 
many DAMPs that bind TLRs, it was hypothesised that TLRs could be mediating 
this inhibition. The previous chapter analysed the TLR induced inhibition of 
CCL17, therefore the synovial fluid could be influencing the GM-CSF induction of 
CCL17 in the same mechanism. Initially, it was investigated whether TLR2 or 
TLR4 were involved, so inhibiting antibodies were used. Initially a dose response 
was tested to determine the concentration of antibodies to use in the assay. The 
inhibiting anti-TLR2 and anti-TLR4 were pre-incubated with monocytes for 30 
minutes prior to the addition of the relevant TLR ligand (LPS or FSL1). This pre-
incubation was to allow the antibodies to bind to the receptor to prevent 
competition with the ligand. With no antibody, after GM-CSF stimulation, both 
LPS and FSL1 inhibited CCL17, as predicted (Figure 4.7A). The IgG1 isotype had 
no effect on the inhibition of CCL17 by LPS or FSL1, which was to be expected. 
The anti-TLR4 antibody successfully prevented LPS from inhibiting GM-CSF 
induced CCL17 secretion at all concentrations analysed. The anti-TLR2 antibody 
was not as successful at preventing the binding of FSL1 to TLR2. At 1µg/ml, 
there was no difference between the FSL1 alone and the pre-treated with the 
antibody. At 3µg/ml and 10µg/ml there was a slight increase in the level of 
CCL17 secreted, suggesting that it had partially inhibited TLR2. For the following 
assay, both antibodies were used at 10µg/ml. 
To examine whether the anti-TLR2 or anti-TLR4 antibodies could reverse the 
inhibition of CCL17 observed with RA synovial co-stimulation with GM-CSF, they 
were used both individually or in combination. Monocytes were pre-treated with 
the anti-TLR2, anti-TLR4 or both for 30 minutes prior to the co-stimulation with 
RA synovial fluid. Stimulation with GM-CSF and RA synovial fluid significantly 
inhibited the ability of monocytes to secrete CCL17, as previously observed 
(Figure 4.3). The anti-TLR2 and anti-TLR4 antibodies individually or in 
combination were unable to reverse the inhibition by RA synovial fluid. However, 
as the anti-TLR2 antibody did not have good inhibition, this was potentially only 
anti-TLR4 antibody that was unable to reverse the inhibition by RA synovial fluid 
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(Figure 4.7). This suggests that RA synovial fluid inhibition of GM-CSF driven 
CCL17 is either via a different TLR or another distinct mechanism.   
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Figure 4.7 TLR2 and TLR4 inhibiting antibodies could not reverse the CCL17 inhibition by 
RA synovial fluid. 
A) Monocytes isolated from buffy coats (n=2) were pre-treated with increasing doses of anti-TLR4, 
anti-TLR2 antibodies, or with the relevant isotype, for 30 minutes. Monocytes were then stimulated 
with 1ng/ml GM-CSF with either 10ng/ml LPS (TLR4) or 10ng/ml FSL1 (TLR2) for 24 hours. B) 
Monocytes from buffy coats (n=3) were pre-treated with 10µg/ml anti-TLR4, anti-TLR2 antibodies, 
in combination or with relevant isotype, IgG1 for 30 minutes. Monocytes were further stimulated 
with 1ng/ml GM-CSF or co-stimulated with 5% RA synovial fluid (n=3). The supernatants were 
collected and analysed for CCL17 by ELISA. B) statistically analysed by 2-way ANOVA with 
Bonferonni’s post test. **** = p<0.0001.   
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The RA synovial fluid inhibition of CCL17 was not reversed using anti-TLR2 or 
anti-TLR4 antibodies, either individually or in combination. Therefore, to 
determine whether inhibition of CCL17 by RA synovial fluid was due to multiple 
TLR agonists within the synovial fluid, MyD88/TRIF double knockout mice were 
used, which are unable to signal through any TLR pathway. MyD88/TRIF knockout 
mouse monocytes were isolated from the bone marrow and stimulated with GM-
CSF and RA synovial fluid. The purity of the monocytes isolated from the bone 
marrow, was analysed by flow cytometry to ensure the cultured cells were pure. 
The total bone marrow contained 14.6% cells that were CD11b, Ly6C positive and 
the isolated monocytes were 83.9% pure, which was within the expected range 
(Figure 4.8A-D).    
Upon GM-CSF stimulation, the wildtype monocytes secreted CCL17, which was 
comparable with human monocytes. In the wildtype monocytes, GM-CSF induced 
CCL17 secretion was inhibited by RA synovial fluid (Figure 4.8E). LPS was used as 
a control as it also inhibited CCL17 in wildtype monocytes. GM-CSF stimulation 
of the MyD88/TRIF double knockout monocyte caused secretion of CCL17, 
however, this was at lower levels in comparison to the wildtype. LPS was unable 
to inhibit the induction of CCL17, confirming that these monocytes were unable 
to signal via TLRs. Interestingly, RA synovial fluid caused inhibition of CCL17 in 
the MyD88/TRIF knockout monocytes. Although, this was not a significant 
inhibition due to the variation in the GM-CSF alone condition, the level of CCL17 
secreted in the RA synovial fluid co-stimulation was lower than the wildtype 
control. 
RA synovial fluid still had the ability to inhibit GM-CSF induced CCL17 in 
MyD88/TRIF double knockout monocytes. This suggests the mechanism causing 
inhibition of CCL17 by RA synovial fluid is TLR independent. 
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Figure 4.8 MyD88/TRIF knockout mouse monocyte GM-CSF induced CCL17 induction 
inhibited by RA synovial fluid. 
Monocytes isolated from bone marrow were assessed for purity. A) Bone marrow cells which were 
further gated for single cells (B). The CD11b and Ly6C positive cells were analysed in total bone 
marrow (C) and the isolated monocytes (D). Wildtype (C57BL/6) (n=4) and MyD88/TRIF double 
knockout (n=4) mouse monocytes were isolated from bone marrow and stimulated with 10ng/ml 
GM-CSF or co-stimulated with 10ng/ml LPS or 5% RA synovial fluid (n=1) (E). Statistically 
analysed using one-way ANOVA with Boferroni’s post test. *** = p<0.001, **** = p<0.0001, ns = not 
significant. 
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4.2.7 IFNα  and small immune complexes can inhibit the induction 
of CCL17 by GM-CSF stimulation. 
Synovial fluid not only contains endogenous TLR ligands, but also high levels of 
immune complexes and type I interferons, and it was hypothesised that other 
factors could lead to the inhibition of GM-CSF induced CCL17. Therefore, we 
investigated small immune complexes and IFNα and the impact on CCL17, when 
co-stimulated with GM-CSF. Small immune complexes (SIC) were formed by 
making an IgG-SpA complex, at a ratio of 2 IgG to 4 SpA molecules, using a pre-
defined method from the group (Section 2.3.1). Monocytes co-stimulated with 
SIC had a significant down-regulation in the level of GM-CSF induced CCL17 
produced, comparable with the level of inhibition observed in the RA synovial 
fluid (Figure 4.9A). The IgG and SpA alone controls were unable to inhibit CCL17, 
suggesting the molecules had to form immune complexes in order to inhibit 
CCL17. This suggests that Fc Receptor-mediating signalling, via immune 
complexes, can also contribute to the inhibitory milieu that results in the 
inhibition of GM-CSF driven CCL17. 
To establish whether immune complexes are a component of the inhibitory 
factor in synovial fluid causing the down-regulation of CCL17, immune 
complexes were depleted from RA synovial fluid. Using magnetic protein G, 
protein A or protein A/G/L beads, synovial fluids were depleted and compared 
to their matched, non-depleted synovial fluid to assess their ability to inhibit 
CCL17 in monocytes after GM-CSF stimulation. There was no difference between 
protein G or protein A depleted RA synovial fluid in comparison to complete 
synovial fluid, despite the non-significant difference between GM-CSF alone and 
protein G depleted synovial fluid (Figure 4.9B). This was in relation to their 
ability to inhibit CCL17. Protein A/G/L depleted synovial fluid caused a greater 
inhibition of CCL17 than the non-depleted synovial fluid. This was an unexpected 
finding as depleting the synovial fluid of immune complexes would be expected 
to potentially reverse the inhibition. The level of inhibition was comparable to 
the LPS inhibition, therefore it was suggested that there was potential endotoxin 
contamination in the depleted synovial fluid, through the reagents used for the 
depletion. To assess whether this was the case, the depleted and complete 
synovial fluids were analysed for endotoxin using the kinetic limulus assay. The 
results of this assay showed that there was no contamination, compared with the 
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LPS positive control (Figure 4.9C). Therefore, the greater inhibition observed in 
the protein A/G/L depleted synovial fluid was not due to endotoxin 
contamination. 
To elucidate whether another major component of RA synovial fluid could cause 
inhibition of GM-CSF induced CCL17 that would not have been removed after 
depletion of immune complexes, type I interferons were analysed. To investigate 
this, monocytes were co-stimulated with GM-CSF and 10ng/ml or 100ng/ml IFNα. 
LPS was used as a positive control. At both 10ng/ml and 100ng/ml, IFNα 
inhibited the GM-CSF driven CCL17 (Figure 4.10). At 100ng/ml, the level of 
inhibition was significant and at a similar level to that of LPS. The ability of IFNα 
to cause inhibition of CCL17 supports the concept that there are multiple factors 
within synovial fluid causing the inhibition as TLR ligands also have this ability. 
These data suggest that there are multiple methods of causing inhibition of GM-
CSF induced CCL17 including by IFNα and small immune complex co-stimulation. 
This suggests that as synovial fluid contains many of the factors that have been 
found to cause inhibition, there are several mechanisms in which synovial fluid 
can employ to cause inhibition of CCL17 after GM-CSF stimulation of monocytes.   
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Figure 4.9 Immune Complexes inhibit CCL17, but depletion was unable to reverse the 
inhibition. 
A) Monocytes isolated from buffy coats (n=3) were stimulated with 1ng/ml GM-CSF, with or without 
RA synovial fluid (n=1) or small immune complexes formed from complexing 2 human IgG 
molecules with 4 SpA molecules. IgG and SpA used alone as controls. B) Protein A, Protein G or 
Protein A/G/L magnetic beads were used to deplete RA synovial fluids (protein A n=3, protein G 
n=2, protein A/G/L n=5). Monocytes isolated from buffy coats (n=3) were stimulated with 1ng/ml 
GM-CSF and RA synovial fluids with matched depleted synovial fluids. Supernatants were 
collected after 24 hours and analysed for CCL17 by ELISA (A and B). C) Depleted and non-
depleted synovial fluids were analysed for endotoxin contamination by the kinetic limulus assay. 
10ng/ml LPS was used as a positive control. Statistically analysed using Kruskal-Wallis non-
parametric test with Dunn’s post test. * = p<0.05.  
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Figure 4.10 IFNα  inhibited GM-CSF induced CCL17 in monocytes. 
Monocytes isolated from buffy coats (n=3) were stimulated with 1ng/ml GM-CSF with or without 
10ng/ml LPS, 10 or 100ng/ml IFNα for 24 hours. Supernatants were then analysed for CCL17 by 
ELISA. Statistically analysed using Kruskal-Wallis non-parametric test with Dunn’s post test. * = 
p<0.05. 
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4.2.8 Investigation into GM-CSF and CCL17 associated signalling. 
The previous data demonstrated that RA synovial fluid was able to inhibit GM-
CSF driven CCL17 and multiple factors within synovial fluid could potentially 
cause this inhibition. To investigate the underlying mechanism causing synovial 
fluid-mediated inhibition of this pathway, associated signalling pathways were 
investigated. Despite the ability of synovial fluid to inhibit CCL17 4 hours after 
initial GM-CSF stimulation, STAT5 which is downstream of GM-CSFR signalling 
(306) was assessed to confirm that it was not involved. The binding site for the 
transcription factor, STAT6, has been identified on the CCL17 locus, and 
therefore could have the potential to be inhibited by synovial fluid (307).  In 
order to elucidate the signalling pathway involved in the inhibition of CCL17 by 
RA synovial fluid, pSTAT5 and pSTAT6 were analysed.  
Monocytes were incubated with synovial fluid for 4 hours prior to stimulation 
with GM-CSF for 10 minutes. With no GM-CSF stimulation, the pSTAT5 Mean 
Fluorescent Intensity (MFI) was 115 ± 17 (Mean ± SD) in CD14+ monocytes, 
however with GM-CSF stimulation, there was a significant increase in pSTAT5 
expression to 233 ± 76 (Mean ± SD) (Figure 4.11). Pre-incubation with RA synovial 
fluid had varying effects on the MFI of pSTAT5 in CD14+ monocytes. Interestingly, 
this was not due to the synovial fluid used, but the monocyte donor that caused 
the variability, suggesting that monocytes from different donors respond 
differently to the stimuli in RA synovial fluid. The CD16+ monocytes were much 
more variable when stimulated with GM-CSF as some increased expression of 
pSTAT5, however this was not a consistent finding. The pre-incubation with RA 
synovial fluid also made no change to the level of pSTAT5. The analysis of 
pSTAT6 in monocytes showed that unstimulated monocytes have a residual level 
pSTAT6 (Figure 4.12). In CD14+ monocytes this was an MFI of 433 ± 8 (Mean ± SD) 
however, in CD16+ monocytes this was much lower at 185 ± 8 (Mean ± SD). There 
was a slight increase in pSTAT6 expression in GM-CSF stimulated CD16+ 
monocytes, however this was very small and there was no change to the CD14+ 
monocytes. Interestingly, both RA synovial fluids analysed caused a down-
regulation in pSTAT6, below the unstimulated level in the CD14+ monocytes but 
not the CD16+ monocytes. This could potentially suggest that STAT6 is involved in 
the pathway of inhibition, however this was only investigated in 2 monocyte 
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donors, so more work needs to be performed to investigate the validity of this 
finding.  
Analysis of signalling pathways associated with GM-CSF signalling and CCL17 
transcription suggest that STAT5 is not involved in RA synovial fluid inhibition of 
CCL17 transcription. STAT6, which is potentially the transcription factor for 
CCL17 after GM-CSF stimulation, could be involved in the down-regulation of 
CCL17 transcription after RA synovial fluid stimulation, however further work is 
required to evaluate this.  
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Figure 4.11 pSTAT5 analysis after RA synovial fluid and GM-CSF stimulation. 
Monocytes isolated from buffy coats (n=5) were incubated either in media alone or with 5% RA 
synovial fluid for 4 hours. Monocytes were cell surface stained, and stimulated for 10 minutes with 
GM-CSF before immediate fixation. After pSTAT5 staining, samples were analysed on the BD 
LSRII. A) Representative histograms of pSTAT5 gated on CD14 positive cells. Pre-gating on 
PBMCs and CD3-CD19-. Graphically represented in right hand pane. B) Representative histograms 
of pSTAT5 gated on CD16 positive cells. Pre-gating on PBMCs and CD3-CD19-. Graphically 
represented in right hand pane. Gating determined by FMOs. Statistically analysed using One-way 
ANOVA with Bonferonni’s post test. * = p<0.05.  
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Figure 4.12 pSTAT6 analysis after RA synovial fluid and GM-CSF stimulation. 
Monocytes isolated from buffy coats (n=2) were incubated either in media alone or with 5% RA 
synovial fluid for 4 hours. Monocytes were cell surface stained, and stimulated for 10 minutes with 
GM-CSF before immediate fixation. After pSTAT6 staining, samples were analysed on the BD 
LSRII. A) Representative histograms of pSTAT6 gated on CD14 positive cells. Pre-gating on 
PBMCs and CD3-CD19-. Graphically represented in right hand pane. B) Representative histograms 
of pSTAT6 gated on CD16 positive cells. Pre-gating on PBMCs and CD3-CD19-. Graphically 
represented in right hand pane. Gating determined by FMOs. 
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4.2.9 Investigation into CCL17 inhibition by RA synovial fluid 
through the inhibition of JAK1 and JAK3. 
The analysis of STAT5 and STAT6 phosphorylation supported the theory that the 
factor in synovial fluid causing inhibition was not directly interfering with GM-
CSFR signalling upstream of STAT5. However, STAT6, a transcription factor 
known to bind to the CCL17 promoter, is potentially down-regulated by RA 
synovial fluid. It is unknown how the factor within RA synovial fluid is causing 
inhibition of CCL17; therefore the mechanism was further investigated. 
Therefore, in order to further dissect potential signalling pathways involved, 
Tofacitinib, a JAK1/3 inhibitor was used to pre-treat monoyctes. JAK1 is 
upstream of STAT6 signalling (308), therefore, this inhibitor would give us a 
potential indication as to whether JAK signalling was involved in the inhibition. 
However, Tofacitinib is known to have off-target effects by slight inhibition of 
JAK2. As GM-CSFR signals via JAK2, the effect of Tofacitinib was analysed by 
measuring CCL17 after increasing doses of Tofacitinib and GM-CSF stimulation.  
With no pre-treatment with Tofacitinib, GM-CSF was able to induce between 600 
and 6000pg/ml CCL17 (Figure 4.13). This was variable due to the monocyte 
donors. With the vehicle control (DMSO) pre-treatment, there was no difference 
to the level of CCL17 secreted. However, there was a dose dependent decrease 
in CCL17 produced with an increase in concentration of Tofacitinib. This 
confirmed that there were some off-target effects of Tofacitinib on JAK2. 
Therefore, to reduce the impact of Tofacitinib on GM-CSF signalling and to 
ensure CCL17 induction after GM-CSF stimulation, the 2 lower doses of 
Tofacitinib were used for further experiments. Previous data have shown that 
100nM and 300nM both effectively inhibited JAK1/3 pathways in T cells and DCs, 
therefore, these doses were assumed viable to use in this experiment (198,309). 
In order to establish whether Tofacitinib was able to reverse the observed 
inhibition by RA synovial fluid, monocytes were pre-treated with 100nM, 300nM 
Tofacitinib or vehicle control (0.001% DMSO) and GM-CSF for 30 minutes. 
Following treatment, monocytes were further stimulated with RA synovial fluid 
or LPS. Monocytes pre-treated with the vehicle control secreted 3088pg/ml ± 
3194 (Mean ± SD) CCL17 (Figure 4.14). There was a large level of variability, 
therefore to compare each individual monocyte donor to the GM-CSF alone 
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control, percentage change was also calculated with GM-CSF alone at 100% and 
the other conditions relative to this. LPS co-stimulation caused a 90% (mean ± 
SD) reduction in CCL17 secretion and RA synovial fluid co-stimulation led to 
greater than 60% (mean ± SD) inhibition. After monocytes were pre-treated with 
100nM Tofacitinib, GM-CSF caused the secretion of 1045pg/ml ± 1159 (mean ± 
SD), which was lower than the vehicle control and also variable between 
monocyte donors. LPS co-stimulation with 100nM Tofacitinib caused 80% 
inhibition (mean ± SD) of CCL17 secretion and RA synovial fluid also inhibited 
CCL17 by greater than 60% (mean ± SD). Pre-treatment of monocytes with 300nM 
Tofacitinib led to a reduction in GM-CSF stimulated CCL17 as monocytes only 
secreted 184pg/ml ± 100 (mean ± SD). LPS only caused a 38% (mean ± SD) 
reduction in CCL17 secretion, whereas RA synovial fluid inhibited CCL17 
production by 50% (mean ± SD).  
This analysis suggests that pre-treatment of monocytes with Tofacitinib at 300nM 
caused less inhibition of CCL17 when monocytes were co-stimulated with GM-CSF 
and LPS. Therefore JAK1 and/or JAK3 could potentially have a role in LPS 
inhibition of CCL17. However, the actual level of CCL17 after LPS stimulation 
was similar across all pre-treatment conditions, so the outcome of this 
experiment is difficult to conclude.  
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Figure 4.13 Tofacitinib effect on GM-CSF induction of CCL17 
Monocytes isolated from buffy coats (n=3) were stimulated with Tofacitinib at 100nM, 300nM or 
1000nM in the vehicle control (0.001% DMSO) and 1ng/ml GM-CSF for 24 hours. Supernatants 
were collected and analysed for CCL17 by ELISA. Horizontal Bar represents the median. 
Statistically analysed using Kruskal-Wallis non-parametric test. No significance identified. 
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Figure 4.14 CCL17 inhibition analysed using Tofacitinib 
Monocytes isolated from buffy coats (n=3) were stimulated with 1ng/ml GM-CSF and treated with 
Tofacitinib at 100nM, 300nM or 1000nM in vehicle control (0.001% DMSO) for 30 minutes. DMSO 
used as a control. Monocytes were then treated with 10ng/ml LPS or 5% RA synovial fluid (n=3). 
After 24 hours, supernatants were collected and analysed for CCL17 by ELISA. Data analysed as 
actual values, and percentage change in relation to GM-CSF alone for each donor. Horizontal Bar 
represents the median. Statistically analysed using Kruskal Wallis non-parametric test with Dunn’s 
post test. * = p<0.05 
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4.3 Discussion 
There have been several studies profiling the contents of synovial fluids from 
proteomics to metabolomics, to try and detect whether there are any synovial 
biomarkers (84,132,133). The analysis of synovial fluid aimed to assess the level 
of cytokines in comparison to OA. Most inflammatory cytokines and chemokines 
were present in RA synovial fluid and in some cases in OA synovial fluid (Figure 
4.1 and Figure 4.2). There were no statistically significant differences between 
RA and OA synovial fluids, which was due to the low numbers of synovial fluids 
analysed, and the heterogeneity between different fluids. To improve this, more 
RA and OA synovial fluids would have to be profiled. This analysis clarified the 
large differences between individual patient RA synovial fluids. This suggested 
that the effect of the RA synovial environment on GM-CSF induced monocytes 
had the potential to be extremely variable dependent on the stimuli present in 
the synovial fluids.  
We investigated monocytes stimulated with GM-CSF in a synovial environment to 
determine whether the stimuli within the synovial fluid such as cytokines, DAMPs 
or immune complexes would exacerbate the secretion of chemokines. Analysing 
the secretion of chemokines after GM-CSF and RA synovial fluid or OA synovial 
fluid co-stimulation showed that there were great differences between the 
response of monocytes to stimuli as well as the differences between the 
individual synovial fluids. The only robust response from RA synovial fluid was in 
its inhibition of CCL17 both at 2.5% and 5% (Figure 4.3B). OA synovial fluid was 
variable in its ability to inhibiting CCL17. Interestingly, co-stimulation of GM-CSF 
with OA synovial fluid, caused differing effects on CCL17 production. This 
suggests that the factor within the synovial fluid causing the inhibition of CCL17 
is robustly found in RA synovial fluids, and only occasionally in OA synovial fluid. 
However, the OA synovial fluids significantly inhibited GM-CSF induced CCL3 and 
CCL4, which RA synovial fluid had no impact on. This suggests an OA specific 
phenomenon and disease specific factors in synovial fluid that impact monocyte 
inflammatory secretions. However, more work needs to be done to interrogate 
the properties of OA SF that can lead to inhibition of CCL3 and CCL4. In this 
study, we were particularly intrigued by the inhibition of CCL17 by RA synovial 
fluid. This was interesting as the previous chapter analysed how CCL17 was 
inhibited by TLR ligands.  
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Similarly to LPS in the previous chapter, RA synovial fluid significantly inhibited 
the induction of CCL17 transcript at 18 and 24 hours, suggesting a comparable 
mechanism (Figure 4.4). The other ligand for CCR4 is CCL22, and interestingly 
the CCL22 transcript is also inhibited by RA synovial fluid. This suggests a CCR4 
specific effect that could impact the contribution of monocyte driven 
recruitment of CCR4+ cells into the synovium. The up-regulation of the CCL17 
transcript after GM-CSF stimulation was between 6 and 18 hours. This is an 
extended time period from stimulation to transcription, suggesting a potential 
indirect signalling pathway either intracellularly or via a secreted factor that 
further stimulates the cell. To investigate whether GM-CSF stimulates the 
secretion of a factor that then induces the monocyte to secrete CCL17, 
conditioned media was used to analyse this (Figure 4.5). Several time points 
were used to take media after the initial GM-CSF stimulation of monocytes. As 
residual GM-CSF would still be in the media, Mavrilimumab was used to pre-treat 
monocytes and within the media itself to prevent any residual GM-CSF causing 
the up-regulation of CCL17. This experiment showed, however, that at all 
analysed time points, the conditioned media with Mavrilimumab was unable to 
induce CCL17. Therefore, the GM-CSF signalling pathway to CCL17 transcription 
must be intracellular. 
To begin to understand the ability of synovial fluid to intracellularly inhibit the 
transcription of CCL17, we investigated stimulating monocytes with synovial 
fluid up to 8 hours after the initial GM-CSF stimulation. Interestingly, synovial 
fluid was able to inhibit GM-CSF induced CCL17 when added to monocytes up to 
4 hours after the initial GM-CSF stimulation (Figure 4.6). This supports the 
transcriptional data, which showed the induction CCL17 after GM-CSF 
stimulation was potentially an indirect intracellular pathway due to the delay in 
transcription. Therefore, the synovial fluid must inhibit a downstream signalling 
molecule that prevents CCL17 transcription.  
Due to the results of the previous chapter where TLR agonists inhibited CCL17, 
we hypothesised that endogenous DAMPs in the synovial fluid that bind TLRs 
were causing this effect. DAMPs have previously been shown to activate TLRs, 
for example the S100 proteins that are up-regulated in RA synovial fluid (84). 
S100A12 activates TLR4 in monocytes and induces inflammatory gene expression 
(82). Tenascin C is also a ligand for TLR4 and leads to the production of 
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inflammatory cytokines. In Tenascin C knockout mice, there was significantly 
reduced CIA disease scores and an abrogation in the cytokines produced (86). 
DAMPs are involved in RA pathogenesis, therefore we questioned whether DAMPs 
within synovial fluid were causing the inhibition in CCL17 through the binding of 
TLRs. 
To determine whether the inhibition of CCL17 was due to TLR binding DAMPs 
within the synovial fluid, anti-TLR2 and anti-TLR4 antibodies were used (Figure 
4.7). Initially, a dose response was performed to determine the concentration of 
the antibodies to use in further assays. The anti-TLR4 antibody successfully 
reversed the LPS inhibition of CCL17 at all concentrations, however the anti-
TLR2 antibody was less successful at reversing FSL1. At the higher 
concentrations, the anti-TLR2 antibody made a slight impact on the FSL1 
inhibition, however the antibody was not as effective as the anti-TLR4 antibody. 
To improve this experiment, a number of concentrations of FSL1 should have 
been used to assess the competition and whether the anti-TLR2 antibody had the 
ability at lower concentrations of FSL1 to reverse the inhibition of CCL17. 
However, the anti-TLR2 antibody was still used to determine whether the 
inhibition by RA synovial fluid could be reversed. The anti-TLR2 and anti-TLR4 
antibodies, both individually and in combination were unable to reverse the 
inhibition by RA synovial fluid inhibition on GM-CSF induced CCL17. Despite the 
less effective anti-TLR2 antibody, in comparison to the anti-TLR4 antibody, 
there was no difference in the level of inhibition by synovial fluid. This led us to 
question whether it was a redundancy mechanism, whereby the inability of 
signalling via TLR2 or TLR4 led to the other TLRs being activated. Previous 
experiments showed signalling via other TLRs could also inhibit CCL17 therefore 
to test this theory, all TLRs had to be inhibited.  
In order to assess this, MyD88/TRIF knockout mice were obtained and monocytes 
isolated from their bone marrow. MyD88 and TRIF are the adaptor molecules for 
signalling pathways downstream of TLRs (310). Inhibiting MyD88 prevents the 
majority of TLR signalling, however TRIF allows residual signalling via TLR3 and 
TLR4 in MyD88 knockout mice, therefore a double knockout of MyD88 and TRIF 
prevents signalling via TLRs (310,311). C57BL/6 mouse monocytes were used as a 
control, with LPS and RA synovial fluid significantly inhibiting GM-CSF induced 
CCL17 (Figure 4.8). This was a surprising, but useful finding that human RA 
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synovial fluid had the ability to inhibit CCL17 in mouse monocytes as it suggested 
cross-reactivity of the inhibitory factor within RA synovial fluid. Furthermore, 
LPS, which inhibited wildtype monocyte CCL17, would be expected to be 
ineffective in MyD88/TRIF double knockout mouse monocytes. This was the case 
as there was no inhibition of CCL17 by LPS in these monocytes, confirming that 
these mice lacked the ability to signal via downstream molecules from TLRs. 
However, surprisingly, the RA synovial fluid still inhibited the GM-CSF induction 
of CCL17 in MyD88/TRIF knockout monocytes. This showed that the factor 
causing inhibition of CCL17 in synovial fluid was not acting via TLRs and 
therefore had a different mechanism causing the inhibition than the TLR ligands. 
Synovial fluid is known to contain a whole milieu of inflammation inducing 
factors, from DAMPs, to immune complexes and cytokines (84,134,137).  
Identifying that RA synovial fluid had the ability to inhibit GM-CSF induced 
CCL17, independently of TLR signalling, we analysed whether the inhibition 
could be replicated by other means. Initially small immune complexes were 
investigated as a high proportion of RA synovial fluids contain immune complexes 
(296). Small immune complexes also significantly inhibited GM-CSF stimulated 
secretion of CCL17 (Figure 4.9). Although these were manmade immune 
complexes and not the immune complexes found in the RA synovial fluid, it 
supports the hypothesis that immune complexes can also inhibit this pathway. 
Immune complexes bind to Fcγ receptors and previous studies with SIC show that 
through Fc mediated pathways, macrophages can be primed towards more 
regulatory and anti-inflammatory pathways (245). The inhibition of CCL17 by SIC 
suggests that the down-regulation caused by synovial fluid, could in fact be a 
regulatory mechanism, preventing the migration of CCR4+ cells into the 
synovium. To determine whether eliminating immune complexes from the 
synovial fluid would reverse the observed inhibition of CCL17, protein A, protein 
G and protein A/G/L magnetic beads were used (Figure 4.9). We undertook 
studies to determine the efficacy of the depletion, however, the assay was 
inconclusive and we were unable to repeat due to time restraints and sample 
availability. Due to the nature of the technique, we were confident that 
depletion occurred, however, this is an uncertainty. There was no effect on the 
inhibition by synovial fluid when protein A or protein G were depleted, however 
we were unable to assess the level at which the immune complexes were 
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removed. Interestingly with the depletion of protein A/G/L, there was an even 
greater inhibition of RA synovial fluid to the level of LPS inhibition. This 
suggested that endotoxin contamination could be a possibility, but after a 
limulus assay, the synovial fluids were not contaminated. This showed that by 
removing more of the immune complexes, there was a larger inhibition of 
CCL17. The reasons for this are unknown, however we confirmed that immune 
complex depletion did not reverse the inhibition of CCL17. This suggests that 
there are other factors in synovial fluid that would be unaffected by immune 
complex depletion, but that also have the ability to inhibit CCL17. Type I 
interferons, specifically IFNα, is known to be highly expressed within RA synovial 
fluid but not in OA synovial fluid, which we know had less ability to inhibit CCL17 
(302). This cytokine would be unaffected by depletion of immune complexes, 
therefore could explain why no reversal of inhibition was observed. Using 
recombinant IFNα, there was inhibition of CCL17 to comparable levels as LPS 
inhibition (Figure 4.10). This highlighted that there are multiple factors, 
commonly found within RA synovial fluid, which had the ability to inhibit GM-CSF 
driven CCL17. To investigate the intracellular mechanism leading to inhibition of 
CCL17, the downstream signalling of GM-CSFR was analysed. 
GM-CSF binds its receptor GM-CSFR (formed of α and β chains) and signals via 
JAK2 and STAT5. To determine whether STAT5 signalling was impacted by 
synovial fluid, we investigated its phosphorylation status after pre-stimulation 
with synovial fluid, and a short 10 minute stimulation with GM-CSF (Figure 4.11). 
This analysis showed that in comparison to unstimulated monocytes, GM-CSF 
stimulation caused an upregulation in pSTAT5 MFI in CD14+ monocytes. There 
was a difference between CD14+ and CD16+ monocytes in the induction of 
pSTAT5 after GM-CSF stimulation as this was more apparent in the CD14+ 
monocytes than CD16+ monocytes suggesting different responses to GM-CSF. 
Interestingly in some monocytes donors there was no effect on the MFI of 
pSTAT5 in monocytes with the RA synovial fluid pre-treatment. However, some 
monocyte donors had fewer pSTAT5 positive monocytes after RA synovial fluid 
pre-treatment. This suggests that there are perhaps multiple mechanisms 
leading to the inhibition of CCL17. 
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Transcription of CCL17 was not induced when monocytes were co-stimulated 
with GM-CSF and RA synovial fluid (Figure 4.4), and the signalling directly 
downstream of GM-CSFR through STAT5 was not consistently targeted (Figure 
4.11). Therefore to determine whether RA synovial fluid was affecting the direct 
transcription of CCL17, we analysed a known transcription factor. Binding sites 
for STAT6 have been identified in the promoter region of the CCL17 locus 
through reporter assays examining IL-4 induction of CCL17 in T cells (267,307). 
As STAT6 had been identified as a transcription factor for CCL17 in T cells, we 
aimed to analyse whether its phosphorylation was potentially inhibited by RA 
synovial fluid, thereby preventing the transcription of CCL17. Monocytes 
expressing pSTAT6 were present even in unstimulated conditions suggesting a 
basal level of signalling through STAT6. There was a very slight increase in the 
percentage of pSTAT6 positive monocytes after GM-CSF stimulation, however 
due to the small number analysed, this was difficult to interpret. Furthermore, 
phosphorylation is indicative of an involvement of STAT6 after GM-CSF signalling, 
however it does not confirm whether STAT6 translocated to the nucleus, or 
whether it is the transcription factor for CCL17 after GM-CSF stimulation. For 
nuclear translocation of STAT6, it must be phosphorylated but also dimerized, 
therefore analysis of dimerization would be required to assess the involvement 
of STAT6 (312,313). Interestingly, both RA synovial fluids analysed appear to 
inhibit pSTAT6 to below the basal level in CD14+ monocytes, however this was 
not the case in CD16+ monocytes. The difference between the response of CD14+ 
monocytes and CD16+ monocytes suggests their differing phenotypes could 
impact their response to GM-CSF. However, this experiment required further 
repeats to be conclusive. Another caveat to this finding was that if GM-CSF did 
not induce a high level of pSTAT6 positive cells, it suggests that this was not the 
transcription factor response for inducing CCL17 in response to GM-CSF. 
However, the previous transcript analysis showed a lag time between GM-CSF 
stimulation and CCL17 transcription (Figure 4.4). Therefore, the 10 minute GM-
CSF stimulation of monocytes to analyse the potential transcription factor for 
CCL17 could have been extended to multiple later time points. The RA synovial 
fluid had a 4 hour pre-stimulation with the monocytes, which could explain why 
there was an inhibition observed below the basal level of the unstimulated 
monocytes as there was enough time for this transcription factor to be inhibited. 
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Therefore, further analysis of STAT6 is required to elucidate whether it has an 
involvement in RA synovial fluid inhibition of GM-CSF driven CCL17. 
Tofacitinib is a small molecule inhibitor that preferentially inhibits JAK3 and 
JAK1 signalling (198,314). Inhibition of this pathway, it had the potential to shed 
light onto the signalling pathway in which the synovial fluid was inhibiting CCL17 
transcription as the JAK molecules are upstream signalling molecules of STATs. 
Specifically, JAK1 is an upstream of STAT6 signalling (308). Initially, we analysed 
whether Tofacitinib had any off-target effects by assessing the impact of 
treatment on the CCL17 production by GM-CSF stimulated monocytes (Figure 
4.13). There was a dose dependent decrease in the level of CCL17 secreted with 
increasing concentrations of Tofacitinib, suggesting that the GM-CSF signalling 
molecule JAK2 was also partially inhibited. This has been observed before 
despite the major target molecules of JAK1 and JAK3 (314,315). Due to this 
targeted inhibition of GM-CSF induced CCL17, the effect of Tofacitinib on LPS or 
RA synovial fluid inhibition of CCL17 was analysed in comparison to the GM-CSF 
with matched pre-treatment for a more accurate comparison (Figure 4.14). At 
100mM, there was no reversal of the RA synovial fluid inhibition of CCL17, 
however at 300mM, there was an increase in the percentage change in the LPS 
inhibition of CCL17. This appears to show a slight reversal in the inhibition 
observed, however, when the specific concentration of CCL17 was analysed, the 
level of CCL17 secreted with LPS co-stimulation was comparable across all 
conditions. This was therefore difficult to interpret, as there were too many 
variables that affected the result. Therefore, as we have been unable to 
determine the precise intracellular signalling pathway leading to CCL17 
inhibition, we analysed the potential factors within the synovial fluid that could 
be causing the inhibition.  
Initially, after establishing that RA synovial fluid inhibited GM-CSF induced 
CCL17, we investigated the potential factor within the synovial fluid that was 
causing this inhibition. However, these studies identified that there were 
multiple factors that had the ability to cause inhibition all of which are present 
in RA synovial fluid. These ranged from the cytokine IFNα, to immune complexes 
and TLR binding DAMPs (Figure 4.15). The ability of GM-CSF driven CCL17 
induction to be inhibited in several ways suggests a regulatory mechanism to 
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prevent the infiltration of CCR4 positive cells into the joint. GM-CSF is abundant 
in the joint, and therefore there is huge potential for high levels of CCL17 to be 
secreted. The ability of the inflamed synovial milieu to dampen the secretion of 
CCL17 shows a mechanism to prevent further excessive inflammation through 
the migration of Th17 cells into the joint. There are other regulatory 
mechanisms within the joint such as the secretion of IL-10 from macrophages, 
which is highly expressed in the synovial fluid (136) and in the blood there are 
significantly higher levels of IL-10 in RA blood compared with healthy controls 
(316). IL-10 is classed as a more anti-inflammatory cytokine that classically 
dampens the immune response through suppressing interactions between 
macrophages and T cells and down-regulation of macrophage inflammatory 
cytokine secretion (317,318). However, as IL-10 as well as other anti-
inflammatory cytokines are not at high local concentrations, they are unable to 
mediate a response against the more abundant pro-inflammatory cytokines. 
Therefore, despite their presence, other pathogenic factors prevent resolution, 
and drive inflammation.  Potentially, synovial fluid inhibition is a regulatory 
mechanism that is too little, too late to alter disease pathogenesis.  
The ability of multiple factors within the RA synovial fluid to inhibit GM-CSF 
induction of CCL17 in monocytes is potentially another regulatory mechanism in 
RA, to try to dampen the immune response. The inhibition of chemokines that 
would chemoattract Th17 cells suggests a preventative mechanism, without 
which, hugely exacerbated inflammation of the joint would exist. The synovial 
milieu has the capacity to influence cell responses that are exposed to it, 
making the understanding of the synovial environment and cellular responses 
hugely important. 
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Figure 4.15 Schematic of updated hypothesis 
Upon stimulation with GM-CSF, monocytes secrete CCL17, which leads to the recruitment of 
CCR4+ T cells to the synovium. The CCR4+ T cells upon activation, produce GM-CSF in a positive 
feedback loop. Synovial fluid, or specifically: TLR ligands; Small Immune Complexes; and IFNα 
can inhibit GM-CSF induction of CCL17 in monocytes. 
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Chapter 5 Macrophage and monocyte  
 phenotypes in the synovial environment  
5.1 Introduction 
The previous chapter assessed how GM-CSF induced CCL17 in monocytes, but 
also how the RA synovial milieu inhibited this induction. Multiple components 
within the synovial fluid had the ability to cause inhibition of CCL17, suggesting 
the synovial fluid can influence the cellular secretome and have an impact on 
cellular phenotype.  
Human monocytes can be classified into subsets by their expression of CD14 and 
CD16 (319). The majority of monocytes lack CD16 expression and are classified 
as classical monocytes (CD14++CD16-). They are present in blood at 10 times 
greater levels than other subsets (52). The subset that are CD16+, are classed as 
non-classical monocytes (CD14+CD16++), however some state these monocytes 
are pro-inflammatory as they respond to LPS and secrete TNFα. Even under non-
inflammatory conditions, non-classical monocytes can migrate into tissues (320). 
Monocytes are not only classified by their expression of CD14 and CD16 but 
expression of chemokine receptors such as CCR2 or the presence of specific TLRs 
(Section 14.1.1). Cytokine and chemokine secretion can also allow the 
classification of the populations.  
The traditional viewpoint is that when monocytes receive specific environmental 
cues, they differentiate into monocyte-derived cells, however, there have also 
been studies to suggest that there are tissue resident monocytes that do not 
differentiate into macrophages (321). When macrophages differentiate, they are 
classified into distinct categories, depending on specific transcriptional markers, 
surface receptors or cytokines released. Until recently, the nomenclature of 
macrophage classification has ranged from M1 and M2 macrophages to 
alternatively activated, classically activated and regulatory macrophages. These 
terms have been generated in the main from in vitro cultured human blood 
monocyte derived macrophages or mouse bone marrow macrophages (63). 
Traditionally, monocytes were differentiated into macrophages using growth 
factors such as GM-CSF for an M1 macrophage or M-CSF for an M2 macrophage 
(265). Alternatively activated macrophages were differentiated in IL-4 with or 
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without IL-13 and classically activated macrophages were differentiated in IFNγ. 
However, there are several other in vitro stimuli that are used to differentiate 
macrophages such as IL-10, immune complexes and LPS (62,63).  
There are specific transcriptional markers that are used to define in vitro 
derived macrophage subsets to form a transcriptional signature, such as CD64, 
which is an M1 marker, and CD23, which is an M2 marker (322). However, the 
spectrum of macrophages isolated from tissue, or differentiated in vitro under 
different conditions, has led to cells that do not fit into a distinct category. 
There is still dispute over macrophage classifications, however, it is now widely 
accepted that tissue resident macrophages are embryonic derived. Monocytes 
that infiltrate into a tissue in response to inflammatory cues, differentiate 
dependent on the specific stimuli in the milieu, or interactions with other cells, 
into a broad spectrum of monocyte-derived cells, which do not necessarily fit 
into a distinct category (50). They may have aspects of an M1 or an M2 but are 
unique (57). Monocyte-derived cells can be classified with transcriptional 
markers, scavenger receptors, metabolic profiles cytokines and chemokines 
(63,323).  
Macrophages within the RA synovium reside primarily in the intimal lining layer, 
where they interact with synovial fibroblasts and are exposed to the synovial 
milieu (67). Monocytes increase in number in the synovium upon inflammatory 
insult, and as they differentiate into macrophages, the 30-40% increase in 
macrophage numbers in the RA patient synovium suggests that monocyte 
infiltration directly contributes to this (255,324,325). In general, macrophages 
within the RA synovial lining are positive for GM-CSFRα, as there was a 
significant up-regulation of GM-CSFRα positive macrophages in RA patients in 
comparison to OA patients(238). The presence of increased levels of GM-CSFRα 
in the RA synovial tissue suggests that there is the capacity for more GM-CSF 
signalling to occur. Therefore, inhibition of this receptor via Mavrilimumab could 
alter the phenotype of macrophages or their monocyte precursors, particularly 
within the synovial milieu, which was shown in the previous chapter to influence 
the secretion of chemokines (Fig 4.3). 
154 
 
The RA synovial environment contains many stimuli that could impact monocyte 
and macrophage phenotypes. Understanding the effect of these stimuli on 
polarisation of macrophages and the activation of monocytes is not well 
understood. Therefore, this chapter aims to identify the impact of the synovial 
environment on macrophage polarisation and monocyte activation.  
Chapter Aims: 
• To assess the impact of synovial fluid on macrophage polarisation. 
• To determine how monocyte activation markers are affected by synovial 
fluid. 
• To establish whether Mavrilimumab affects monocyte phenotypes. 
  
155 
 
5.2 Results 
5.2.1 The effect of in vitro stimuli on macrophage polarisation 
Transcriptional signatures for macrophage polarisation states have been well 
defined for M1 and M2 macrophages. Investigations were undertaken to 
determine whether a transcriptional profile could be generated that were 
comparable with previously reported studies, to then be used in further 
experiments. The effect of disease-specific stimuli on these transcriptional 
profiles could then be evaluated. Differentiation of macrophages has 
traditionally been with individual stimuli such as M-CSF or GM-CSF for 7 days 
(265). These experiments investigated whether macrophages differentiated with 
M-CSF could then be skewed with alternative stimuli, to create different 
polarisation states. This would aim to understand macrophage plasticity after 
stimulation with differing environmental factors. Therefore monocytes isolated 
from buffy coats were differentiated using M-CSF for 7 days for an M0 
macrophage. From this M0 macrophage, further stimulations with IFNγ, IL-4 or 
GM-CSF were used to create different polarised macrophages.  
There are multiple methods described to determine macrophage polarisation 
state, however in initial studies, transcriptional profile was interrogated. 
Specific transcriptional markers were chosen from a particular paper from Beyer 
et al., (322) in which transcriptional profiles were analysed, specifically in M1 
and M2 differentiated human macrophages. The majority of available data has 
only looked at specific polarisation states; therefore this was expanded to 
interrogate alternative polarisation states. This was achieved by identifying 
transcriptional profiles for 4 experimentally differentiated macrophage 
phenotypes. 
Therefore, investigations into macrophages polarised with M-CSF followed by 
IFNγ (M1), IL-4 (M2) or GM-CSF (M-GM) were compared to M-CSF (M0) 
differentiated macrophages. The evaluation of transcriptional signatures in M1, 
M2 and M-GM macrophages revealed that M1 macrophages have a different 
transcriptional signature in comparison to other macrophage phenotypes. M1 
macrophages had significantly higher transcript expression of APOL2, APOL3, 
APOL6 and IRF7 compared with M0 macrophages (Figure 5.1). Macrophages 
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differentiated with IL-4, or M2 macrophages, also differed from M0, M1 and M-
GM macrophages. M2 macrophages had significantly elevated expression of CD23 
with 10 fold greater expression than M0 macrophages. However, M2 
macrophages had significantly lower expression of CD64 with greater than M0 
and M1 macrophages. IRF4 and IRF5 were also significantly higher, with a greater 
than 3 fold increase in expression in M2 macrophages in comparison to M0 
macrophages. Macrophages differentiated with GM-CSF, or M-GM macrophages, 
had no specific marker that was more highly expressed than other macrophages. 
Despite this, M-GM macrophages had greater than 2 fold increase in expression 
of IRF4 and IRF5 in comparison to an M0 macrophage.  
This transcriptional analysis confirmed that experimental stimuli, in this case, 
IFNγ, IL-4, GM-CSF or M-CSF have differing effects on macrophage phenotypes. 
Dependent on the stimuli received, the polarisation of these macrophages was 
altered, even after initial differentiation with M-CSF showing their plasticity. 
This suggests that these macrophages could be altered by their micro-
environment.  
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Figure 5.1 Experimental macrophage transcriptional profiles. 
Monocytes isolated from human buffy coats (n=4) (n=3 for APOL3) and cultured in 100ng/ml M-
CSF for 7 days. Media was replaced with further stimulations of 100ng/ml M-CSF for M0, 20ng/ml 
IFNγ for M1, 100ng/ml IL-4 for M2 or 100ng/ml GM-CSF for M-GM for 24 hours. Cells were lysed 
and RNA extracted for analysis of specific transcripts by qPCR using SYBR green. Transcripts 
were normalised to GAPDH housekeeping. RQ was calculated for each experimental macrophage 
transcript in relation to an M0 macrophage was analysed. Horizontal bar indicates the median. 
Statistically analysed using Kruskal-Wallis non-parametric test, followed by Dunn’s post test. 
*=p<0.05, **=p<0.01.  
  
158 
 
5.2.2 Evaluation of valid housekeeping genes. 
For further evaluation of macrophage transcriptional phenotypes, Taqman Low 
Density Arrays (TLDA) were used. For this technique, multiple housekeeping 
genes could be used, therefore, it was necessary to identify the most suitable 
housekeeping genes prior to further evaluation. For this, the most consistent 
housekeeping genes after experimental macrophage polarisation were 
determined by using a housekeeping TLDA plate.  
Monocytes were differentiated in M-CSF for 7 days, followed by polarisation 
stimuli with IFNγ, IL-4 or GM-CSF. In addition to evaluating the best 
housekeeping gene to use for macrophage polarisation states, studies were also 
undertaken to determine a housekeeping gene that stayed at comparable CT 
values from monocyte separation through to macrophage differentiation for 
consistent analysis of monocytes and macrophages. Therefore monocytes were 
assessed (n=1) as well as polarised macrophages (n=3). PBMCs and LPS 
stimulated M0 and M-GM macrophages were also analysed as a comparison. 
The CT values were assessed for each condition and every gene on the array 
plate. Commonly used housekeeping genes such as GAPDH, ACTB and TBP, did 
not have consistent CT values across all conditions (Figure 5.2). In several of the 
genes, PBMCs were different to the other conditions, however, as there was no 
intention to transcriptionally analyse whole PBMCs, this was not a concern. 
There was also variability observed between the 3 donors used between the 
macrophage phenotypes. However, CT values for UBC and GUSB were found to 
be the most comparable across all conditions. These housekeeping genes were 
therefore carried on into further experiments using TLDA transcriptional 
analyses.  
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Figure 5.2 Housekeeping Array analysis 
cDNA was analysed from 3 buffy coat donors cultured into 4 phenotypes of macrophages with the 
additional stimuli of LPS in an M0 or MGM macrophage or a CD14 monocyte immediately after 
separation or a PBMCs. CT values of each labelled gene are shown across all conditions. 
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5.2.3 The effect of disease stimuli on macrophage polarisation 
The initial experiments showed that macrophages can be polarised and 
expressed different macrophage transcriptional markers depending on the 
stimuli. To assess the effect of the diseased microenvironment on macrophage 
polarisation, macrophages were stimulated with synovial fluid from RA patients. 
Stimulating macrophages with synovial fluid in vitro, aimed to artificially 
recreate the environment in which monocytes infiltrating the tissue would be 
subjected to. By determining how macrophages differentiate in this 
environment, we could establish whether these macrophages were similar to 
particular polarisation states of the experimental macrophages (Figure 5.1). OA 
synovial fluid had a different effect on monocytes when co-stimulated with GM-
CSF in comparison to RA synovial fluid in the previous chapter. Therefore, to 
determine whether different synovial fluids affected the polarisation of 
macrophages, RA, and OA synovial fluids were used. 
Macrophages stimulated with synovial fluid from RA or OA patients, termed MSF, 
had some transcript similarities to experimental macrophages, however, despite 
aspects of specific experimental macrophages, their overall transcriptional 
profile was different. Individual samples came from buffy coats donated from 
the Scottish National Blood Transfusion Service (Section 2.2.1). It was observed 
that there was variation between the buffy coats and their response to synovial 
fluid. M1 macrophages expressed APOL3 at greater levels, and one buffy coat 
also expressed this transcript highly with the addition of either RA or OA synovial 
fluid, however due to the variation observed, it was difficult to confirm a 
specific MSF transcriptional phenotype (Figure 5.3). CD36 had similar levels of 
expression across all experimental macrophages, however, there was an up-
regulation of this transcript in both OA and RA MSFs. M1 and M-GM macrophages 
had greater levels of CLEC4E and this was mirrored by both the OA and RA MSFs. 
M2 and M-GM macrophages had increased expression of CSF2RA in comparison to 
M0 macrophages, and 1 buffy coat donor MSF had higher expression. The 
transcript LILRA2 in the OA and RA MSFs was more comparable in lower 
expression than M0 and M2 macrophages to the M1 and M-GM macrophages. MSR1 
and TLR4 transcripts had greater expression in the MSFs in comparison to the 
experimental macrophages. 
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Analysis of macrophage transcriptional profiles differentiated with RA and OA 
synovial fluids showed that MSFs are different from a specific experimental 
macrophage. However, MSFs had properties of the experimental macrophages, 
as there was not a transcript that was up-regulated in the MSFs, that was not 
also up-regulated in another condition. Synovial fluid provides another profile in 
the spectrum of macrophage activation. There was also no transcriptional profile 
that was consistent across all donors, therefore it was difficult to conclude a 
specific MSF phenotype. The RA and OA MSFs had comparable transcriptional 
profiles suggesting the synovial fluid had a similar impact on macrophage 
polarisation, however functional studies would be needed to determine whether 
these macrophages were the same.  
As macrophages polarised with OA or RA synovial fluid had a very similar 
transcriptional phenotypic profile, it was investigated whether synovial fluid 
from PsA patients also had the same impact on macrophage transcriptional 
phenotypes. After 7 days differentiation of monocytes with M-CSF, macrophages 
were further stimulated for 24 hours with RA, OA or PsA synovial fluid. 
Transcripts were analysed by qPCR for genes that were identified as markers of 
specific experimental macrophages (Figure 5.1). The synovial fluid stimulations 
caused very minor changes to transcription in comparison to M0 macrophages 
(Figure 5.4) and expression of transcripts in MSFs was much lower than in Figure 
5.3. This confirmed the variability between monocyte donors, and the difficulty 
in making conclusions. However, the RA, OA and PsA MSFs had comparable levels 
of transcript expression suggesting they were of a similar transcriptional 
phenotype (Figure 5.4). 
The transcriptional observation, suggested a similar transcriptional phenotype 
between MSFs polarised with RA, OA or PsA synovial fluid. Therefore, to 
determine whether the similar MSF transcriptional phenotype could be 
translated into their functional output, chemokine levels were investigated. To 
ensure the chemokine induction was measured, without interference from the 
level in synovial fluid, the chemokine content of the synovial fluids that were 
added to the culture, was deducted from the level of the supernatants. In 2 of 
the 3 buffy coat donors, LPS up-regulated chemokine expression, acting as a 
positive control, however, this was not the case for 1 donor, which was 
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unresponsive to LPS stimulation. None of the chemokines were up-regulated by 
stimulation with synovial fluids, which would potentially be expected due to the 
number of pro-inflammatory DAMPs within the fluid. Interestingly, the MSFs had 
a suppressed level of CCL7 and CCL8 in comparison to M0 macrophages, and the 
synovial fluid had a similar impact on functional chemokine output, whether it 
was derived from RA, OA or PsA patients.  
Although there is not a robust signature in the transcriptional analysis or the 
secreted chemokines that have been looked at, it is clear that synovial fluid 
from any arthropathy has a comparable impact on macrophage polarisation with 
regards to transcriptional profile or chemokine induction. 
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Figure 5.3 Transcriptional analysis by TLDA of macrophages differentiated with RA or OA 
synovial fluid. 
Monocytes isolated from human buffy coats (n=3) were cultured with 100ng/ml M-CSF for 7 days, 
followed by 24 hour stimulation with: 100ng/ml M-CSF for M0; 20ng/ml IFNγ for M1, 100ng/ml IL-4 
for M2; 100ng/ml GM-CSF for M-GM; or 10% synovial fluid (n=4) from RA or OA patients for MSF. 
Transcripts were analysed by TLDA relative to GUSB housekeeping gene and the RQ calculated 
over M0 macrophages. Horizontal bar indicates mean.  
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Figure 5.4 Transcriptional analysis by qPCR of macrophages differentiated with diseased 
synovial fluid. 
Monocytes isolated from human buffy coats (n=3) were cultured with 100ng/ml M-CSF for 7 days, 
followed by stimulation for 24 hours with: 10% synovial fluid (n=4) from RA, OA or PsA patients. 
Transcripts were analysed by qPCR relative to GUSB housekeeping gene and the RQ calculated in 
relation to M0 macrophages. Horizontal bar indicates mean. 
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Figure 5.5 Chemokine induction after synovial fluid stimulations. 
A) Monocytes isolated from buffy coats (n=3) were cultured in 100ng/ml M-CSF for 7 days. M0 
macrophages were stimulated with M-CSF for a further 24 hours with or without 15.63ng/ml LPS or 
with RA, OA or PsA synovial fluid (n=2,3,4). The supernatants were removed and were analysed 
for chemokine induction by Luminex. B) The synovial fluids themselves were also analysed and the 
level (pg/ml) that was added to the culture deducted from the MSF to ensure induction was 
quantified (A). Horizontal bar indicates mean.  
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5.2.4 Monocyte and macrophage transcriptional profile 
comparison after synovial fluid stimulation. 
The previous data found that the disease origin of the synovial fluid did not 
impact the macrophage phenotypic markers investigated. To determine whether 
this was also the case for infiltrating monocytes into the joint, monocytes were 
also stimulated with synovial fluid and directly compared with the macrophage. 
In several of the analysed genes, transcriptional expression of was significantly 
different between monocytes and macrophages. There were no significant 
differences in any of the analysed transcripts between unstimulated monocytes 
and monocytes stimulated with RA, OA or PsA synovial fluid (Figure 5.6). 
However, despite the lack of significance, transcript expression was more 
variable across the conditions in comparison to macrophages. Monocytes 
stimulated with OA synovial fluid had significantly less expression of CSF2RA, 
CREB1, IRF5 and CCL13 in comparison to PsA synovial fluid stimulated 
monocytes, suggesting these monocytes have a different transcriptional 
signature. There was no significant difference between the RA and OA synovial 
fluid stimulated monocytes, however, there was slightly increased expression of 
the analysed transcripts in the RA synovial fluid stimulated monocytes. In 
comparison to macrophage transcript expression, there was significantly less 
APOL3 transcript in comparison to all MSFs. Monocytes stimulated with OA and 
RA synovial fluid also had significantly lower levels of CSF2RA in comparison to 
comparative MSFs. Interestingly this was not the case for the PsA synovial fluid 
stimulated monocytes. Although there were no significant differences, 
monocytes stimulated with all synovial fluids had greater levels of CCL2 
transcript expression in comparison to the macrophages. CCL13 expression was 
significantly higher in monocytes compared with their corresponding 
macrophages when stimulated with RA or PsA synovial fluid.  
Looking specifically at the monocytes stimulated with synovial fluid, the PsA 
stimulated monocytes had significantly greater expression of APOL3, CSF2RA, 
CREB1, CD36, CCL13 and IRF5 in comparison to the OA synovial fluid (Figure 5.7).  
The caveat to this experiment was that it was only tested in one matched 
monocyte and macrophage donor, however, the use of 4 synovial fluid from each 
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disease showed the consistent response to these fluids by the monocytes or 
macrophages. Thus the data generated supports the concept that monocytes are 
more responsive to disease stimuli in comparison to differentiated macrophages 
at least, with respect to the transcripts measured in this study.   
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Figure 5.6 Transcriptional comparison between monocyte and macrophages after synovial 
fluid stimulation. 
Monocytes isolated from a buffy coat (n=1) were either cultured in complete media for 24 hours or 
for 7 days in M-CSF. The stimulations with 10% RA, OA or PsA synovial fluids (n=4) were for 24 
hours. Cells were lysed and analysed for transcripts by TLDA in relation to GUSB housekeeping. 
RQ calculated over the freshly isolated monocyte. MSFs statistically analysed using 2-way ANOVA 
with Bonferroni’s post test. *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001.   
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Figure 5.7 TLDA analysis of monocytes stimulated with RA, OA or PsA synovial fluid. 
Monocytes separated from a human buffy coat (n=1) were stimulated with 10% synovial fluid from 
RA, OA or PsA patients (n=4) for 24 hours. Cells were lysed and transcripts analysed by TLDA, 
relative to GUSB housekeeping. RQ calculated in relation to monocytes alone with no synovial 
treatment. Horizontal bar indicates mean. Statistically analysed using one-way ANOVA and 
Bonferroni’s post test. *=p<0.05, **=p<0.01, ***=p<0.001.  
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5.2.5 Monocyte phenotype analysis after stimulation with 
synovial fluid and Mavrilimumab. 
Monocytes stimulated with synovial fluid from RA, OA or PsA patients have 
different transcriptional profiles (Figure 5.7). The previous chapters examined 
GM-CSF stimulation of monocytes, which causes the induction and the secretion 
of pro-inflammatory chemokines (Figure 3.2). The interplay between GM-CSF 
and synovial fluid with regards to monocyte secretion of CCL17 was also 
analysed. Synovial fluid contains GM-CSF (326), therefore the involvement of 
GM-CSF on monocyte activation and differentiation was elucidated through the 
use of Mavrilimumab (CAM3001).  
Synovial fluid stimulated monocytes previously showed differential expression of 
transcripts associated with macrophage polarisation (Figure 5.7). Therefore, to 
elucidate whether monocyte activation and differentiation were affected after 
synovial fluid stimulation, an alternative transcriptional profile was analysed. 
This also assessed whether Mavrilimumab impacted monocyte activation or 
differentiation. Monocytes were pre-treated with Mavrilimumab (CAM3001) for 
30 minutes before the addition of synovial fluid, to allow binding of the antibody 
to GM-CSFRα prior to the addition of a potential GM-CSF stimulus. 
There were no large differences in transcriptional patterns between monocytes 
that were pre-treated with the isotype, and the monocytes pre-treated with 
CAM3001 with and without synovial fluid. The pre-treatment with the isotype 
followed by RA synovial fluid caused an increase in CCL3, CCL4, CD36 and IL-8 
transcripts in most buffy coat donors, however this was not a robust finding and 
there was variability between the buffy coat donors and the synovial fluids used 
(Figure 5.8). CD1A and TLR4 were up-regulated by pre-treatment with CAM3001 
followed by RA synovial fluid. OA synovial fluid stimulation caused a down-
regulation after pre-treatment with CAM3001 in CCL22, CHI3L1, CXCL2 and 
CLEC4E, however these differences were marginal.  
This data shows that there were no significant differences in the transcripts that 
were analysed. This suggests that Mavrilimumab has no effect on the activation 
of monocytes, although there was a large amount of variability between the 
buffy coat donors. Only transcripts were analysed, which prevents accurate 
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conclusions, therefore further functional analysis or flow cytometric profiles 
could improve the understanding of the effect of Mavrilimumab on monocytes.  
There was substantial variability observed in Figure 5.8 that caused difficulty in 
interpretation of results. Therefore, to assess whether the observed variability 
was due to the buffy coat donors, an experiment was performed to limit other 
variables. In order to ensure consistency, monocytes were all isolated from buffy 
coats on the same day, and all RNA isolations and qPCR was done at the same 
time.  
Monocytes alone, after 24 hours, up-regulated in CD36 and MRC1 expression, 
however, CLEC4E was down-regulated (Figure 5.9). RA synovial fluid had no 
effect on the analysed transcripts after 6 hours, however, after 24 hours, there 
was a significant increase in MRC1. As monocytes alone after 24 hours also up-
regulated MRC1, the RA synovial fluid had no distinct effect on transcript 
expression. There was no difference with the other analysed transcripts.   
There was still variability between the buffy coat donors, despite the measures 
to keep the experiment consistent. This suggests that the buffy coat donors 
were causing variability observed in Figure 5.8. 
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Figure 5.8 Effect of Mavrilimumab on monocyte phenotypes. 
Monocytes isolated from human buffy coats (n=3) were pre-stimulated with Mavrilimumab 
(CAM3001) or the isotype (CAT004) for 30 minutes. After pre-stimulation, synovial fluid from RA 
(n=4 or n=3 for buffy coat 3), OA (n=3) or PsA (n=4 for 2 buffy coats, n=1 or n=2 for buffy coat 3) 
patients was added at 10% for 24 hours. Cells were lysed, and transcripts analysed by TLDA in 
relation to GUSB housekeeping. RQ calculated relative to monocytes with the isotype pre-
treatment. Horizontal bar indicates mean. 
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Figure 5.9 Assessment of variability by qPCR. 
Monocytes isolated from buffy coats (n=3) on the same day were stimulated with 10% RA synovial 
fluid (n=3) for 6 or 24 hours. Cells were lysed and RNA extractions were performed at the same 
time to ensure consistency. Transcripts were analysed by qPCR relative to GUSB housekeeping. 
RQ calculated in relation to un-stimulated monocytes after 6 hours of culture. Horizontal bar 
indicates the median. Statistically analysed using Kruskal-Wallis non-parametric test with Dunn’s 
post test. *=p<0.05. 
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5.2.6 Mavrilimumab caused induction of CCL17 and TNFα  in 
synovial fluid treated monocytes. 
Mavrilimumab had little impact on the transcriptional phenotype of synovial 
fluid stimulated monocytes (Figure 5.8). To determine whether there were any 
functional differences, cytokine and chemokine secretion were analysed. 
Isolated monocytes were pre-incubated with Mavrilimumab or the isotype for 30 
minutes prior to stimulation with synovial fluid. Chapter 4 analysed how CCL17 
was inhibited by synovial fluid after GM-CSF stimulation. Therefore, it was 
determined whether inhibition of GM-CSF had an impact on CCL17 induction. 
The pro-inflammatory cytokines: IL-6; IL-8; and TNFα were also analysed. 
Secretion of IL-6 was unaffected by pre-treatment with Mavrilimumab 
(CAM3001), however there was a large amount of variability with the level of 
cytokine produced. IL-8 was induced by pre-treatment with Mavrilimumab, and 
one sample was out of range above detection of the assay. The addition of 
synovial fluid stimulation had no impact on both IL-6 and IL-8 secretion. CCL17 
was undetected in the monocytes pre-treated with the isotype, however 
stimulation of monocytes with RA, OA or PsA synovial fluids caused detectable, 
but low levels of CCL17 induction (Figure 5.10). Pre-incubation with 
Mavrilimumab had no effect on the monocytes stimulated with OA or PsA 
synovial fluid, but caused a significant increase in CCL17 induction in monocytes 
stimulated with RA synovial fluid. In chapter 4, GM-CSF and RA synovial fluid co-
stimulation inhibited CCL17 secretion. Therefore, in this situation, perhaps 
inhibition of GM-CSF allowed the up-regulation of CCL17. TNFα had a very low 
level of induction in the monocytes pre-treated with the isotype, which slightly 
increased in the Mavrilimumab pre-treated monocytes. Surprisingly, in the 
monocytes pre-incubated with Mavrilimumab, and stimulated with synovial fluids 
from RA, OA or PsA patients, there was a significant increase in the induction of 
TNFα in comparison to the monocytes pre-incubated with the isotype.  
The significant induction of TNFα after pre-treatment of monocytes with 
Mavrilimumab was an unexpected and surprising finding, however, this study was 
only an ‘n’ of 2 buffy coats. Although this suggests that Mavrilimumab causes an 
up-regulation of TNFα, further studies were required to validate this finding. 
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Figure 5.10 Monocytes pre-treated with Mavrilimumab secreted TNFα  and CCL17. 
Monocytes isolated from buffy coats (n=2) were pre-treated with Mavrilimumab (CAM3001) or the 
isotype (CAT004) for 30 minutes prior to the addition of 10% RA, OA or PsA synovial fluid (n=4). 
After 24 hours, supernatants were collected and analysed for CCL17, IL-8, IL-6 and TNFα by 
ELISA. Horizontal bar indicates the mean. Statistically analysed using one-way ANOVA with 
Bonferroni’s post test. *=p<0.05 and ***=p<0.001. 
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5.2.7 Investigation into the induction of TNFα  by Mavrilimumab. 
The previous data showed that Mavrilimumab could potentially cause the 
induction of TNFα in monocytes. Therefore, to analyse this, a dose response of 
both Mavrilimumab and the isotype was investigated.  
Increasing concentrations of the isotype, increasing concentrations of 
Mavrilimumab and 50ng/ml GM-CSF were used to stimulate monocytes as well as 
monocytes cultured alone. Stimulation for 4, 16 and 24 hours showed that 
monocytes alone had a basal level of TNFα secretion (Figure 5.11A). All 
concentrations of Mavrilimumab resulted in a similar level of TNFα secretion to 
monocytes alone, whereas the isotype inhibited TNFα production in a dose 
dependent manner. The GM-CSF positive control caused induction of TNFα, 16 
hours after stimulation.  
It was an unexpected finding that the isotype for Mavrilimumab inhibited the 
basal level of TNFα after pre-stimulation. Therefore, it was considered that it 
could be due to non-specific binding. To examine whether this was the case, 
monocytes were cultured in media containing human serum to prevent 
unspecific binding of the antibody. The isotype still inhibited the basal level of 
TNFα secretion at all analysed concentrations, whereas Mavrilimumab had no 
change in TNFα production in comparison to the untreated monocyte control 
(Figure 5.11B).  
Therefore, it was necessary to elucidate why this was occurring. One hypothesis 
was that the isotype was inducing cell death, and therefore preventing the 
induction of TNFα. To investigate this hypothesis, monocytes were cultured 
alone, with Mavrilimumab, the isotype or with GM-CSF as a positive control and 
analysed for apoptosis via FACS (Figure 5.12A-D). Monocytes treated with 
Mavrilimumab or the isotype had similar levels of apoptosis, comparable with 
monocytes alone, therefore this was not the reason for inhibition of TNFα. It was 
possible that the isotype was actually binding to cells, therefore the isotype was 
fluorescently labelled with vioblue. Using FACS, it was possible to compare 
binding of the isotype to cells in comparison to unstained cells and FACS beads, 
which were a positive control. There was a marginal shift in the expression of 
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isotype labelled-vioblue positive cells in comparison with unstained cells 
suggesting there was some binding of the isotype to the cells (Figure 5.12E). 
Controls were used to confirm the isotype was successfully labelled using FACS 
beads, and so a comparison of vioblue-labelled FACS beads were compared with 
unstained beads and another pacific blue antibody. The isotype was successfully 
labelled with the vioblue-fluorescent probe as there was a large shift between 
unstained and labelled beads (Figure 5.12F) and it was comparable with another 
pacific blue antibody fluorescence (Figure 5.12G). 
These data confirm that Mavrilimumab was not inducing TNFα in monocytes, 
however, the relevant isotype inhibited TNFα induction. Investigations into the 
mechanism in which the isotype caused TNFα inhibition were inconclusive, 
however, the data showed that inhibition was not due to unspecific binding 
through the use of human serum. Apoptosis was not induced but the isotype had 
only slight binding to the cells. As I was unable to include an appropriate control 
antibody there was difficulty in interpretation of the effect of Mavrilimumab on 
monocytes.  
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Figure 5.11 Dose response of Mavrilimumab and isotype analysing TNFα  induction. 
A) Monocytes isolated from buffy coats (n=3) were incubated with increasing concentrations of 
Mavrilimumab (CAM3001) or the isotype. Supernatants were collected at 4, 16 and 24 hours and 
analysed by ELISA for TNFα. B) Monocytes separated from buffy coats (n=2) were cultured in 
media containing human serum and increasing concentrations of Mavrilimumab or the isotype. 
Supernatants were analysed after 24 hours for TNFα by ELISA. 50ng/ml GM-CSF was used to 
treat monocytes as a positive control in both A) and B). 
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Figure 5.12 Isotype does not induce apoptosis in monocytes. 
Monocytes isolated from a buffy coat (n=1) were cultured for 24 hours A) alone or with B) 50ng/ml 
GM-CSF, C) 10µg/ml Mavrilimumab or D) 10µg/ml Isotype for 24 hours. Monocytes were assessed 
for apoptosis by Annexin V and PI by FACS. E-G) The isotype was fluorescently labelled with 
vioblue fluorophore and used to analyse binding to monocytes. E) Unstained cells (red) in relation 
to cells stained with the vioblue isotype (blue). F) Beads labelled with the vioblue isotype (blue) 
relative to unstained beads (red). G) Beads labelled with the vioblue isotype (blue) in relation to the 
beads with another pacific blue antibody (red). 
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5.3 Discussion 
Macrophages are highly plastic cells that change their phenotype and activation 
in response to environmental triggers such as endogenous DAMPs and cytokines 
(57). In this chapter, investigations were undertaken into macrophage 
polarisation in response to disease relevant stimuli. Specifically, arthropathy 
derived synovial fluids were used in order to assess the impact of Mavrilimumab 
on macrophage phenotypes. 
Initial experiments examined macrophage phenotypes under experimental 
stimuli. The classification system widely used in the macrophage field is the M1 
or M2 phenotype. There have been studies suggesting M1 macrophages are in 
vitro derived through stimulation with IFNγ, IFNγ with LPS or GM-CSF, whereas 
M2 macrophages are derived through stimulation with IL-4, IL-4 and IL-13 or M-
CSF (61). In this chapter, macrophages were defined as M0 if they were 
differentiated with M-CSF alone, M1 for macrophages differentiated with IFNγ, 
M2 for macrophages differentiated with IL-4 and M-GM for macrophages 
differentiated with GM-CSF. The nomenclature devised for these experiments 
was for ease of comparison of macrophages differentiated with synovial fluid 
with experimental macrophages. We aimed to determine whether there were 
transcriptional phenotypic similarities between an experimental macrophage and 
the synovial fluid stimulated macrophages. The M0, M1 and M2 macrophages had 
distinct transcriptional phenotypes, however the M-GM did not have a specific 
transcript that was more highly expressed than the other phenotypes. In 
comparison to the Beyer et al paper (322), in Figure 5.1 there was a significant 
reduction of CD64 in M2 macrophages in comparison to M1 macrophages. There 
was also an increase in CD23 expression in M2 macrophages, as well as M1 
macrophages highly expressing APOL2, APOL3 and APOL6. Interestingly, Beyer et 
al., also observed M1 macrophages expressing APOL1, LILRA2 and LILRB3 at 
significantly higher levels than M2 macrophages, which were not reproduced in 
this experiment. Krausgruber et al., (327) found M1 macrophages, or 
macrophages differentiated in GM-CSF to highly express IRF5, whereas in Figure 
5.1, M2 macrophages had significantly greater expression of IRF5 than M0 
macrophages. M-GM macrophages had a 2.5 fold increase in IRF5 in comparison 
to M0 macrophages, which could potentially explain why Krausgruber et al., saw 
an increase in expression. However, M2 macrophages differentiated with IL-4 
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had greater expression of IRF5. GM-CSF has also been shown to induce IRF4 
(328), however this analysis found a greater expression of IRF4 in M2 
macrophages. Comparing our findings with the literature shows how there are 
many different ways of differentiating M1 and M2 macrophages, and variability 
in assay conditions can lead to differences in expression of transcriptional 
markers. To improve our findings, we could have used RNAseq or a microarray to 
fully identify macrophage profiles.  
Before examining the effect of synovial fluids on macrophage phenotypic 
transcripts by TLDA, confirmation of the most consistent housekeeping gene was 
determined to ensure accurate further analysis. Commonly used housekeeping 
genes such as GAPDH and ACTB were not consistent across all macrophage 
phenotypes or the monocyte alone (Figure 5.2). This showed that using a well-
defined housekeeping that is popular in the literature is not necessarily the most 
appropriate for all conditions. In this analysis of 3 buffy coat donors 
differentiated into macrophages as well as monocytes and PBMCs, the most 
consistent housekeeping genes were GUSB and UBC, which are less commonly 
used in the literature. To ensure the housekeeping had a steady CT value, these 
were used for all further transcriptional analysis.  
Analysis of the effect of RA or OA synovial fluid on the polarisation of 
macrophages was investigated through the analysis of transcriptional profiles. 
The transcriptional data shown in Figure 5.3 compared monocytes differentiated 
with experimental stimuli with macrophages stimulated with with RA or OA 
synovial fluid. Multiple buffy coats and multiple synovial fluids were used to look 
at the robustness of the observed transcriptional signatures.  Both  RA and OA 
synovial fluids had similar effects on the analysed transcripts. This was 
potentially due to both containing many DAMPs (84). However, this was also 
surprising considering the previous chapter where OA and RA synovial fluids had 
different effects on GM-CSF induced secretion of chemokines in monocytes 
(Figure 4.3). Both OA and RA MSFs had greater expression of CD36, MSR1 and 
TLR4 in comparison to all experimental macrophages. Despite using multiple 
buffy coats and multiple synovial fluids to try and gain a robust signature, the 
data has led us to conclude that there is substantial heterogeneity across 
healthy donor cells and their response to synovial fluids. This data confirmed 
that there is a spectrum of activation in macrophages (57) and that the specific 
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transcriptional analysis of macrophage markers  are not necessarily definitive 
measure of macrophage polarisation. There are other methods of analysis such 
as flow cytometric analysis of surface receptors and functional assays such as 
the secretion of cytokines or chemokines (63). RA and OA synovial fluid 
differentiated macrophages were comparable in the analysed transcript 
expression. Therefore, we considered whether all arthropathy derived synovial 
fluids caused a similar phenotype of macrophage. To further investigate, PsA 
synovial fluids were used and compared with the RA and OA MSF transcript 
expression. The analysis by qPCR showed the all MSF had a similar transcriptional 
profile to the M0 macrophages stimulated with LPS suggesting that the origin of 
the synovial fluid has no impact on the transcriptional phenotypes of 
macrophages (Figure 5.4). However, the unchanged cellular response between 
synovial fluids from RA, OA or PsA could be due to: storage as long term storage 
at -80oC could have caused protein degradation; and the synovial fluid was used 
at 10% as a greater concentration is cytotoxic, however, this dilutes the 
cytokines and DAMPs to low concentrations which would have less of an effect 
than recombinant cytokines. The cytokine content of synovial fluids (Figure 4.1) 
is very heterogeneous, and in some cases, once diluted, would contain negligible 
levels of factors, such as cytokines. 
Functionally, through chemokine analysis, there were also no differences 
between macrophages differentiated with RA, OA or PsA synovial fluid. The 
secretion of chemokines is used to define macrophage phenotypes, with CCL3 
and CCL5 secretion associated with M1 macrophage phenotypes (329). CCL7 has 
also been associated with increased induction in M1 macrophages in comparison 
to M2 macrophages (330), whereas CCL8 is secreted more in an M2 macrophage 
(266). CXCL1 secretion is not specifically associated with a phenotype of 
macrophage, however it is produced upon stimulation with LPS, therefore it is 
potentially a more pro-inflammatory M1 chemokine (331). These chemokines 
were analysed using a multiplex assay. Synovial fluids caused no induction of 
chemokines in macrophages, however as the LPS positive control led to the 
induction of chemokines, the assay was functional (Figure 5.5). There were also 
no differences between RA, OA or PsA differentiated macrophages, suggesting 
that all synovial fluids have a similar impact on macrophage phenotypes. For 
most of the analysed chemokines, there was no difference in comparison to the 
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control, however for CCL7 and CCL8, there was a potential suppression of 
induction with the addition of synovial fluids.  
Despite analysing macrophages polarised with synovial fluids from RA, OA and 
PsA patients via transcriptional markers and chemokine induction, there were no 
differences. This suggests either that macrophages have less of an inflammatory 
response to synovial fluid, or that the diluted synovial fluid was not enough of a 
stimulus for more dynamic activation where differences between the diseases 
would be observed. RA and OA synovial fluid have widely been compared and 
there are many differences in the DAMPs and cytokines content (84,133,140). 
Therefore, as macrophages are plastic and known to alter phenotypes in 
response to their environment, it would be expected for differences to be 
observed. There was also a large level of variability between the buffy coat 
donors used to differentiate into macrophages. This could potentially have been 
improved with an increase in the number of buffy coats analysed. A large 
limitation of the phenotypic analysis of macrophages was the factors analysed. 
FACS analysis of surface receptors would assess the protein expression of 
multiple markers such as CD206 and CD23, and the analysis of cytokine secretion 
such as IL-10, IL-6, TNFα or TGFβ could have been used to more thoroughly 
evaluate macrophage phenotypes.  
Macrophages stimulated with synovial fluids from different arthropathies had 
similar transcriptional profiles and chemokine expression. As macrophages are 
tissue resident cells, we aimed to determine whether monocytes were more 
responsive to synovial fluid, as they infiltrate the synovium in response to 
inflammatory cues. Monocytes had differing levels of most of the transcripts in 
comparison to macrophages (Figure 5.6), showing that despite originating from 
monocytes, the differentiation process alters many aspects of the cell’s 
phenotype. Interestingly monocytes transcribe less of CSF2RA (GM-CSFR gene) in 
comparison to macrophages, which are known to highly express the GM-CSFR on 
their surface (238). Monocytes had a greater level of CCL2 expression in 
comparison to macrophages although this was not a significant difference due to 
the donor variability. Not only were differences observed between monocytes 
and macrophages, but there were also differences in transcriptional profiles 
between monocytes stimulated with RA, OA or PsA synovial fluids. PsA synovial 
185 
 
fluid stimulated monocytes had a greater expression of most transcripts in 
comparison to monocytes stimulated with OA synovial fluid, with monocytes 
stimulated with RA synovial fluid at a level in between (Figure 5.7). Monocytes 
appeared to be more responsive to the differences in synovial fluid in 
comparison to macrophages, which may be due to monocytes infiltrating the 
synovium in response to inflammatory cues, and therefore the factors within the 
synovial fluid have more of an impact on the fate of the monocyte (56). The 
differences observed between diseased synovial fluid stimulations suggest that 
the components are important with regards to monocyte activation.  However, 
this was only analysed in one buffy coat with 4 different synovial fluids from 
each disease. This would need to be repeated in a greater number of buffy coat 
donors to confirm the differences between monocytes and macrophages. Due to 
the ability of monocytes to respond to synovial fluid from RA, OA or PsA patients 
in different ways, monocytes were used to take forward and assess for activation 
markers with the addition of Mavrilimumab. 
Pre-treatment of monocytes with Mavrilimumab led to no differences between 
synovial fluid treated monocytes and monocytes alone. This was hard to 
interpret due to the large level of variability between the monocyte donors. The 
variability was confirmed to be due to the monocytes and not a batch effect in 
repeating the assay. When transcripts were analysed from monocytes that were 
isolated on the same day, with the whole assay taking place at the same time, 
there was still variation (Figure 5.9). Mavrilimumab had little effect on 
monocyte activation transcripts, however due to the variation between 
monocyte donors, no differences could be observed (Figure 5.8). To improve this 
experiment, more donors could be used to try to minimise variability as this 
would allow more conclusions to be drawn. Specific activation markers could be 
analysed by FACS or functionally by cytokine or chemokine analysis. Analysis of 
cytokines and chemokines was attempted, but the lack of a suitable 
unstimulated monocyte control prevented further analysis. The lack of this 
control also gave the impression that monocytes pre-treated with Mavrilimumab 
were causing the induction of TNFα and CCL17 (Figure 5.10). Based on the 
interpretation of the data and the missing control, experiments were repeated 
to investigate the impact of Mavrilimumab on TNFα secretion. Mavrilimumab 
caused comparable levels of TNFα induction to the unstimulated monocyte 
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confirming that Mavrilimumab was not inducing TNFα (Figure 5.11A). During 
development of Mavrilimumab, studies were conducted into the secretion of 
TNFα from the monocyte, which showed a down-regulation of TNFα with 
increasing concentrations of Mavrilimumab (332). The experiments revealed 
however, that the isotype, used in the studies, caused inhibition of TNFα. The 
inhibition caused by the isotype was an issue as this prevented comparison with 
Mavrilimumab, thereby preventing any conclusions being drawn.  
We therefore aimed to determine how the isotype was causing such a dramatic 
dose dependent inhibition of TNFα. Initially human serum was used instead of 
FBS in the media to block unspecific binding and could prevent the observed 
inhibition. This was not the case, as even with human serum in the media, there 
was inhibition of TNFα by the isotype. This suggested that the isotype was either 
binding to cells, inhibiting TNFα signalling, or that it was causing the cells to 
apoptose (Figure 5.11B). Apoptosis analysis revealed that monocytes treated 
with Mavrilimumab or the isotype had similar levels of apoptosis to monocytes 
alone, suggesting that this was not the cause of TNFα inhibition (Figure 5.12A). 
Fluorescent labelling the isotype allowed us to assess the ability of the isotype 
to bind to monocytes. There was a marginal shift in isotype expression in 
comparison to unstained cells, showing that the labelled isotype was not fully 
binding to cells. This suggested that by directly binding to the monocyte, the 
isotype was causing inhibition of TNFα from the basal level. Despite this unusual 
finding, it was not possible to pursue this any further. However, the hypothesis 
that the IgG4 isotype could be binding to Fcγ receptors and causing down-
regulation of TNFα is unlikely. It has been shown that binding of immune 
complexes to Fcγ receptors caused a down-regulation of IL-12 secretion in 
monocytes (333), however TNFα secretion was induced in macrophages and DCs 
upon FcγR triggering (68,334). Interestingly, however, binding of mouse FcγRI by 
small immune complexes have shown to have induce IL-10 responses and down-
regulate IL-12 (245). Furthermore FcγRI has been shown to bind IgG4 (335). The 
effects of non-complexed IgG4 binding in human monocytes has also been 
examined in monocyte-derived macrophages, whereby IgG4 inhibited IFNγ 
mediated events such as the secretion of CXCL10 via FcγRI (336). Therefore, 
there could be the potential for IgG4 to bind FcγRI and inhibit the induction of 
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TNFα in monocytes, as a hypothesis for the observation in Figure 5.11. However, 
as the inhibition of TNFα by the isotype was not the main focus of the 
experiment it was not fully investigated. 
This chapter has shown how macrophages stimulated with synovial fluids are a 
polarised macrophage and a part of the macrophage phenotypic spectrum. The 
synovial macrophage phenotype, both from the synovial membrane and the 
synovial fluid also has broad qualities and are incompletely understood (325). 
These macrophages secrete pro-inflammatory mediators such as TNFα and IL-1, 
suggesting an M1 phenotype, but also IL-10, IL-1RA and TGFβ, which are more 
M2-like traits (325,337). Interestingly, the macrophages that were polarised with 
RA, OA and PsA synovial fluids were comparable both transcriptionally and in 
chemokine induction. Monocytes were much more responsive to diseased 
synovial fluids, and differentiating the monocytes in synovial fluids from day 1 
rather than in M-CSF first could have created a more accurate in vitro derived 
synovial macrophage. Analysis of Mavrilimumab with respect to monocyte 
phenotype was inconclusive due to the large level of variability between buffy 
coat donors and the effect of the isotype on monocytes. In order to move 
forward with this research, it would be interesting to analyse the phenotype of 
macrophages directly from synovial membranes and synovial fluid in relation to 
an in vitro stimulated macrophage. Also, the effect of Mavrilimumab on 
macrophage and monocyte phenotypes stimulated with synovial fluid would be 
interesting as this would determine whether GM-CSF has in a synovial context 
has an effect on macrophage activation. However, a more robust assay that 
would limit donor heterogeneity and an isotype that caused no inhibitory effects 
on the cells would be required for conclusive analysis of Mavrilimumab. More 
ways of analysing phenotypes by methods such as FACS could also provide 
information on the activation of the cells. Overall, this chapter has determined 
that macrophages that are exposed to synovial fluid are polarised to a unique 
phenotype. Monocytes, that would potentially infiltrate the synovium, appear 
more responsive to synovial fluid stimulation and transcriptionally have altered 
phenotypes dependent on synovial fluid disease origin. Further studies are 
warranted to understand in greater detail the impact of synovial fluid on 
macrophage differentiation, as these are key cell types involved in RA 
pathology.  
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Chapter 6 General Discussion 
This thesis has examined the relationship between the synovial environment and 
GM-CSF and their impact on monocytes and macrophages. When monocytes 
infiltrate the synovium, they are exposed to multiple factors that influence their 
inflammatory response (320). The monocyte response to environmental stimuli, 
prior to differentiation was unknown. Therefore, we aimed to evaluate the 
effect of GM-CSF on chemokine responses secreted from monocytes, as well as 
the influence of the environment on monocytes and macrophage polarisation. 
These data have highlighted that monocytes secrete substantial quantities of the 
CCR4 binding chemokine, CCL17, after 24 hours of stimulation with GM-CSF. GM-
CSF is a relevant cytokine to examine as it has been found at high levels within 
the synovial fluid and CD4+ T cells have been shown to be producers of GM-CSF in 
the RA synovium (326,338). However, as Chapters 3 and 4 have identified, the 
capacity of monocytes to secrete CCL17 can be inhibited my multiple factors, 
including TLR ligands, RA synovial fluid, Small Immune Complexes and IFNα. The 
ability of RA synovial fluid to inhibit the secretion of a pro-inflammatory 
chemokine was unique, as RA synovial fluid has previously been found to be 
stimulatory rather than inhibitory. RA synovial fluid has prevented the apoptosis 
of neutrophils, thereby leading to the persistence of activated neutrophils, 
exacerbating the inflammatory pathology (339). Monocytes differentiated with 
IL-4 or IL-13 for 3 or 6 days had an increase in secretion of CCL18 when co-
stimulated with RA synovial fluid, showing that RA synovial fluid can cause an 
up-regulation in chemokine secretion (340). We found RA synovial fluid inhibited 
the GM-CSF induced secretion of CCL17, which is a novel inhibitory response 
opposed to the multiple stimulatory responses that have previously been 
observed. This suggests that not only are there pro-inflammatory responses 
involved in RA pathogenesis, but to some level there are more regulatory 
mechanisms. In this instance, monocytes have the ability, prior to their 
differentiation, to cause the influx of CCR4+ T cells into the joint, however the 
synovial milieu prevents this. 
Analysis of CCL17, CCR4 and GM-CSFRα in the RA synovium, in Chapter 3, found 
that CCL17 and CCR4 were prevalent in the tissue. This suggests that despite 
synovial fluid inhibiting the secretion of CCL17 from monocytes, there must be 
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other cell types that are secreting CCL17, leading to the infiltration of CCR4+ 
cells that are observed in the tissue. Dendritic cells are also known to secrete 
CCL17 upon TSLP stimulation, and TSLP has been found in the RA synovial fluid 
(180,268). Interestingly, RANKL, which is present within the RA synovium (341) 
has been found to mediate an increase in the secretion of TSLP induced CCL17 
from DCs (342). This suggests that the induction of CCL17 from DCs could be up-
regulated by factors within synovial fluid, whereas for monocytes, this induction 
is inhibited.  
Our investigations into the mechanism of inhibition by RA synovial fluid initially 
analysed pSTAT5 as it was downstream in the signalling cascade from GM-CSFRα. 
There was no difference observed in unstimulated monocytes compared with 
monocytes pre-treated with RA synovial fluid. We concluded that pSTAT5 or 
upstream molecules were not impacted by synovial fluid. Interestingly, STAT6 
has been identified as a transcription factor for CCL17 downstream of IL-4 
signalling (267). Therefore, we investigated whether this transcription factor 
was down-regulated after RA synovial fluid signalling. There was a slight down-
regulation after RA synovial fluid, but as this was a preliminary study, it was 
inconclusive, but repeating this experiment would confirm whether STAT6 was 
involved. Identifying the transcription factor that GM-CSF signalling activates to 
transcribe CCL17 is important to confirm whether Immune complexes, TLR 
ligands and IFNα affect activation of this transcription factor.  
We have identified that RA synovial fluid differs from OA synovial fluid in the 
capacity to inhibit GM-CSF induced CCL17 in monocytes. However, the effect of 
synovial fluid on macrophage polarisation, showed that it was not dependent on 
the disease origin. Despite synovial fluid polarisation forming distinct 
macrophages, they had comparable transcriptional profiles despite the origin of 
the synovial fluid. Whether these macrophages were comparable with 
macrophages that were directly isolated from the synovium it is unknown, but 
this would be an interesting comparison. Synovial macrophages are generally 
associated more with an M1 phenotype due to the pro-inflammatory cytokines, 
such as TNFα and IL-1, that they secrete. However, they are also known to 
secrete the more anti-inflammatory cytokine IL-10 (343). This suggests that 
there could be multiple subsets of macrophages within the synovium. It could 
190 
 
also suggest that the mixed M1 and M2 phenotype observed in our 
experimentally produced macrophages differentiated with synovial fluid, are 
similar to those observed in synovial macrophages. Further investigation would 
be required to examine this observation. Understanding macrophages of the 
synovium is important to understand RA pathogenesis, as macrophages of the 
sub-lining layer have been suggested as a potential biomarker to predict 
therapeutic efficacy (344). For this reason we aimed to establish the effect of 
Mavrilimumab on macrophage and monocyte phenotypes, as GM-CSFRα was 
identified at high levels in areas where CD68 was also expressed (Chapter 3). 
However, due to the large level of variability between human monocyte donors 
and the isotype phenotype that caused inhibition of TNFα, this could not be 
achieved.  
6.1 Future Work 
We found in Chapter 3 that the ability of monocytes to secrete CCL17 was 
inhibited by TLR ligands. When we observed in Chapter 4 that RA synovial fluid 
also inhibited GM-CSF induced CCL17 in monocytes, it was assumed that TLR 
ligands within the fluid were causing this. However, TLR ligands were not the 
only factor with the capacity to cause inhibition of CCL17. Therefore, future 
work would include identifying the specific factors within synovial fluid that 
cause inhibition of CCL17. In order to achieve this, fractionating the synovial 
fluid based on size would be the initial method to narrow down the 
investigations. As we know that small immune complexes can mimic the RA 
synovial fluid in causing inhibition, it would be interesting to isolate the ACPA or 
RF from the fluid to determine whether they have the same effect. It would also 
be important to identify the specific mechanism leading to inhibition of CCL17. 
Our data suggests there could be multiple pathways as there are several factors 
that cause inhibition of GM-CSF driven CCL17, however, it would be important to 
confirm this. There is the possibility that there are multiple signalling pathways 
that lead to the same factor that inhibits transcription of CCL17.  
These data have analysed monocytes as a whole, however it would be 
interesting to determine whether the different subsets of monocytes, 
categorised by their CD14 and CD16 expression, had varying responses to GM-CSF 
and RA synovial fluid.  
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OA synovial fluid had variable effects on the inhibition of CCL17, therefore, it 
would be important to identify whether the factor within OA synovial fluid that 
caused inhibition was the same as the RA synovial fluid. OA synovial fluid 
significantly inhibited GM-CSF induced CCL3 and CCL4, and it would be 
interesting to understand the mechanism of inhibition, as well as its biological 
relevance and impact on disease pathology.  
It would still be of interest to understand the impact of Mavrilimumab on 
monocyte and macrophage phenotypes within the synovium, however, a reliable 
isotype and experimental system would be required for this. Also, analysis via 
flow cytometry or assessing cytokine and chemokine release as well as 
transcriptional analysis or RNAseq would give a greater depth to phenotypic 
profile analysis. Mavrilimumab impacted on CCL17 and CCL22 in serum of 
patients, highlighting that GM-CSF driven CCL17 and CCL22 could be involved in 
RA pathogenesis (295). 
6.2 Conclusions 
This thesis has identified a novel regulatory system within the RA synovium. 
Monocytes exposed to GM-CSF secrete CCL17, however, in the RA synovial 
environment, this induction is inhibited. CCL17 chemoattracts CCR4+ cells into 
the synovium, which upon activation secrete GM-CSF. Therefore, the inhibition 
of CCL17 could potentially prevent the influx of CCR4+ cells into the synovium, 
thereby regulating the inflammatory cell infiltration into the joint. However, as 
there are other cells such as dendritic cells that secrete CCL17, there is still the 
possibility of CCR4+ T recruitment into the tissue. Inhibition of GM-CSF driven 
CCL17 by RA synovial fluid was mimicked by TLR ligands, small immune 
complexes and IFNα. This suggests multiple mechanisms can cause inhibition of 
this pathway, which need further investigation.  
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Appendix 
Media 
 
Complete RPMI: 
 500ml Incomplete RPMI (Gibco, Invitrogen) 
 50ml Heat Inactivated Foetal Bovine Serum (Invitrogen) 
 5ml Penicillin-Streptomycin (Sigma) 
 
Human Serum RPMI: 
 500ml Incomplete RPMI (Gibco, Invitrogen) 
 50ml Human Serum (Biowest) 
 5ml Penicillin-Streptomycin (Sigma) 
 
T Cell Media: 
 500ml Incomplete RPMI (Gibco, Invitrogen) 
 50ml Heat Inactivated Foetal Bovine Serum (Invitrogen) 
 5ml Penicillin-Streptomycin (Sigma) 
 5ml L-Glutamine (Sigma) 
 
Complete Dulbecco’s Modified Eagle Medium (D-MEM): 
 500ml Incomplete D-MEM 
 50ml Heat Inactivated Foetal Bovine Serum (Invitrogen) 
 5ml Penicillin-Streptomycin (Sigma) 
 5ml L-Glutamine (Sigma) 
 
Buffers 
 
Cell Separation Buffer: 
 500ml dPBS (Gibco, Invitrogen) 
 10ml FBS (Invitrogen) 
  
FACS buffer: 
 1L 1x PBS 
 3% BSA 
 1mM EDTA 
 0.05% Sodium Azide 
 
ELISA Coating Buffer: 
 1L 1x PBS 
 
ELISA Assay Buffer: 
 1x PBS 
 1% BSA 
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ELISA Wash Buffer: 
 1x PBS 
 0.05% Tween 
 
IHC Citrate Buffer (pH6) 
 2.1g Citric Acid 
 1L dH2O 
  
IHC Wash Buffer (TBST) 
 1x TBS 
 0.05% Tween 
 
Protein A/G/L magnetic bead binding buffer 
 50 mM Tris 
 150 mM NaCl 
 In dH2O, pH 7.5 
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